Human Osteoblast Differentiation and Bone Formation: Growth Factors, Hormones and Regulatory Networks by Eijken, H.J.M. (Marco)
Human Osteoblast Differentiation
and Bone Formation:
Growth Factors, Hormones and Regulatory Networks
Marco Eijken
M
arco
E
ijken
H
u
m
an
O
steo
b
last
D
ifferen
tiatio
n
an
d
B
o
n
e
Fo
rm
atio
n
Omslag Eijken def  06-08-2007  10:23  Pagina 1
Human Osteoblast Differentiation and Bone Formation:
Growth Factors, Hormones and Regulatory Networks
Humane osteoblast differentiatie en botvorming:
groeifactoren, hormonen en regulerende netwerken
The research described in this thesis was performed at the Department 
of Internal Medicine of the Erasmus MC, Rotterdam, The Netherlands.
Publication of this thesis was financially supported by: 
Cover: Digitally enhanced photo of an osteoblast culture stained for 
mineralization (Alizarin red staining). 
© Marco Eijken, 2007
All rights reserved. No part of this publication may be reproduced 
or transmitted in any form or by any means, electronic, mechanical, 
photocopying, recording or otherwise, included a complete or partial 
transcription, without the prior written permission of the author.
Alle rechten voorbehouden. Niets uit deze opgave mag worden 
verveelvoudigd, opgeslagen in een geautomatiseerd gegevensbestand 
of openbaar worden gemaakt, in enige vorm of op enige wijze, zonder 
voorafgaande schriftelijke toestemming van de auteur.
Printed by Haveka BV, Alblasserdam, The Netherlands
Human Osteoblast Differentiation and Bone Formation:
Growth Factors, Hormones and Regulatory Networks
Humane osteoblast differentiatie en botvorming:
groeifactoren, hormonen en regulerende netwerken
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. S.W.J. Lamberts
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 5 september 2007 om 15:45 uur
door
Hermanus Johannes Marco Eijken
geboren te ’s-Gravenhage
Promotiecommissie 
Promotor:    Prof.dr. J.P.T.M. van Leeuwen 
Overige leden:  Prof.dr.  H.A.P. Pols 
   Prof.dr.  F.H. de Jong
   Prof.dr.  P.J. van der Spek
Contents
Chapter 1 General Introduction 7
Chapter 2 The essential role of glucocorticoids for proper  27
 human osteoblast differentiation and matrix
 mineralization
Chapter 3 11β-Hydroxysteroid dehydrogenase expression 41
 and glucocorticoid synthesis are directed by 
 a molecular switch during osteoblast 
 differentiation
Chapter 4 Identification of regulatory genes, gene  61
 networks and cellular processes in 
 glucocorticoid-induced human osteoblast
 differentiation and mineralization
Chapter 5 The activin A-follistatin system: potent   87
 regulator of human extracellular matrix
 mineralization
Chapter 6 Wnt signaling acts and is regulated in a  109
 human osteoblast differentiation dependent
 manner
Chapter 7 General discussion 127
Chapter 8 Appendices 145
  Samenvatting
  Summary
  Abbreviations
  Dankwoord
  Curriculum Vitae
  List of Publications
  

Chapter 1
General Introduction
C
ha
pt
er
 1
8
G
eneral Introduction
9
C
ha
pt
er
 1
8
G
eneral Introduction
9
1.1 Bone
Bone is a highly specialized form of connective tissue that provides internal support to the body in all higher vertebrates. In addition to its supportive function, it has several 
metabolic functions, it houses the brain, the spinal cord and bone marrow, and plays 
an essential role in maintaining blood calcium levels and supporting hematopoiesis 1. 
Bones are built up from an organic extracellular matrix, which is strengthened by the 
deposition of mineral. Although bones are hard and mineralized, bone is a living tissue 
containing blood vessels and various cell types. A typical bone consists of a hard and 
compact outer shell, the cortex, which surrounds a hollow cavity that is filled with bone 
marrow. At specific locations in the bone cavity the bone is strengthened with a fine 
network of sponge-like trabecular bone. The combination of the relative heavy cortex 
together with the relative light trabecular bone gives the bone strength with minimal 
weight.
1.2 Bone cells
Bone is a dynamic tissue that is continuously maintained and renewed by four different 
kinds of bone cells; 1] osteoclasts, 2] osteoblasts, 3] osteocytes, and 4] lining cells (see 
figure 1.1). Osteoclasts are located at the bone surface where they degrade (resorb) 
small pieces of bone tissue. They are giant multinucleated cells and resorb bone via local 
acidification and secretion of various proteases. Acidification is necessary to dissolve 
the mineral in bone, whereas the proteases degrade the proteins of the extracellular 
matrix 2. New bone is produced by osteoblasts that synthesize the organic matrix of bone 
by secretion of a wide variety of extracellular matrix proteins. In addition to matrix 
production, they also participate in the mineralization process and in the control of 
osteoclast function 3. When an osteoblast is in its terminal differentiation stage and 
resides entrapped in its self produced bone matrix it is called an osteocyte. Osteocytes 
are the most abundant cells in bone and are believed to maintain the bone by sensing 
mechanical strains and bone damage 4-6. They have a typical morphology with long thin 
cytoplasmic processes, which form a fine network of connections with other osteocytes 
and with the osteoblasts located at the surface of the bone (see osteocyte structures in 
figure 1.1). Another bone cell that is derived from osteoblasts is the lining cell; lining 
cells cover the bone surfaces and thereby separate the bone surface from the bone 
marrow. However, the exact function of bone lining cells remains unclear 3, 7.
1.3 Bone remodeling
To carry out its function, bone is continuously resorbed by osteoclasts and rebuild by 
osteoblasts at millions of microscopic sites. This process is called bone remodeling, which 
main function is to renew  bone tissue to retain bone strength during adulthood 8, 9. During 
bone remodeling, bone is first resorbed by osteoclasts and subsequently, osteoblasts 
arrive and rebuild the resorbed bone by synthesizing new bone matrix (figure 1.1).
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Albeit that mechanical strength is of great importance for the skeleton, there 
is a certain hierarchy among factors that regulate bone mass. For example, calcium 
homeostasis overrides other functions of the skeleton. During hypocalcaemia due to 
poor calcium diet, calcium deficiency, renal disease, or other pathology, osteoclast 
activity is increased to release calcium from the bone to restore calcium homeostasis. 
Other factors that initiate bone remodeling are mechanical loading of bone and bone 
damage 8. During mechanical loading osteocytes respond to the mechanical stimuli, 
which results in bone remodeling at specific locations in the bone to obtain maximal 
bone strength 5, 10. In case of bone damage, osteocytes go into apoptosis at the site of 
damage, which eventually initiates bone remodeling and subsequent bone repair 6.
Bone resorption and bone formation are coupled to each other, this means, if 
one goes up or down the other usually follows. This coupling between formation 
and resorption is controlled by several mechanisms, which are not yet completely 
understood. First, osteoblasts are able to stimulate osteoclast differentiation by 
production of osteoclast stimulating factors such as RANKL (receptor activator of NF-kB 
Osteocytes
OsteoblastsOsteoclast
Lining cells
Bone resorption Bone formation
Bone
tissue
Figure 1.1. Bone remodeling. Four different bone cells reside in bone; 1] osteoclasts that resorb bone, 2] 
osteoblasts that produce new bone 3] osteocytes that sense mechanical strains, and 4] lining cells covering the 
bone tissue. During bone remodeling bone mass is controlled by the balance between osteoclastic bone resorption 
and osteoblastic bone formation. First osteoclasts resorb bone by acidification and secretion of a wide variety of 
proteases and, in turn, osteoblasts replace the resorbed bone by producing new bone matrix.
M-CSF
c-FmsRANK
RANKL
Osteoclasts
+
+
Bone
resorption
Growth
factors
Osteoblasts
Bone formation
Figure 1.2. Coupling between bone formation and bone 
resorption. Osteoblast and osteoclast differentiation and 
function are coupled. Osteoblasts activate osteoclast 
differentiation by expressing RANKL and M-CSF, which 
bind to RANK and c-Fms receptors on the surface of 
osteoclasts. During bone resorption osteoclasts release 
various growth factors from the bone matrix, which in 
turn stimulate osteoblast differentiation. Picture adapted 
from Weitzmann et al. 14.
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ligand) and M-CSF (macrophage colony-stimulating factor) 11. RANKL is a key cytokine for 
osteoclast formation. Its discovery was followed by the identification of its soluble decoy 
receptor OPG (osteoprotegerin), which binds RANKL with high affinity 2, 12. Besides that 
osteoclast activity is coupled to osteoblast activity, the activity of osteoblasts is also 
influenced by the activity of osteoclasts. During osteoclastic bone resorption multiple 
factors are released from the extracellular matrix, including IGF-I (insulin-growth 
factor I) and TGFβ (transforming growth factor β) 8, 13, which control the differentiation 
and activity of osteoblasts after their release (figure 1.2).
Although bone resorption and formation are coupled these processes are not 
always in balance. During growth the balance favors bone formation to reach peak 
bone mass. After adults reach their peak bone mass there is evidence of a reduction 
of bone formation, which eventually results in bone loss and structural bone damage 
during ageing 15, 16. In case of hormonal imbalance the coupling between osteoblasts and 
osteoclasts can also be out of equilibrium (discussed in paragraph 1.9).
1.4 Bone quality & bone mineralization
The quality of bone is determined by its material composition and its structure. During 
loading, bone must be stiff and able to resist deformation, but on the other hand bone 
must be flexible to absorb energy by deformation 4. The most abundant extracellular 
matrix (ECM) protein in bone is collagen type I which gives the bone its flexibility 17, 
whereas the mineral in bone gives the bone its mechanical strength. As a consequence 
variations in the amount of mineral and collagen affect the properties and quality of 
bone (e.g. stiffness and flexibility). When bone is too stiff (too much calcium) it will 
result in micro cracks and/or eventually complete fracture, when bone is too flexible 
(too little calcium) it is not sufficient for supportive function. An optimal mineral density 
is therefore essential. Mammalian bone is about 60 % (mass percentage) mineralized, 
whereas other bone-like structures responsible for other functions have a different 
mineral content 18. For example, auditory ossicles contain 90 % mineral for efficient 
sound transmission, whereas deer antlers contain 40 % mineral needed to absorb the 
impact of head butting during fight 4. Albeit that mineral is a crucial substance in 
bone, little is known about the optimal mineral density of bone and how bone becomes 
mineralized.
Osteoblasts as the bone forming cells are primarily responsible for the mineralization 
process in bone. First, osteoblasts produce a non-mineralized ECM (osteoid), which 
predominantly consists of collagen type I. Besides that collagen fibers provide structural 
strength and flexibility to the bone, collagen fibers also determine the structural 
organization for other ECM proteins and act as a template for mineral deposition 19. 
Osteoblasts also produce a wide variety of so-called noncollagenous ECM proteins. 
This group of ECM proteins includes enzymes, growth factors, calcium binding proteins 
and several other proteins important for the structure of the ECM. Osteocalcin and 
osteopontin are well-known noncollagenous proteins localized in bone and are frequently 
used as markers of osteoblast differentiation. Moreover, in the clinic osteocalcin serum 
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levels are used as marker for bone turnover. But the exact roles of osteopontin and 
osteocalcin in the bone matrix are still unclear. The knowledge so far indicates that 
these proteins act as negative regulators of the mineralization process 20-25.
After osteoblasts have produced a complete and maturated ECM, hydroxyapatite 
mineral (Ca10[PO4]6[OH]2) is deposited in the ECM. Bone mineralization is a complicated 
process controlled by many factors including calcium and phosphate concentrations, 
enzyme activity, and the composition of the ECM. Initiation of mineralization requires 
the precipitation and attachment of hydroxyapatite crystals to the ECM 17. One possible 
mechanism of hydroxyapatite crystal formation is via extracellular matrix vesicles 
(MVs). It has been demonstrated that osteoblasts produce MVs by polarized budding and 
pinching-off vesicles from specific regions of their outer plasma membranes. After MVs 
are released into the ECM they initiate formation of the first mineral crystals 17, 26, 27. The 
osteoblast differentiation marker alkaline phosphatase is suggested to play a role in the 
mineralization process, where it hydrolyses organic phosphate substrates to release free 
inorganic phosphate 28. This enzyme is highly expressed in MVs together with several 
phosphate and calcium transporters 29. These transporters increase local calcium and 
phosphate concentrations and thereby initiate hydroxyapatite crystal formation 30, 31. 
Although there is evidence for these MVs it might well be that mineralization in bone is 
initiated via other additional mechanisms as well 32, 33.
Mineralization of the ECM is not unique for bone tissue as demonstrated by ectopic 
calcification in pathological conditions 34. In case of vascular calcification regions of the 
vascular wall are calcified 35. There are important similarities and differences between 
bone mineralization and vascular mineralization. This led to increased interest to 
investigate how and why bone-like mineral deposits are formed in the arteries. Vascular 
smooth muscle cells are believed to initiate this calcification process in various types 
of vessel wall calcification. For unclear reasons these cells undergo an osteoblast-like 
differentiation process expressing osteoblastic factors including alkaline phosphatase 
and runt-related transcription factor 2 (RUNX2), causing mineralization of the ECM in 
the vessel wall 34, 36-39.
1.5 Mesenchymal stem cells
The cavity in bone is filled with bone marrow that retains both mesenchymal and 
hematopoietic stem cells. Both types of stem cells are able to self-renew and differentiate 
into various cell types, including osteoblasts and osteoclasts. Hematopoietic stem cells 
are the most abundant in the bone marrow and give rise to different kinds of blood cells. 
They can differentiate into myeloid (erythrocytes and megakaryocytes), lymphoid (T and 
B cells) and granulocyte/monocyte progenitors. Osteoclasts are also from hematopoietic 
origin and derived from the same lineage as monocytes.
Osteoblasts on the other hand are derived from mesenchymal origin. In addition to 
osteoblasts, mesenchymal stem cells (MSCs) give rise to a wide variety of other cell types 
such as chondrocytes, fibroblasts, adipocytes, and myoblasts 3, 40, 41 (figure 1.3). MSCs 
reside mainly in the bone marrow but is has been shown that they can be found in almost 
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all other tissues to maintain tissue homeostasis 41, 42. In humans, fat tissue is nowadays 
also used as a source for MSC isolation. The use of MSCs in general has generated a great 
deal of interest because of their multipotency and relative easy accessibility. They have 
great potential as regenerative medicine and in tissue engineering 41, 43. Some interesting 
examples of therapeutic use of mesenchymal stem cells have been reported, including 
cardiovascular repair, treatment of lung fibrosis, spinal cord injury and bone and 
cartilage repair 44. However, albeit that MSCs can be studied and committed to different 
cell lineages in vitro 41, the molecular control of these processes are poorly understood. 
More knowledge is required about MSC commitment and differentiation in order to use 
MSCs in a robust and controlled manner in therapeutic applications.
1.6 Osteoblast differentiation
The life of an osteoblast consists of multiple differentiation steps (osteoblastogenesis, 
see figure 1.4). First commitment of mesenchymal stem cells to the osteoblast lineage 
will arise. These committed osteoblasts are called osteoprogenitor cells. They proliferate 
MSCs
Osteoblasts
Myocytes
Adipocytes
Fibroblasts
Chondrocytes
Bone marrow
Figure 1.3. Mesenchymal stem cell differentiation. Bone marrow retains mesenchymal stem cells (MSCs), which 
give rise to a variety of cell types such as osteoblasts, chondrocytes, fibroblasts, adipocytes, and myoblasts. Picture 
adapted from Yin et al. 40.
Stem cell MSC Osteoprogenitor Pre-osteoblast
Mature
osteoblast
Lining cell
Osteocyte
Self -renewal Lineage
commitment
Proliferation/
Matrix synthesis
Matrix maturation/
Mineralization
Bone maintenance
Figure 1.4.  Osteoblast differentiation. Osteoblasts undergo a complex differentiation program. Each differentiation 
stage is controlled by different kinds of morphogens, hormones, growth factors, cytokines, and ECM proteins.
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and will differentiate into pre-osteoblasts. Pre-osteoblasts in turn start to produce the 
ECM and differentiate into mature osteoblasts. Subsequently, these mature osteoblasts 
continue ECM synthesis and initiate mineralization of the ECM. Only a fraction of the 
mature osteoblasts will be incorporated into newly formed bone matrix and remains 
settled as an osteocyte. The remaining mature osteoblasts will die or become bone-
lining cells 3.
It is believed that each of the differentiation steps during osteoblastogenesis is 
regulated by different kinds of morphogens, hormones, growth factors, cytokines and 
ECM proteins. These external signals initiate several signaling cascades and transcription 
factors that mediate and control osteoblastogenesis.
Steroid hormones including estrogens, androgens, progesterone, glucocorticoids 
and 1,25α(OH)2D3 (vitamin D3) are well-known for their stimulatory effect on osteoblast 
differentiation and activity 3, 45, 46. The most significant impact on osteoblastogenesis 
in vitro is accomplished by glucocorticoids. Glucocorticoid treatment is essential for 
the induction of osteoblastogenesis and initiation of matrix mineralization in rat and 
human osteoblast models 47-52. The role of glucocorticoids in osteoblast differentiation is 
discussed in more detail in paragraph 1.8.
Members of the TGFβ superfamily such as TGFβ and bone morphogenic proteins 
(BMPs) are other well-known regulators of bone formation. Both TGFβ and BMPs 
promote bone development by stimulating osteoprogenitor cells 53, 54. However, TGFβ 
also seems to act negatively on later phases of osteoblast differentiation by inhibiting 
mineralization 53, 55, 56.
The Wnt signaling pathway is only relatively recently known to be involved in bone 
metabolism 57. Wnt signaling plays a widespread role in skeletogenesis from embryonic 
skeletal patterning, through fetal skeletal development, and bone remodeling in adults. 
Multiple skeletal defects have been described in mice deficient for various genes involved 
in the Wnt signaling pathway 57. In humans, loss-of-function mutations in the Wnt co-
receptor LDL receptor-related protein 5 (LRP5) are associated with the osteoporosis-
pseudoglioma syndrome, which is characterized by low bone mass and skeletal fragility 
58. In contrast, gain-of-function mutations in LRP5 are associated with a high bone 
mass phenotype 59, 60. Despite all these data, the functions of Wnt signaling in bone 
biology remain unclear. The Wnt-induced skeletal defects are at least accomplished by 
regulating osteoblast differentiation and activity. Several reports show that Wnt signaling 
contributes to osteoblast differentiation 61-63, whereas other reports show the ability of 
Wnt signaling to inhibit osteoblast differentiation 64-66. These conflicting data are likely 
to reflect the diverse function of Wnt signaling at different stages of osteoblastogenesis. 
More data in different models will be required to understand the complex role of Wnt 
signaling in osteoblast differentiation.
Several transcription factors are known that control bone development and 
osteoblast differentiation. Two specific osteoblast transcription factors are RUNX2 67-69 
and SP7 (SP7 transcription factor, also known as osterix) 70. RUNX2 and SP7 are crucial 
for skeletogenesis and osteoblast differentiation. They target osteoblast-related genes 
such as osteocalcin, bone sialoprotein, osteopontin and collagen type Iα1 71. In addition, 
several other non-osteoblast specific transcription factors have been identified that 
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TGFβ family members elicit their cellular response via formation of heteromeric 
complexes of specific type I and II serine/threonine kinase receptors which are located 
at the cell surface of target cells. Upon ligand binding and type I and II receptor 
heterodimerization the type I receptors activate Smad proteins through phosphorylation. 
Phosphorylated Smad complexes in their turn accumulate in the nucleus where they bind 
to DNA and regulate gene transcription of target genes 75, 84.
Five type II and seven type I receptors have so far been identified. Activins use the 
type II receptors ACVR2A or ACVR2B (also known as ActRII or ActRIIB) and the type I 
receptor ACVRIB (also known as ALK4) which results in phosphorylation of Smad2 and 3. 
Interestingly, TGFβs have their own type I and II receptors but share Smad2 and 3 with 
activins for signaling to the nucleus. BMPs on the other hand signal via distinct Smads 
�A �A �A �B �B �B
Activin-
A AB B
�
�A
�
�B
Inhibin-
A B
INHA / ��precursor
18kD
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Figure 1.5. Structure of activins and inhibins. Homo- and heterodimerization of only β-subunits results in the 
formation of activins. Heterodimerization of a α-subunit together with a β-subunit results in formation of inhibins.
control osteoblast differentiation, including TWIST1 (twist homolog 1), ZBTB16 (zinc 
finger and BTB domain containing 16), DLX5 (distal-less homeobox 5) and MSX2 (msh 
homeobox homolog 2) 3, 8, 72-74.
1.7 Activin signaling
Activins are members of the TFGβ superfamily, that besides activins, includes inhibins, 
BMPs, TGFβs, growth and differentiation factors (GDFs), Nodel, Myostatin, anti-Müllerian 
hormone (AHM) and several other growth and differentiation factors 75, 76. Activins 
and inhibins were initially purified from gonadal fluids and characterized on basis of 
their ability to modulate follicle stimulating hormone (FSH) secretion from pituitary 
gonadotropes 76, 77. Nowadays, however, it is known that activins can affect the function 
of several other cell types and tissues, like the adrenal gland, liver, neurons, pancreas 
and bone 78-82. They control processes such as proliferation, differentiation, immune 
responses, wound repair, tumor development and various endocrine activities 76, 83.
The inhibin subunits βA, βB, and α (INHBA, INHBB and INHA) are produced as 
precursors, which after cleavage dimerize to form inhibin or activin proteins. Like in all 
other members of the TGFβ superfamily covalent disulfide bond links the two subunits. 
Homo- or heterodimerization of only β-subunits results in the formation of activin A 
(βAβA), activin AB (βAβB), or activin B (βBβB) 76. Heterodimerization of an α-subunit 
with a β-subunit results in the formation of inhibin A (αβA) or B (αβB) (see figure 1.5). 
Additional β-subunits have been identified in humans (INHBC and INHBE) but their 
biological roles remain unclear.
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(Smad 1,5 and 8) but bind to the same type II receptors as activin. This illustrates 
the complexity of the system and indicates that so far only little is known about the 
signaling of these family members and ligand specificity.
The activity of activins is inhibited by the extracellular action of inhibins and 
follistatin 85. Inhibins need the presence of a type III TGFβ receptor, betaglycan, to 
inhibit activin signaling via competitive binding to the activin type II receptor for 
activin  86, 87. Follistatin is a soluble extracellular protein that functions as an activin 
binding protein. It binds activins with high affinity preventing activins to interact with 
their cell-surface receptors and thereby inhibits activin signaling 88. The binding affinity 
of follistatin is ten time higher for activin A than for activin B. Follistatin is found in the 
circulation but is also expressed and secreted by several activin target cells 76.
Several studies have now demonstrated that activins are involved in bone 
metabolism. In the extracellular matrix of bovine bone large quantities of activin 
are found 89 and activin A seems to promote bone formation and fracture healing in 
rodents 89-91. At the cellular level it has been shown that activin A enhances osteoclast-
like cell formation as well as osteoblastogenesis in murine bone marrow cultures 92, 93. 
However, other reports demonstrated an inhibitory effect of activin on osteoblast 
differentiation in rat and murine osteoblasts 94, 95.
1.8 Glucocorticoid signaling in bone
Glucocorticoids are named after their role in maintaining glucose homeostasis. 
Glucocorticoids regulate numerous processes in the human body such as mediation of the 
stress response 96, regulation of lipid and glucose metabolism 97, immunosuppressive and 
anti-inflammatory actions 98, and cellular differentiation 48, 99, 100. The active glucocorticoid 
in humans is cortisol, which is produced in the adrenal gland 101. After cortisol is released 
in the circulation about 80 to 90 % binds with high affinity to cortisol-binding globulin 
(CBG) 102, 6 to 15 % binds with low affinity to albumin, whereas 4-5 % is unbound. The 
albumin-bound and free levels are considered as biological active 103. The primary role 
of CBG is to regulate the bioavailability and metabolic clearance of cortisol 102. However, 
CBG might also contribute to the localization of cortisol. Localization of CBG in certain 
tissues may serve to locally enhance or inhibit free cortisol action. To enhance cortisol 
action at the tissue level it has been shown that cortisol can be released by local 
cleavage of CBG or by cellular uptake of the CBG-cortisol complex 102.
At the cellular level glucocorticoids mediate signaling via binding to the glucocorticoid 
receptor (GR) 104. The GR belongs to the superfamily of nuclear steroid receptors which 
also includes the thyroid-hormone receptor, estrogen receptor, androgen receptor and 
vitamin D receptor 105. GR is expressed in almost all cell-types including osteoblasts 106, 
where it regulates gene expression by binding to glucocorticoid responsive elements 
(GREs) in the regulatory regions of glucocorticoid target genes 104 such as osteocalcin, 
collagen Iα1 and TGFβ1 107-109. 
In vitro, glucocorticoids (GCs) such as cortisol are crucial initiators of human 
osteoblast differentiation 47-52. Despite clear stimulation of bone formation by GCs 
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In bone cortisol action is also controlled by action of 11β-HSDs. 11β -HSD type 1 is the 
most prominent isozyme in bone, whereas 11β -HSD type 2 is barely detectable  121,  122. 
This indicates that in bone tissue cortisone is converted to active cortisol resulting in 
enhanced glucocorticoid signaling in bone.
Figure 1.6. Simplified scheme of glucocorticoid signaling. Cortisol is produced by the adrenal gland. After release 
in the circulation, the majority of cortisol is bound by cortisol binding globulin (CBG). Free cortisol can enter target 
cells where it binds to the glucocorticoid receptor (GR). After binding the GR is translocated into the nucleus where 
it binds to glucocorticoid responsive elements (GRE) to regulate gene transcription. Cortisol is regulated at the 
pre-receptor level by 11β-HSDs. 11β-HSD type 2 acts as an inactivating enzyme converting cortisol into biologically 
inactive cortisone to protect the nonselective mineralocorticoid receptor (MR) from activation by glucocorticoids. 
11β-HSD1 acts as an activating enzyme converting inactive cortisone into cortisol.
in vitro, GCs are still regarded as negative regulators of bone formation. This is mainly 
based on clinical use of GCs, which frequently results in bone loss and increased risk 
of fractures (GC-induced osteoporosis) 110 (see further below in section 1.9). The exact 
mechanism of GCs in regulating bone formation is unclear. It might depend on the 
duration and concentration of GC treatment and on the differentiation stage of both 
osteoblasts and osteoclasts 111-114.
In glucocorticoid target tissues glucocorticoid signaling is regulated at the 
pre-receptor level by 11β-hydroxysteroid dehydrogenases (11β-HSDs) (figure 1.6). 
Two distinct 11β-HSDs have been described in humans. 11β -HSD type 2 acts as an 
inactivating enzyme converting cortisol into biologically inactive cortisone. This 
enzyme is found primarily in mineralocorticoid target tissues in which it protects the 
nonselective mineralocorticoid receptor against activation by glucocorticoids 115-117. 11β-
HSD type 1 on the other hand is found in almost all glucocorticoid target tissues and 
acts as an activating enzyme converting cortisone into biologically active cortisol 118, 119. 
The principle source of circulating cortisone is the kidney which expresses high levels of 
11β-HSD type 2 120.
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1.9 Osteoporosis
Osteoporosis is the most common bone disease and can be characterized by low bone 
mass, micro architectural deterioration and decreased bone quality, which results in 
bone fragility and increased risk for fractures. Osteoporosis is an important public health 
issue since 50 % of women and 20 % of men older then 50 years will have a fragility 
fracture in their remaining lifetime 123. In elderly people fractures have a great impact 
on the quality of life. Hip fractures are the most devastating; they require the patient 
to be admitted to hospital and cause serious disability and excess mortality. The costs 
and other economic implications of treatment and rehabilitation of osteoporosis related 
fractures are high. The combined annual cost of all osteoporotic fractures in Europe 
only are 25 billion euros 124. Osteoporosis is an ageing related disease and since elderly 
people represent worldwide the fastest growing age group osteoporosis will impose a 
major economic burden on healthcare worldwide. 
Estrogen deficiency is a well-known cause of osteoporosis. Estrogens play a 
fundamental role in skeletal growth and homeostasis. Postmenopausal women who 
suffer from estrogen deficiency have frequently imbalanced bone remodeling. The 
absence of estrogens results in increased osteoclast activity resulting in significant bone 
loss and increased risk for fractures 14.
Another well-known cause of osteoporosis is caused by long-term glucocorticoid 
treatment. Glucocorticoids (e.g., prednisone) are one of the most frequently used drugs 
and are prescribed to control acute and chronic inflammation, auto immune disease, 
for treatment of leukemia and lymphomas and after organ transplantation. However, 
therapeutic use of glucocorticoids has negative side effects on bone remodeling and 
frequently results in glucocorticoid-induced osteoporosis (GIO). GIO occurs in two 
phases: first a rapid early phase in which bone mineral density is reduced as a result 
of excessive bone resorption. Secondly a slower progressive phase exists in which 
bone mineral density declines because of impaired bone formation 125, 126. Although the 
adverse effects of therapeutic glucocorticoid use on bone are known for a very long time 
little is known about the mechanism behind GIO. It is believed that GIO is at least in part 
induced by increased osteoblast and osteocyte apoptosis and stimulation of osteoclast 
formation 127-129. This negative effect is in marked contrast to the essential role of 
glucocorticoids for osteoblastogenesis as mentioned above. It should be considered, 
however, that the negative effect on bone is caused by high pharmacological levels of 
glucocorticoids for longer periods of time and does not reflect the normal physiological 
role of glucocorticoids in bone.
1.10 Treatment of osteoporosis
The majority of bone diseases are caused by increased bone resorption, rendering 
its inhibition a primary therapeutic objective 130. Inhibition of bone resorption can 
be accomplished by inhibiting osteoclast differentiation and/or osteoclast activity. 
Examples of drugs that can inhibit bone resorption are: estrogens and selective estrogen 
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receptor modulators (SERMs), calcitonin and bisphosphonates. Estrogens and SERMs 
inhibit osteoclast differentiation, whereas calcitonin and bisphosphonates inhibit the 
activity of osteoclasts. Bisphosphonates are, to date, the most effective drugs that 
inhibit bone resorption. Bisphosphonates are chemically stable analogues of inorganic 
pyrophosphate. They concentrate in bone and are absorbed by osteoclasts, where they 
inhibit osteoclast activity and survival. Consequently, this results in reduced bone 
resorption, lower bone turnover, and a positive bone balance. Since bisphosphonates 
inhibit osteoclast activity regardless of cause, they are used to treat several forms 
of bone loss including postmenopausal and glucocorticoid-induced osteoporosis, and 
cancer-induced bone loss 130. Currently, several novel drugs are in development that 
inhibit bone resorption. A promising one is based on inhibition of RANKL, a key cytokine 
in stimulating osteoclast differentiation 131, 132.
In contrast to the drugs that target bone resorption only a few therapies are known 
that promote bone formation in vivo. Parathyroid hormone (PTH) is an example of a 
bone-stimulating hormone. The anabolic activity of PTH on bone has been demonstrated 
in several clinical studies, which showed that intermittent PTH treatment enhances bone 
mass and reduces the risk of fractures 130, 133-136. In contrast, continuous PTH treatment 
decreases bone mass by an indirect stimulation of bone resorption 136. A relatively 
novel drug that seems to affect both bone resorption and bone formation is strontium 
ranelate. Although its mechanism of action is poorly understood it seems to inhibit bone 
resorption and stimulate bone formation in vitro and in vivo, resulting in enhanced bone 
quality and reduced risk for fractures 137.
1.11 Aim of this thesis
In the treatment of bone diseases only little attention has been paid to the development 
of compounds that promote bone formation. Inhibitors of bone resorption only prevent 
additional bone loss in the patient but cannot restore the initial loss in bone mass. 
Additional therapies that promote bone formation are therefore highly desirable and 
will be a valuable adjunct therapy in patients receiving inhibitors of bone resorption. 
To develop novel drugs that enhance bone formation, it is crucial to understand 
the biology of osteoblasts. In this thesis the control of human osteoblast differentiation 
and function (mineralization of the ECM) was studied in detail. This was achieved by 
culturing osteoblasts that under the proper stimuli produce a mineralized extracellular 
matrix. Importantly, we only used cells from human origin, which in the end will make 
the translation from in vitro finding to in vivo significance easier, especially since several 
discrepancies have been described in the control of osteoblasts derived from humans 
and osteoblasts derived from other species. 
In general, the following approaches were used to gain more insight into the biology 
of osteoblasts; 1] the impact of osteoblast regulatory factors on osteoblast differentiation 
and bone formation was studied, 2] the endogenous control of these regulatory factors 
during osteoblast differentiation was investigated, 3] genome-wide gene expression 
arrays were used, to map the genetic control of osteoblast differentiation. Together 
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these approaches should generate more knowledge about bone biology, which might 
guide us to the development of novel therapies that stimulate bone formation. The 
studies presented in this thesis primarily focused on the role of glucocorticoid, activin 
and Wnt signaling pathways in osteoblasts using the 3 approached described above.
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Abstract
Glucocorticoids (GCs) exert profound effects on bone and are essential for human 
osteoblast differentiation. However, GCs are still interpreted as negative regulators 
of bone formation, mainly caused by the detrimental effects on bone after clinical 
use of GCs. In this paper we emphasize the importance of GCs for proper human 
osteoblast differentiation and matrix mineralization. We show that human osteoblast 
differentiation needs to be triggered by GCs in a specific time-window during the early 
stages of development. Exposure to GCs in the beginning of osteoblast development 
induces a dose dependent increase in alkaline phosphatase activity and matrix 
mineralization. GC-induced differentiation stimulated expression of genes involved 
in bone formation and suppressed genes that negatively regulate bone formation and 
mineralization. Furthermore, we highlight the importance of local cortisol activation  in 
osteoblasts by expression of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1)
28
C
ha
pt
er
 2
G
lucocorticoid-induced osteoblast differentiation
29
2.1. Introduction
Osteoblast differentiation is a complex process regulated by many endocrine, paracrine and autocrine factors. In human and rat bone marrow stromal cells GCs 
are crucial for the induction of osteoblast differentiation and formation of a mineralized 
extracellular matrix 1-6. Although the exact role of GCs in regulating bone formation is 
unclear, it might be dependent on the duration and concentration of GC treatment and 
on the differentiation stage of both osteoblasts and osteoclasts 7-10. 
At a molecular level GC signaling is mediated via the GC receptor (GRα). GRα 
is expressed in almost all cell-types including osteoblasts 11 where it regulates gene 
expression by binding to GC responsive elements in the regulatory regions of several 
target genes, including osteocalcin, collagen Iα1 and transforming growth factor-β1 12-14.
Despite clear stimulation of bone formation by GCs in vitro, GCs are still interpreted 
as negative regulators of bone formation. This idea is mainly caused by the clinical use of 
GCs. GC therapy frequently results in bone loss and increased risk for fractures 15-17. This 
negative effect on bone is caused by high levels of GCs for longer periods and might not 
reflect the normal in vivo role of GCs in bone. Furthermore, most studies on osteoblast 
differentiation are performed using mouse osteoblasts that lack the need for GC treatment 
for the induction of differentiation 18, 19, which is in contrast to the human situation.
Therefore we emphasize in this paper the importance of GCs for proper human 
osteoblast differentiation and matrix mineralization. Moreover, we want to highlight 
the significance of pre-receptor regulation of GCs in osteoblasts by expression 
of 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1). 11β-HSD1 is found in almost 
all GC target tissues including osteoblasts 20, 21 and primarily displays reductase 
activity converting relative high levels of free cortisone into the biologically 
active cortisol. As a consequence 11β-HSD1 activity in osteoblasts provides an 
efficient mechanism for the local activation of GCs in bone and is an important 
autocrine determinant of osteoblast proliferation, differentiation and function 22-24.
2.2. Results and discussion
The essential role of glucocorticoids for proper osteoblast function
To demonstrate the importance of GCs for human osteoblast differentiation in more 
detail we used the pre-osteoblast model SV-HFO 25, which is a well-characterized 
osteoblast cell-line showing a controlled GC-induced differentiation process in a 3-week 
period. During this differentiation process an extracellular matrix (ECM) is formed 
and the process of mineralization is initiated around day 14 (Fig. 2.1 A). Moreover, 
GC-induced differentiation leads to increased sensitivity to mechanical loading 26. 
GC-induced differentiation was dose dependently increased by DEX as demonstrated 
by increased alkaline phosphatase (ALP) activity (Fig. 2.1 B) and mineralization. Matrix 
mineralization was induced at a minimal dose of 10 nM (data not shown). When we used 
mesenchymal stem cells derived from bone marrow GC treatment was as important for 
the induction of osteogenesis and proper matrix formation/mineralization (data not 
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shown), which is also demonstrated in several other studies 18, 17. 
Studies using human osteosarcoma cells and mouse osteoblasts show that GC 
treatment inhibits osteoblast cell number and proliferation 29-32. In contrast, other 
experiments show increased cell number and proliferation after GC treatment 33, 1, 5, 
which is supported by our observation of increased proliferation and cell number after 
GC-induced differentiation in human osteoblasts. Furthermore the number of apoptotic 
cells was not changed. This is shown in Fig. 2.1 C where we show increased cell number 
measured by the cultures DNA content, higher proliferation measured by thymidine 
incorporation and rate of apoptosis measured by annexin V staining.
Fig. 2.1. (A) DEX-induced matrix mineralization by SV-HFO osteoblasts. Cells were cultured in the presence and 
absence of 100 nM DEX. Cultures were stained for calcium deposition using Alizarin Red S. (B) Dose dependent 
increase of ALP activity (nmol/µgDNA/min) by DEX at days 7, 14 and 21 of SV-HFO culture, data shown represent 
a typical SV-HFO culture. (C) Effects of DEX on cultures DNA content (day 14), proliferation (day 6) and apoptosis 
(day 14).Values are means ± SEM **p < 0.01 compared to control. 
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Osteoblasts need to be directed by GCs at the early stages of development
Data clearly show that osteoblasts need to be directed by GCs to differentiate and 
mineralize. Moreover, osteoblasts need to be triggered by GCs in a specific time-window 
during the early stages of development. This is demonstrated in Fig. 2.2 where we 
treated osteoblasts with DEX in different time periods followed by quantification of 
mineral deposition at day 21. Continuous DEX treatment resulted in strong mineralized 
cultures as shown in Fig. 2.1 A and in the upper line in Fig. 2.2. Interestingly, shortening 
the treatment until days 16 and 12 also resulted in strongly mineralized cultures. When 
the treatment was further shortened (to day 9 or 7) matrix mineralization was decreased 
but still occurred. In contrast, cultures that were only treated with DEX starting at day 
12 or later failed to initiate mineralization. In summary, osteoblasts are directed by 
GCs at the beginning of development to differentiate, which eventually leads to matrix 
mineralization. Once the cells have entered the osteoblast differentiation pathway the 
mineralization process seems to be independent of GCs.
Fig. 2.2. Time dependent induction of mineralization by DEX. SV-HFO cultures were treated with DEX for different 
time periods indicated by the horizontal bold gray lines. Mineralization was measured at day 21.
GC-induced differentiation results in differential expression of genes involved in 
osteoblast differentiation and bone formation
Besides clear phenotypic characteristics like matrix mineralization, GC-induced 
differentiation regulates a wide variety of genes that control proper osteoblast 
differentiation and matrix mineralization. Here we show several examples of genes that 
are regulated after GC-induced differentiation. In these experiments we analyzed gene 
expression (mRNA) in the first, second and third week of culture in both differentiated 
(DEX-treated) and non-differentiated cultures (non-treated control). GC-induced 
differentiation resulted in up-regulation of osteoblast markers like Runx2, collagen Iα1 
and ALP (Fig. 2.3 A–C). In contrast, the non-collagenuous ECM protein osteopontin 
(OPN) was decreased by GC-induced differentiation together with the collagenase 
MMP1 (matrix metalloproteinase-1), which showed a strong suppression by DEX (40-
fold reduction) (Fig. 2.3 E and F). MMPs are extracellular proteins involved in ECM 
degradation and tissue turnover 34, 35. MMPs in turn are modulated by tissue inhibitors of 
metalloproteinase (TIMPs). Interestingly, GC-induced differentiation resulted in a strong 
(30-fold) induction of TIMP4 (Fig. 2.3 D). TIMPs are the major endogenous inhibitors of 
the MMPs and four TIMPs have been identified, although their specific inhibitory activities 
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towards the MMPs are not specified 35, 36, 37. Together, this indicates that during osteoblast 
differentiation and bone formation when matrix synthesis is needed, matrix degradation 
is suppressed by decreasing MMP1 expression and increasing TIMP4 expression. 
A more complex regulation of gene expression by DEX is shown for osteocalcin 
(OCN). OCN is the most abundant noncollagenuous protein in bone matrix, which gene 
contains a Vitamin D responsive element (VDRE) 38 resulting in increased levels of OCN 
mRNA and protein after 1α,25-dihydroxyvitamin D3 (vitD) treatment (10 nM, Fig. 2.4). 
At basal unstimulated conditions DEX did not influence OCN expression, however, vitD-
induced OCN expression was significantly reduced by DEX (Fig. 2.4) (day 14 of culture).
Both OCN and OPN are markers of osteoblast differentiation and OCN is used as a 
Fig. 2.3. Q-PCR data (mRNA expression) from non-differentiating (control) and differentiating (DEX treated) 
SV-HFO cultures at weeks 1–3. (A) Runx2/Cbfa1, (B) collagen Iα1, (C) alkaline phosphatase, (D) TIMP4, (E) 
osteopontin and (F) MMP1. Values are means ± SEM *p < 0.05; **p < 0.01 compared to control.
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Fig. 2.4. DEX inhibition of vitD-induced osteocalcin (OCN) expression. (A) OCN mRNA expression after DEX 
treatment in basal and vitD stimulated cultures (day 14). (B) OCN protein levels in the cultures supernatant after 
DEX treatment in basal and vitD stimulated cultures (day 14). Values are means ± SEM **p < 0.01 compared to vitD 
stimulated cultures.
serum marker for bone turnover. Nevertheless, these genes are down regulated by GC-
induced differentiation. At first sight this seems to contradict a positive role of GCs in 
osteoblast differentiation. However, despite their use as markers of bone formation, the 
exact role of OPN and OCN in the bone matrix is not fully understood. In contrast, they 
seem to act as negative regulators of the mineralization process. OPN- and OCN-deficient 
mice show increased amounts of mineral in their bones 39-41 and in vitro mineralization 
studies show that they directly inhibit hydroxyapatite crystal formation 42-44. 
In summary, during GC-induced osteoblast differentiation genes are either up-
regulated or down-regulated to stimulate osteoblast differentiation and proper matrix 
development. The genes discussed here are only a small set of the genes that account 
for osteoblast differentiation and matrix mineralization. In the literature also other 
genes are described that are regulated by DEX treatment in osteoblasts like, TGFβ1, 
bone sialoprotein, osterix and others 45, 46. GC-induced osteoblast differentiation 
probably results in differential expression of a large set of genes influencing pathways 
and processes involved in osteoblast differentiation and bone formation.
Osteoblasts produce cortisol via 11β-HSD1 expression
The importance of GCs for proper osteoblast differentiation and bone forming function is 
emphasized by osteoblastic expression of 11β-HSD1. Expression of 11β-HSD1 in osteoblasts 
provides an efficient mechanism for the local activation of GCs in bone. In a previous 
study we showed that 11β-HSD1 is regulated in a differentiation dependent manner in 
osteoblasts 24. This differentiation dependent regulation is summarized in Fig. 2.5 A, 
which shows that non-differentiated osteoblasts have low ALP activity but have strong 
increased levels of 11β-HSD1 to compensate for the lack of cortisol. Their differentiating 
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Fig. 2.5. Significance of 11β-HSD1 expression in human osteoblasts. (A) ALP activity (nmol/µgDNA/min) and 
11β-HSD1 activity (cortisone to cortisol conversion per µg DNA) in non-differentiating and differentiating osteoblasts 
at day 21 of culture. (B) SV-HFO cultures continuously incubated with 100 and 1000nM cortisone after which ALP 
activity was measured at day 30 of culture. Values are means ± SEM **p < 0.01 compared to control.
counterparts have high ALP activity but low 11β-HSD1. Fig. 2.5 B summarizes our previous 
results demonstrating the significance of 11β-HSD1 for osteoblast differentiation. High 
11β-HSD1 activity induced ALP activity by converting cortisone into biologically active 
levels of cortisol. This process eventually leads to matrix mineralization 24. Pre-receptor 
hormone regulation is not unique for GCs. Local levels of androgens and estrogens are 
also regulated by enzymes present in target tissues 47. Our previous work also showed 
that human osteoblasts express all the enzymes involved in the production of estradiol, 
e.g., aromatase, sulfatase and 17β-HSD isoenzyme 48.
Conclusion
The major aim of this study was to underscore the significance of GCs for proper human 
osteoblast differentiation. GCs are essential for human osteoblast differentiation, which 
is in marked contrast to the widely studied murine osteoblast differentiation. The human 
GC-induced differentiation process is summarized in Fig. 2.6 A. In the beginning of 
osteoblast development precursor cells need to be directed by GCs to differentiate into 
bone forming osteoblasts. During this process several genes are regulated which either 
stimulate or inhibit bone formation (Fig. 2.6 B). The importance of GCs on osteoblast 
differentiation is emphasized by the increasing conversion of inactive cortisone into 
active cortisol via 11β-HSD1 when cells are refrained from GCs. This process might then 
act as a feed-back mechanism by the cells for delayed differentiation.
The detrimental effects on bone after clinical use of GCs is in this respect unclear 
but might be caused by various potential mechanisms. It might be duration (i.e. long 
term) or concentration dependent. However, in our studies we examined a range of 
concentrations and treated the cells continuously. GC effect might be dependent on 
osteoblast differentiation stage and act inhibitory at very late stages of osteoblast 
differentiation and osteocytes 49, 50. Alternatively, the predominant negative effect of 
GCs could be mediated by the osteoclasts instead of the osteoblasts. Alternatively, in 
vivo interaction of GCs with other hormones/factors might be important. Moreover 
several secondary effects (e.g., at the intestine, kidney, parathyroid glands) after GC 
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treatment 
could impair proper bone formation and might not reflect the normal in vivo role of 
GCs in bone. To address these issues and to pinpoint the mechanism of the negative effect 
of GCs on bone extensive additional research is needed. Nevertheless the current study in 
conjunction with other data in literature unequivocally demonstrates the significance of 
GCs for proper osteoblast differentiation.
2.3. Materials and methods
Cell culture
SV-HFO cells were cultured in αMEM (GIBCO, Paisley, UK) supplemented with 20mM HEPES, 
pH 7.5 (Sigma, St. Louis, MO); streptomycin/penicillin; 1.8mM CaCl2 (Sigma); and heat-
inactivated FCS (GIBCO) at 37°C and 5 % CO2 in a humidified atmosphere. Thawed cells 
were precultured for 1 week in the presence of 10 % FCS. In this preculture, cells were 
seeded in a density of 5×103 vital cells/cm2 and were subcultured every week. During 
this preculture, SV-HFO cells remained in an undifferentiated stage. After preculturing, 
Fig. 2.6. (A) Schematic diagram depicting the role of GCs and 11β-HSD1 on osteoblast differentiation. (B) Regulation 
of gene expression by GCs on genes having either a positive or negative effect on bone formation.
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cells were seeded in a density of 10×103 vital cells/cm2 in the presence of 2 % charcoal-
treated FCS supplemented with 10 mM β-glycerophosphate (Sigma). Medium freshly 
supplemented with hormones was replaced every 2–3 days. Dexamethasone was 
purchased from Sigma and 1α,25-(OH)2D3 was generously provided by Dr. L. Binderup 
(Leo Pharmaceuticals, Ballerup, Denmark). For analysis, medium was collected and 
stored at −20°C and cells were scraped from the culture dish in PBS containing 0.1 % 
Triton X-100 and stored at −80°C. Cell lysates were sonicated on ice in a sonifier cell 
disrupter for 2×15 sec. before analysis.
DNA content
For DNA measurements, 100 μl SV-HFO cell lysates were treated with 200 μl heparin 
(8 IU/ml in PBS) and 100 μl ribonuclease A (50 μg/ml in PBS) for 30 min at 37ºC. This was 
followed by adding 100 μl ethidium bromide solution (25 μg/ml in PBS). Samples were 
analyzed on the Wallac 1420 victor2 (Perkin-Elmer, Wellesley, MA) using an extinction 
filter of 340 nm and an emission filter of 590 nm. For standards, calf thymus DNA (Sigma) 
was used.
Alkaline phosphatase (ALP) activity
ALP activity was assayed by determining the release of paranitrophenol from 
paranitrophenylphosphate (20mM in 1M diethanolamine buffer supplemented with 1mM 
MgCl2 at pH 9.8) in the SV-HFO cell lysates for 10 min at 37ºC. The reaction was stopped 
by adding 0.06M NaOH. Absorption was measured at 405 nm. Results were adjusted for 
DNA content of the cell lysates.
Mineralization
For quantification of the mineral content cell lysates were incubated overnight in 0.24M 
HCl at 4°C. Calcium content was colorimetrically determined with a calcium assay kit 
(Sigma) according to the manufacturer’s description. Results were adjusted for DNA 
content of the cell lysates. For Alizarin Red staining cell cultures were fixed for 60 min 
with 70 % ethanol on ice. After fixation, cells were washed twice with PBS and stained 
for 10 min with Alizarin Red solution (saturated Alizarin Red in demineralized water 
adjusted to pH 4.2 using 0.5 % ammonium hydroxide).
Apoptosis assay
Apoptosis was measured through the binding of annexin V and uptake of propidium 
iodide (PI) by flow cytometry using a Apoptest-FITC kit (Nexins research, Kattendijke, 
The Netherlands). For analysis 10,000 osteoblasts were counted using a FACScalibur 
(Becton Dickinson). Percentage total apoptotic cells was calculated by counting vital 
(unlabeled), apoptotic (annex in V stained), necrotic (PI stained)  and  late  apoptotic 
cells  (double stained).
Proliferation assay
Proliferation was examined by [3H]-thymidine uptake measurements. SV-HFO cells were 
seeded into 96-well plates, in differentiating (100 nM DEX) and non-differentiating 
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conditions. After culture for 6 days [3H]-thymidine (Amersham, UK) was added to a 
concentration of 1 μCi/ml and incubated for 7 h. Cells were then harvested onto glass 
fibre mats (TomtecHarvester96; Hamden, CT) and radioactivity measured with a Wallac 
MicroBeta scintillation counter.
Osteocalcin production
Osteocalcin was determined in the cultures medium. Osteocalcin was assayed by 
radioimmunoassay by incubating overnight with 125Iodide labeled human osteocalcin 
and anti-human osteocalcin, kindly provided by Dr. C.M. Gundberg, Department of 
Orthopaedics and Rehabilitation, School of Medicine, New Haven, Connecticut, USA. 
Results were adjusted for DNA content of the cell lysates.
11β-HSD1 activity
Cortisone  to  cortisol  conversion  in  SV-HFO  cells  was  measured  as  described 
previously 24.
Quantification of mRNA expression
Total RNA was isolated using RNA-Bee solution (Tel-Test, Friendwood, TX) according to 
the manufacturer’s protocol. To remove calcium (derived from extracellular matrix), 
RNA was precipitated by overnight incubation with 4M LiCl and 50mM EDTA at −20°C. 
After precipitation and centrifugation for 30 min at 14,000 rpm and 4°C, the RNA pellet 
was washed four times with 70 % ethanol and dissolved in H2O. The total amount of RNA 
was quantified using the RiboGreen RNA Quantitation Kit (Molecular Probes, Eugene, 
OR). One microgram total RNA was reverse transcribed into cDNA using a cDNA synthesis 
kit and according to the protocol of the manufacturer (MBI Fermentas, St. Leon-Rot, 
Germany), using 0.5 μg oligo(dT)18 and 0.2 μg random hexamer primers. Quantitative 
real-time PCR was carried out using an ABI 7700 sequence detection system (Applied
Biosystems, Foster City, CA). Reactions were performed in 25μl volumes using a qPCR 
core kit (Eurogentec, Seraing, Belgium). Reaction mixes contained 20 ng cDNA, 5mM 
MgCl2, 200 /M dNTPs, and 0.025 U/μl Hot GoldStar enzyme. Primer and probe sets were 
designed, using the Primer Express software (version 1.5; Applied Biosystems), amplicons 
overlapped at least one exon boundary. Cycling conditions were 50°C for 2 min, 95°C for 
10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Statistics
Data presented are the results of at least two independent experiments performed in 
triplicate. Values are the means ± SEM Significance was calculated using the Student’s 
t-test. 
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Chapter 3
11ß-Hydroxysteroid dehydrogenase expression 
and glucocorticoid synthesis are directed 
by a molecular switch during osteoblast 
differentiation
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Abstract
11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) plays an important role in the 
pre-receptor regulation of corticosteroids by locally converting cortisone into active 
cortisol. To investigate the impact of this mechanism on osteoblast development, 
we have characterized 11β-HSD1 activity and regulation in a differentiating human 
osteoblast cell line (SV-HFO). Continuous treatment with the synthetic glucocorticoid 
dexamethasone induces differentiation of SV-HFO cells during 21 days of culture. 
Using this cell system, we showed an inverse relationship between 11β-HSD1 activity 
and osteoblast differentiation. 11β-HSD1 mRNA expression and activity were low and 
constant in differentiating osteoblasts. However, in the absence of differentiation 
(no dexamethasone), 11β-HSD1 mRNA and activity increased strongly from day 12 
of culture onward, with a peak around day 19. Promoter reporter studies provided 
evidence that specific regions of the 11β-HSD1 gene are involved in this differentiation 
controlled regulation of the enzyme. Functional implication of these changes in 
11β-HSD1 is shown by the induction of osteoblast differentiation in the presence of 
cortisone. The current study demonstrates the presence of an intrinsic differentiation-
driven molecular switch that controls expression and activity of 11β-HSD1 and 
thereby cortisol production by human osteoblasts. This efficient mechanism by which 
osteoblasts generate cortisol in an autocrine fashion to ensure proper differentiation 
will help to understand the complex effects of cortisol on bone metabolism.
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3.1 Introduction
Glucocortoids exert diverse effects on bone metabolism. In human and rat bone marrow stromal cells, glucocorticoids are crucial for the induction of osteoblast 
differentiation and formation of a mineralized extracellular matrix 1-3. Paradoxically, 
glucocorticoids in pharmacological doses cause osteoporosis, mainly by suppressing 
bone formation but also through effects on bone resorption 4-6. Overall, the action of 
glucocorticoids on bone is complex, poorly understood, and is dependent on the duration 
and concentration of glucocorticoid treatment and the differentiation stage of both 
osteoblasts and osteoclasts 7-10. 
At a molecular level, glucocorticoid signaling is mediated via the glucocorticoid 
receptor (GRα). GRα is expressed in almost all cell types including osteoblasts 11, in 
which it regulates gene expression by binding to glucocorticoid responsive elements 
in the regulatory regions of several target genes, including osteocalcin, collagen Iα1, 
and transforming growth factor-β1 12-14. Regulation of glucocorticoid responsiveness may 
occur at several levels, including changes in GRα expression 15  and at a postreceptor 
level through variation in GRα accessory proteins 16. Glucocorticoid action has also 
been shown to be regulated at prereceptor level by isozymes of 11β-hydroxysteroid 
dehydrogenase (11β-HSD), which catalyze tissue-specific synthesis and metabolism 
of GRα ligands 17. 11β-HSD type 1 (11β-HSD1) is found in almost all glucocorticoid 
target tissues and primarily displays reductase activity, converting cortisone into the 
biologically active cortisol 18, 19. 11β-HSD2 converts cortisol into inactive cortisone and is 
found primarily in mineralocorticoid target tissues, in which it protects the nonselective 
mineralocorticoid receptor from activation by glucocorticoids 20, 21. In bone, both 
isozymes of 11β-HSD (mRNA, protein, and enzyme activity) have been demonstrated, 
with 11β-HSD1 being the most prominent isozyme in human osteoblasts whereas 11β-
HSD2 is barely detectable 22, 23. Reductase activity of 11β-HSD1 in osteoblasts provides an 
efficient mechanism for the local activation of glucocorticoids in bone. As a consequence, 
the regulation of 11β-HSD1 activity in osteoblasts is likely to be an important autocrine 
determinant of osteoblast proliferation, differentiation, and function 24, 25.
Previous studies have highlighted the potential importance of osteoblastic 11β-HSD1 
in predicting the detrimental effects of corticosteroids on bone 26, 27, but, as yet, the role 
of 11β-HSD1 in normal osteoblast development remains unclear. In studies presented 
here, we have used a nonneoplastic human osteoblast cell line to study the regulation 
of 11β-HSD1 and the specific impact on osteoblast differentiation and mineralization. 
Data indicate that regulation of 11β-HSD1 expression and activity are integral features 
of osteoblast differentiation, providing a potent mechanism for autocrine regulation of 
bone formation
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3.2 Results
Glucocorticoids induce osteoblast differentiation and mineralization
During SV-HFO culture, osteoblast differentiation was monitored by measuring DNA 
levels, alkaline phosphatase (ALP) activity, and mineralization. In basal untreated 
cultures, ALP activity remained very low throughout the entire 23-days culture period. 
In contrast, cultures that were treated continuously with dexamethasone (DEX) showed 
a dose-dependent increase in ALP activity, which peaked around day 14 (see Figs. 3.1 A 
and 3.4 A). In these DEX-treated cultures, mineralization was initiated around day 14 
of culture and increased up to day 19, after which it seemed to level off (Fig. 3.1 B). 
In the absence of DEX, cultures showed no evidence of osteoblast differentiation and 
mineralization (Fig. 3.1 A and B). Both DEX-treated and non-DEX-treated cultures showed 
a continuous increase in DNA content during culture, although differentiating cultures 
Fig. 3.1. ALP Activity (A), Mineralization (B), and DNA content (C) during SV-HFO culture in DEX-treated (1 µM) 
(Differentiating) and nontreated (nondifferentiating) cells. Values shown are the results of one typical SV-HFO 
culture.
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showed a stronger increase in DNA content (Fig. 3.1 C). DEX-induced differentiation and 
mineralization was completely blocked by the GR antagonist mifepristone (2 µM) (data 
not shown). Throughout the remainder of the study, DEX-treated (1 µM) and non-DEX-
treated cultures were referred as differentiating and nondifferentiating osteoblasts, 
respectively.
 GRα mRNA expression in SV-HFO cells
In both differentiating and non-differentiating cultures, GRα mRNA could be easily 
detected and mRNA expression was constant during the entire culture period (day 5 
to 23). However, at all days of culture differentiating osteoblasts showed lower GRα 
mRNA levels (0.7 ± 0.1) compared with their nondifferentiating counterparts (Fig. 3.2).
Fig. 3.2. GRα mRNA expression in differentiating and nondifferentiating SV-HFO cells. Results are presented as 
expression relative to control at week 1, 2, and 3 of culture. Values are means ± SEM (n ≥ 6). **, P < 0.01 compared 
with nondifferentiating cultures.
11β-HSD1 mRNA expression in differentiating and nondifferentiating osteoblasts
At the start of culture (day 5 to 9), 11β-HSD1 mRNA was expressed at similar levels in both 
differentiating and nondifferentiating SV-HFO cultures. However, after day 12, 11β-HSD1 
mRNA expression increased strongly in nondifferentiating osteoblasts. This resulted in 
an up-regulation of about 2-fold at day 12, increasing to a 15-fold higher expression at 
day 19 (Fig. 3.3 A). By contrast, 11β-HSD1 mRNA expression in differentiating cultures 
remained constant during the entire culture period. Induction of differentiation using 
10 nM DEX resulted in similar levels of 11β-HSD1 mRNA when compared with treatment 
with 1 µM DEX (data not shown). To demonstrate that increased 11β-HSD1 mRNA 
expression was not due to differentiation into adipocytes, we tested SV-HFO cultures 
for Oil-Red-O staining as well as mRNA expression of the adipocyte marker adipocyte 
lipid-binding protein (aP2). Cultures were negative for Oil-Red-O staining and, after 40 
cycles of RT-PCR, we could not detect any aP2 expression in both differentiating and 
nondifferentiating cultures (data not shown).
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11β-HSD1 activity in differentiating and nondifferentiating osteoblasts
Next we examined 11β-HSD1 activity in relation to osteoblast differentiation and 
mineralization. To demonstrate 11β-HSD1 reductase activity in SV-HFO cells, we 
analyzed cortisone to cortisol conversion after addition of 1 µM cortisone to the culture 
medium. In differentiating cultures, 11β-HSD1 activity was constant (86 ± 11 pmol/
µg·24 h; mean ± SEM), whereas nondifferentiating cultures showed significantly higher 
11β-HSD1 activity: 341 ± 48 and 391 ± 36 pmol/µg·24 h at day 7 and 12, which increased 
to 701 ± 49 and 748 ± 56 pmol/µg·24 h at day 14 and 19, respectively (Fig. 3.3 B). 
This activity profile shows similarity to the 11β-HSD1 mRNA expression profile in 
differentiating and nondifferentiating cultures. 11β-HSD1 activity was completely 
blocked by addition of the 11β-HSD inhibitor 18β-glycyrrhetinic acid (GA) (Fig. 3.3 C). 
Finally, the presence or absence of β-glycerophosphate had no effect on 11β-HSD1 
activity in either differentiating and nondifferentiating cultures (data not shown). 
Fig. 3.3. Relative 11ß-HSD1 mRNA expression (A) and 11ß-HSD1 activity (B) in differentiating and nondifferentiating 
SV-HFO cultures for incubation protocols, see insets and §3.4 Materials and methods. Values are means ± SEM (n = 4). 
(C) Inhibition of 11ß-HSD1 activity by GA in SV-HFO cells. After 19 days of culture, 11ß-HSD1 activity was measured 
in absence and presence of 2.5 µM GA. Values are means ± SEM (n = 4). **, P < 0.01 compared with nondifferentiating
osteoblasts. #, P < 0.05 compared with levels at day 7 of nondifferentiating osteoblasts.
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Inverse relationship between osteoblast differentiation and 11β-HSD1 activity
The data presented thus far suggested an inverse relationship between osteoblast 
differentiation and 11β-HSD1 expression and activity. To investigate this in more 
detail, SV-HFO cells were cultured for 19 days with various concentrations of DEX. DEX 
treatment caused a dose-dependent increase in ALP activity and mineralization, which 
coincided with a dose-dependent decrease in 11β-HSD1 activity (Fig. 3.4 A and B), 
substantiating the inverse relation between 11β-HSD1 activity and differentiation. This 
inverse relationship between ALP and 11β-HSD1 activity was tightly coupled as indicated 
by the DEX EC50 values of 3 ± 0.5 and 5 ± 0.5 nM, respectively. Mineralization was 
induced by DEX with an EC50 value of 9 ± 1 nM DEX.
Effects of short-term DEX treatment on 11β-HSD1 expression and activity
In the study so far, osteoblast differentiation was induced by continuous DEX treatment, 
resulting in a low and constant 11β-HSD1 mRNA expression and activity. These results are 
Fig. 3.4. Inverse relation between DEX-induced differentiation and 11ß-HSD1 activity. SV-HFO cells were cultured 
for 19 days in the presence of 0, 2, 4, 8, 16, 63, and 250 nM and 1 µM DEX. Subsequently, ALP activity, 11β-HSD1 
activity (A), and mineralization (B) were measured. Values are means ± SEM (n = 4). 
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in contrast to those of other studies using a variety of cell types in which DEX treatment 
stimulated 11β-HSD1 activity. However, these results were obtained after short-term 
DEX incubation. Therefore, we studied the effect of short-term DEX incubation on the 
regulation of 11β-HSD1 mRNA expression and activity in nondifferentiating SV-HFO 
osteoblasts. 
At day 7 of culture, 11β-HSD1 mRNA expression decreased after short-term 
DEX treatment (1 µM, 24 h). However, at later time points during SV-HFO culture 
(day 14 and 19), 11β-HSD1 mRNA expression was not affected by short-term DEX 
treatment (Fig. 3.5 A). To study short-term DEX effects on 11β-HSD1 activity, cells were 
exposed for 48 h to DEX (1 µM); within this 48 h, the final 24 h was used to measure 
11β-HSD1 activity. This resulted in decreased 11β-HSD1 activities at day 7 matching 
the observed data at the mRNA level. At later time points, 11β-HSD1 activity was not 
decreased by short-term DEX treatment. At day 12 and 14, even a significant increase 
was observed (Fig. 3.5 B). These data show that short-term DEX-treatment does not 
Fig. 3.5. Short-term effects of DEX on 11β-HSD1 mRNA expression and activity during SV-HFO culture. (A) Effects 
of 24 h DEX treatment (1 µM) on 11β-HSD1 mRNA expression. Results are presented as expression relative to 
control at day 7, 14, and 19 of culture. For incubation protocols see inset. Values are means ± SEM (n ≥ 4). (B) 
11β-HSD1 activity after 24–48 h of DEX treatment (1 µM DEX) at day 7, 12, 14, and 19 of culture. For incubation 
protocols see insets. Values are means ± SEM (n = 4). *, P < 0.05; **, P < 0.01 compared with control.
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decrease 11β-HSD1 expression and activity at later stages of culture in contrast to DEX-
induced differentiation.
11β-HSD1 promoter activity in differentiating and nondifferentiating cultures
To gain more insight into the background of the differentiation-driven regulation of 
11β-HSD1 expression, we used a luciferase reporter gene under control of the 11β-HSD1 
promoter (HSD11B1). We used several lengths of the HSD11B1 promoter containing 
the –261 to +77, –301 to +77, –804 to +77, –1382 to +77, and –2506 to +77 region of 
the promoter. During SV-HFO culture, these reporter constructs were transiently 
transfected at day 7, 12, 14, or 19 of culture. At day 7 of culture, all the constructs 
showed similar promoter activity in differentiated and nondifferentiated cultures. 
Activity of the short –261 to +77 region of the HSD11B1 promoter was identical at all 
time points in differentiating and nondifferentiating cultures (Fig. 3.6 A). However, 
reporter constructs containing more upstream regions of the HSD11B1 promoter 
were sensitive to induction in the absence of differentiation from day 12 onward
(Fig. 3.6 B, C, D, and E). The reporter construct containing the –1382 to +77 region 
of the HSD11B1 promoter was the most sensitive to induction in the absence of 
differentiation (Fig. 3.6 D). Further increasing the length of the promoter up to 
–2506 resulted in a lower induction (Fig. 3.6 E). These results show that the HSD11B1 
promoter is induced from day 12 onward in the absence of osteoblast differentiation. 
Moreover, important differentiation-dependent regulatory elements are located in 
region –1382 to –261 of the HSD11B1 promoter. To show that promoter activity is not 
silenced shortly after DEX exposure, we analyzed promoter activity after 24 and 48 h 
of DEX exposure (1 µM) at day 7, 12, 14, and 19. We studied both the –804 to +77 (data 
not shown) and –1382 to +77 (Fig. 3.6 F) region of the HSD11B1 promoter in relation 
to short-term DEX treatment. These two promoters showed a clear suppression after 
DEX-induced differentiation (Fig. 3.6 C and D); however, short-term DEX treatment did 
not chance promoter activity (Fig. 3.6 F). These results support the mRNA and activity 
data obtained after short-term DEX treatment.
CAAT/Enhancer binding protein α (C/EBPα) and C/EBPβ mRNA expression in 
differentiating and nondifferentiating osteoblasts
Two important candidates for HSD11B1 promoter regulation are C/EBPα  and C/EBPβ.
The presence of both C/EBPα and C/EBPβ mRNA was demonstrated in SV-HFO 
cells. However, no difference in mRNA expression between differentiating and 
nondifferentiating osteoblasts was found (data not shown).
Functional consequences of osteoblastic 11β-HSD1 activity
To demonstrate a functional role of 11β-HSD1 in osteoblast differentiation, we cultured 
SV-HFO cells in the continuous presence of 100 or 1000 nM cortisone. To prevent total 
removal of osteoblast-produced cortisol at every medium replacement, medium was 
only partially replaced. Treatment with cortisone resulted in a dose-dependent increase 
in ALP activity up to 3.2-fold at day 30 (Fig. 3.7 A). Despite this clear induction of 
ALP activity, cortisone did not induce mineralization. To further study the effect on 
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Fig. 3.6. HSD11B1 promoter activity in differentiating and nondifferentiating SV-HFO cultures. Cultures were 
transiently transfected with luciferase reporter constructs containing the –261 to +77 (A), –301 to +77 (B), –804 
to +77 (C), –1382 to +77 (D) and –2506 to +77 (E) region of the HSD11B1 promoter at day 7, 12, 14, and 19 
of culture. Values are means ± SEM (n ≥ 5). *, P < 0.05; **, P < 0.01 compared with differentiating cultures. 
(F) Promoter activity of the –1382 to +77 region after short-term DEX treatment (1 µM, 24 and 48 h) at
day 7, 12, 14, and 19 of culture.
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mineralization, we cotreated the cells with 1α,25-dihydroxyvitamin D3 (1α,25-[OH]2D3) 
as a facilitator of mineralization. Treatment with 10 nM 1α,25-(OH)2D3 alone increased 
ALP activity, whereas it was not sufficient to induce mineralization. However, 
cotreatment of 1000 nM cortisone with 1α,25-(OH)2D3 resulted in a strong induction of 
mineralization and ALP activity after 30 days of culture (Fig. 3.7 C and D). This effect 
on mineralization and on ALP activity was completely blocked by the addition of the GR 
antagonist mifepristone (2  µM) (Fig. 3.7 C and D). To prove a specific role for 11β-HSD 
in cortisone-induced ALP activity, cells were incubated with the 11β-HSD inhibitor GA. 
Cortisone-induced ALP activity was completely blocked by the addition of 2.5 µM GA. 
Addition of GA had no effect on either basal ALP activity or cortisol-induced ALP activity 
(Fig. 3.7 B).
Fig. 3.7. Functional consequences of osteoblastic 11β-HSD1 expression. (A) Induction of ALP activity after 
cortisone incubation. Cells were cultured in the continuous presence of 100 or 1000 nM cortisone. Results are 
presented as ALP activity compared with non treated controls at day 7, 14, 21, and 30 of culture. Values are means 
± SEM (n = 6). **, P < 0.01 compared with nondifferentiating osteoblasts. (B) Inhibition of cortisone induced ALP 
activity by GA. SV-HFO cells were cultured for 21 days in the presence of cortisone (100 and 1000 nM), cortisol 
(100 and 1000 nM), and vehicle with or without 2.5 µM GA. Values are means ± SEM (n = 3). **, P < 0.01 compared 
with control without GA. (C and D) Cortisone induced ALP activity and mineralization in the presence or absence of 
1α,25-(OH)2D3 (10 nM) and the GR antagonist mifepristone (RU) (2 µM) after 30 days of culture.
3.3 Discussion
The current study demonstrates the presence of an intrinsic differentiation-driven molecular switch that controls the expression and activity of 11β-HSD1 and 
thereby cortisol production in human osteoblasts. In the absence of exogenously added 
glucocorticoids and osteoblast differentiation, 11β-HSD1 expression and activity are 
strongly induced. By contrast, cells induced to differentiate and mineralize in the 
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presence of glucocorticoids show low levels 11β-HSD1 activity. In other words, 11β-HSD1 
acts to generate cortisol in an autocrine fashion to facilitate proper differentiation 
and mineralization. Conversely, when sufficiently high levels of active glucocorticoids 
(cortisol, dexamethasone, prednisolone) are available to induce osteoblast 
differentiation, endogenous glucocorticoid activation via 11β-HSD1 remains minimal. 
An additional benefit of this latter phenomenon is that unwanted and detrimental 
increases in local glucocorticoid concentrations is prevented. This mutual regulation 
provides an elegant and efficient mechanism by which osteoblast differentiation and 
local glucocorticoid levels are regulated in a balanced manner. 
Under the influence of glucocorticoids, SV-HFO cultures proceed through a tightly 
controlled process of differentiation resulting in an extracellular protein matrix that fully 
mineralizes. Without glucocorticoid treatment, SV-HFO cultures do not differentiate and 
show no mineralization, demonstrating the importance of glucocorticoids for human 
osteoblast differentiation and mineralization. As a consequence, the regulation of 
11β-HSD1 activity in osteoblasts is likely to be an important autocrine determinant of 
osteoblast proliferation, differentiation, and function 24, 25 .
The actions of glucocorticoids are mediated via GRα, which is expressed in almost 
all cell types, including osteoblasts 11. In SV-HFO cells, GRα mRNA was clearly expressed 
and, in addition to increased 11β-HSD1 activity, nondifferentiated osteoblasts expressed 
GRα at a higher level than differentiating osteoblasts. Together, these observations 
indicate that absence of glucocorticoid-induced differentiation results in a cellular 
sensitization to the glucocorticoid endocrine system.
In agreement with previous studies using primary cultures of human osteoblasts  22, 23, 
11β-HSD1-mediated cortisol generation appears to be the predominant form of 
glucocorticoid metabolism in SV-HFO cells. Regulation of 11β-HSD1 expression and 
activity by glucocorticoids have been reported for hepatocytes, adipocytes, and 
fibroblast and primary osteoblasts, all of which showed enhanced 11β-HSD1 activity 
after glucocorticoid exposure 26, 28-30, resulting in a “feed-forward” mechanism after 
glucocorticoid exposure. In vivo, Jamieson et al. 31 demonstrated that glucocorticoids 
regulate 11β-HSD1 mRNA in a complex tissue- and time-specific manner, suggesting a 
reduction of 11β-HSD1 by DEX. Glucocorticoid-induced differentiation (continuous DEX 
treatment) of SV-HFO osteoblasts suppressed 11β-HSD1 mRNA expression and activity, 
whereas short-term treatment with DEX did not suppress 11β-HSD1 activities, particularly 
at later stages of culture. Moreover an increase in 11β-HSD1 activity was measured after 
short-term DEX treatment. This demonstrates that, in osteoblasts, glucocorticoids can 
regulate 11β-HSD1 in two different ways. Firstly, short-term glucocorticoid exposure 
directly increases 11β-HSD1 activity, resulting in a feed-forward of glucocorticoid action. 
Secondly, we show that, in osteoblasts, continuous exposure to glucocorticoid indirectly 
regulates 11β-HSD1 expression by inducing a differentiation-driven switch that represses 
11β-HSD1 activity. In the first week of culture, short-term DEX treatment resulted in 
the suppression of 11β-HSD1 activity and mRNA expression. In this first week of culture, 
SV-HFO cells are very sensitive to the induction of differentiation by glucocorticoids. 
Therefore, 24 h of DEX exposure may be sufficient to initiate osteoblast differentiation 
and, as a result, suppression of 11β-HSD1 levels.
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In the absence of glucocorticoid-induced differentiation, 11β-HSD1 mRNA expression 
was strongly induced in the second week of culture. Interestingly, at this same time 
point of culture, differentiating cultures showed peak ALP activity and initiated the 
process of mineralization. Why this induction of 11β-HSD1 expression is initiated after 
exactly 2 weeks of culture is unclear. Promoter reorganization or differential expression 
of transcription factors at this time point might mediate this differentiation-controlled 
switch in 11β-HSD1 expression. In rat osteoblasts, it has been demonstrated that, in 
more differentiated osteoblasts, osteocalcin expression is strongly induced after the 
osteocalcin gene is opened by remodeling of the chromatin structure 32, 33. Luciferase 
reporter-plasmids under the control of various HSD11B1 promoter fragments provided 
evidence that specific regions of the HSD11B1 promoter are sensitive to activation in 
the absence of osteoblast differentiation. This indicates that regulation of the HSD11B1 
promoter during this switch is at least partly regulated by differences in transcription 
factor binding to the HSD11B1 promoter in differentiating and nondifferentiating 
osteoblasts. The absence of promoter induction by the short –261 +77 promoter indicates 
that important differentiation dependent regulatory elements driving expression in 
nondifferentiating cells are located in region –1382 to -261. Two important candidates 
for 11β-HSD1 promoter regulation are C/EBP  α and C/EBPβ. These proteins are known 
to regulate 11β-HSD1 promoter activity in liver cells, in which C/EBPα promotes and 
C/EBPβ represses 11β-HSD1 transcription 34. Furthermore, these genes are known to 
be regulated by cortisol 35, 36. Both C/EBPα and C/EBPβ are expressed in SV-HFO cells. 
However, mRNA expression of these genes was identical in nondifferentiating and 
nondifferentiating SV-HFO osteoblasts.
The current study shows that 11β-HSD1 activity is tightly related to osteoblast 
differentiation and has significant consequences for osteoblast differentiation and 
function. In the presence of sufficient amounts of cortisone, SV-HFO osteoblasts 
induce, in an autocrine/paracrine way, differentiation by generating biologically 
active levels of cortisol. Autocrine regulation of glucocorticoids action has also been 
shown in adipocytes and is a potentially important target for obesity therapy 37. 
Freshly isolated adipose stromal cells mainly convert cortisol into cortisone. 
However, when adipocyte differentiation is initiated, 11β-HSD1 dehydrogenase 
activity is switched into reductase activity generating cortisol and thereby promoting 
adipocyte differentiation 38. This shows that both osteoblast and adipocytes use 11β-
HSD1 activity to regulate their differentiation in an autocrine manner. However, in 
osteoblasts there is an inverse relation between 11β-HSD1 activity and differentiation, 
whereas adipocytes increase their cortisol production during further differentiation.
 In vivo, glucocorticoids are bound to cortisol binding globulin. Cortisol binding globulin 
binds cortisol with approximately 10-fold higher affinity than cortisone 39, resulting in 
higher free levels of the 11β-HSD1 substrate cortisone than the active glucocorticoid 
cortisol. Therefore, local glucocorticoid metabolism might indeed play a significant role 
in regulating osteoblast differentiation and function in vivo. This pre-receptor hormone 
regulation is not unique for glucocorticoids. Local levels of androgens and estrogens are 
also regulated by enzymes present in target tissues 40. Our previous work has shown that 
human osteoblasts express all the enzymes involved in the production of estradiol, e.g. 
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aromatase, sulfatase, and 17β-HSD isoenzymes 41. This means that human osteoblasts 
have the capacity to produce active estrogens and glucocorticoids locally. Moreover, 
production of these hormones is regulated in a differentiation dependent manner.
This study demonstrates the importance of autocrine 11β-HSD1 action for proper 
osteoblast differentiation and function. However, the 11β-HSD1 knockout (–/–) mouse 
does not show a clear change in bone phenotype 42; the authors of this study highlighted 
important caveats why this 11β-HSD1–/– mouse might not be necessarily a good model to 
study the effects of local glucocorticoid metabolism on human bone. Firstly, the global 
loss of 11β-HSD1 leads to a profound alteration in the hypothalamic-pituitary-adrenal 
axis, which may completely alter the set-point of circulating glucocorticoid effects. 
Secondly, the background strain of the 11β-HSD1–/– mouse shows expression of both 
11β-HSD1 and 11β-HSD2 in bone, which is in direct contrast to humans, which show 
only expression of 11β-HSD1. A bone-specific knockout of 11β-HSD1 will clearly provide 
some answers to the issues outlined above. Evidence that endogenous glucocorticoid 
metabolism has significant effects in vivo on bone is illustrated by the 11β-HSD2 bone 
specific transgenic mouse 43. These animals are essentially the bone-specific, transgenic 
equivalents of the 11β-HSD1–/– mice and show changes in a variety of bone parameters 
when compared with wild-type controls.
In conclusion, the current study demonstrates a tight control of 11β-HSD1 activity 
during osteoblast differentiation, thereby supplying adequate amounts of cortisol to 
support osteoblast differentiation and preventing excessive and detrimental amounts of 
cortisol in mature osteoblasts. Furthermore, the data presented indicate the presence 
of a molecular switch that regulates HSD11B1 promoter activity dependent on the state 
of cellular differentiation.
3.4 Materials and methods
Cell culture
SV-HFO 44 cells were cultured in  MEM (GIBCO, Paisley, UK) supplemented with 20 mM 
HEPES, pH 7.5 (Sigma, St. Louis, MO); streptomycin/penicillin; 1.8 mM CaCl2 (Sigma); 
and heat-inactivated FCS (GIBCO) at 37°C and 5 % CO2 in a humidified atmosphere. 
DEX, cortisone, and mifepristone (RU 38486) were purchased from Sigma; 1α,25(OH)2D3 
was generously provided by Dr. L. Binderup (Leo Pharmaceuticals, Ballerup, Denmark). 
Thawed cells were precultured for at least 1 week in the presence of 10 % FCS. In this 
preculture, cells were seeded in a density of 5 x 103 vital cells per centimeter squared 
and were subcultured every week. During this preculture, SV-HFO cells remained in 
an undifferentiated stage and cells were only used between passages 8 and 13. After 
preculturing, cells were seeded in a density of 10 x 103 vital cells per centimeter squared 
in the presence of 2 % charcoal-treated FCS supplemented with 10 mM β-glycerophosphate 
(Sigma) (added as a phosphate donor to facilitate the mineralization process) and 
were grown without subculturing. Medium freshly supplemented with hormones or 
other additives was replaced every 2–3 days. In experiments in which medium was 
partially replaced, replacements were as follows: day 2 and 5, 60 %; day 7 and 9, 75 %; 
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day 12, 14, 19, 21, 26 and 28, 86 %; day 16 and 23, 100 % fresh medium was added. For 
analysis, medium was stored at –20°C and cells were scraped form the culture dish in 
PBS containing 0.1 % Triton X-100 and stored at –80°C. Before analysis, cell lysates were 
sonicated on ice in a sonifier cell disrupter for 2 x 15 sec.
DNA content
For DNA measurements, 100 µl SV-HFO cell lysates were treated with 200 µl heparin 
(8 IU/ml in PBS) and 100 µl ribonuclease A (50 µg/ml in PBS) for 30 min at 37°C. This was 
followed by adding 100 µl ethidium bromide solution (25 µg/ml in PBS). Samples were 
analyzed on the Wallac 1420 victor2 (PerkinElmer, Wellesley, MA) using an extinction 
filter of 340 nm of and emission filter of 590 nm. For standards, calf thymus DNA (Sigma) 
was used.
 
ALP activity
ALP activity was assayed by determining the release of paranitrophenol from 
paranitrophenylphosphate (20 mM in 1 M diethanolamine buffer supplemented with 1 
mM MgCl2 at pH 9.8) in the SV-HFO cell lysates for 10 min at 37°C. The reaction was 
stopped by adding 0.06 M NaOH. Absorption was measured at 405 nm. Results were 
adjusted for DNA content of the corresponding cell-lysates.
Mineralization
SV-HFO cell lysates were incubated overnight in 0.24 M HCl at 4°C. Calcium content 
was colorimetrically determined with a calcium assay kit (Sigma) according to the
manufacturer’s description. Results were adjusted for DNA content of the corresponding 
cell lysates. 
Oil-Red O staining
Cell cultures were fixed for 10 min with 10 % formalin in PBS. After fixation, cells were 
washed with PBS and stained for at least 20 min with Oil-Red-O solution (2:3 vol/vol 
H2O : n-propanol containing 0.5 % Oil-Red-O). After staining, cells were washed twice 
with demineralized water and examined under the microscope for staining.
11β-HSD1 activity during SV-HFO culture
Cells were cultured in the absence or presence of DEX and at various days during culture 
1 µM cortisone was added to the culture medium. After 24 h, culture medium was 
collected and cortisol concentrations were analyzed by a chemoluminescence-based 
immunoassay on the Immulite 2000 (Diagnostic Products Corp., Los Angeles, CA).
Human HSD11B1 promoter-reporter constructs
A yeast artificial chromosome clone of chromosome 1 (kindly provided by Prof. J. Adamski, 
GSF-National Research Center for Environment and Health, Institute of Experimental 
Genetics, Neuherberg, Germany) was used to sequence the promoter for the 11β-HSD1 
gene (HSD11B1) (GenBank accession no. AL031316). The resulting DNA was then used 
to produce smaller DNA fragments corresponding to different lengths of the HSD11B1 
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promoter including a 77-bp region of 5’ untranslated region (exon 1) downstream of 
the ATG site at 2506 bp. The promoter fragments were generated by PCR amplification 
using a single reverse primer (+77 to +65 bp), 5’-TCACCCGGGTCCTCGTTTGCAG-3’ in 
conjunction with various forward primers specific for different regions of the human 
HSD11B1 promoter/exon 1: promoter region –261 to +77, forward primer (–261 to –249 
bp), 5’-TCAGGTACCGTCTCCTCTTGCT-3’; promoter region –301 to +77, forward primer
(–301 to –289 bp), 5’-TCAGGTACCGAATCCAGTCCTG-3’; promoter region –804 to +77, 
forward primer (–804 to –791 bp) 5’-GCTCAGGTACCTTTACAAGACCCAG-3’; promoter 
region -1382 to +77, forward primer (-1382 to -1370 bp), 5’-TCAGGTACCGGCCTTT
GTTGAC-3’; promoter region –2506 to +77, forward primer (–2506 to –2494 bp), 5’-
TCAGGTACCGAGAACCAGCCAT-3’. Each primer contained restriction sites shown in 
italics to facilitate insertion into the pGEM-T Vector (Promega, Madison, WI): reverse 
primer, SmaI (CCCGGG); and forward primers, KpnI (GGTACC). After ligation, the 
promoter constructs were transformed in DH5α competent cells, selected (Luria broth + 
ampicillin), and DNA was extracted by midi-prep (Wizard plus SV Minipreps Purification 
System by Promega). The resulting HSD11B1 promoter constructs were then digested 
with SmaI and KpnI, separated on 1 % agarose gels, reextracted, and recloned into SmaI- 
and KpnI-digested luciferase pGL3-enhancer vector (Promega). Ampicillin-selected 
clones were used to produce DNA, which was then sequenced to confirm the identity of 
each HSD11B1 promoter-reporter fragment.
Luciferase activity
Four hours after medium replacement, SV-HFO cultures were transiently transfected 
with 200 ng pGL3 luciferase reporter plasmid, using FuGENE6 transfection reagent 
according to the manufacturer’s protocol (Roche, Basel, Switzerland). One day after 
transfection, SV-HFO cultures were lysed in 100–200 µl 1x lysis buffer (Promega) for 
20 min with gentle shaking. During the final stages of differentiation when the culture 
was mineralized, a cell scraper was needed to release the cells and initiate cell lysis. 
Luciferase activity was measured using 25 µl cell lysate and the Steady-Glo Luciferase 
Assay System (Promega). Luciferase values were corrected for luciferase activity of 
empty pGL3-enhancer vector.
 
Quantification of mRNA expression
Total RNA was isolated using RNA-Bee solution (Tel-Test, Friendwood, TX) according to 
the manufacturer’s protocol. To remove calcium (derived from extracellular matrix), 
RNA was precipitated by overnight incubation with 4 M LiCl and 50 mM EDTA at –20°C. 
After precipitation and centrifugation for 30 min at 14,000 rpm and 4°C, the RNA pellet 
was washed four times with 70 % ethanol and dissolved in H2O. The total amount of RNA 
was quantified using the RiboGreen RNA Quantitation Kit (Molecular Probes, Eugene, OR). 
One microgram total RNA was reverse transcribed into cDNA using a cDNA synthesis kit 
according to the protocol of the manufacturer (MBI Fermentas, St. Leon-Rot, Germany), 
using 0.5 µg oligo(dT)18 and 0.2 µg random hexamer primers.
Quantitative real-time PCR was carried out using an ABI 7700 sequence detection 
system (Applied Biosystems, Foster City, CA). Reactions were performed in 25 µl volumes 
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Table 3.1 Primer and Probe Concentrations and Sequences.
58
C
ha
pt
er
 3
59
11β-H
SD1 and osteoblast  differentiation
using a qPCR core kit (Eurogentec, Seraing, Belgium). Reaction mixes contained 20 ng 
cDNA, 5 mM MgCl2, 200 µM dNTPs, and 0.025 U/µl Hot GoldStar enzyme. Primer and 
probe sets were designed, using the Primer Express software (version 1.5; Applied 
Biosystems). Primer and probe concentrations and sequences were as described as in 
Table 1. Cycling conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles 
of 95°C for 15 sec and 60°C for 1 min. The amount of human glyceraldehyde-3-phosphate 
dehydrogenase mRNA was used as internal control to normalize for possible differences 
in RNA extraction and degradation as well as efficiency of the cDNA synthesis. The 
expression of this gene was not significantly affected by hormonal treatment and during 
osteoblast differentiation. Data were presented as relative mRNA levels calculated by 
the equation: 2-ΔCt (ΔCt = Ct of target gene minus Ct of glyceraldehyde-3-phosphate 
dehydrogenase). For semiquantitative RT-PCR, 80 ng of cDNA was amplified in a 25 µl 
reaction mix containing 200 µM dNTPs, 2.5 mM MgCl2, 400 nM of each primer, and 1.25 U 
Amplitaq Gold (Applied Biosystems).
Cycling conditions were as follows: 95°C for 10 min followed by 40 cycles of 95°C 
for 15 sec, 56°C for 30 sec, and 72°C for 30 sec and a final extension step of 5 min at 
72°C. Primer sequences for aP2 are described in Table 1. 
Statistics
Data presented are the results of at least two independent experiments performed in 
triplicate. Values are the means ± SEM. Significance was calculated using the Student’s 
t test.
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Chapter 4
Identification of regulatory genes, gene networks 
and cellular processes in glucocorticoid-
induced human osteoblast differentiation and 
mineralization
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 Chad Shaw, Hedeki Chiba, André G. Uitterlinden, Peter J. van der Spek, 
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Abstract 
Glucocorticoids (GCs) are important inducers of human osteoblast differentiation 
and extracellular matrix (ECM) mineralization. Yet the molecular consequences of 
GC-induced matrix mineralization are largely unknown. In the present study gene 
profiles of mineralizing human osteoblast cultures (GC-treated) were compared with 
nonmineralizing cultures. This identified 489 differentially expressed genes that 
consisted of both osteoblast-related and so far -unrelated genes. The expression of the 
osteoblast transcription factor ZBTB16 was specifically increased in mineralizing cultures 
and several other genes, including the cannabinoid receptor 1, paralleled its expression. 
Activation of this receptor caused increased mineralization. The differentially expressed 
genes could be categorized in several biological processes and gene networks. Gene 
ontology enrichment analyses identified a cluster of ECM genes differentially expressed 
between mineralizing and nonmineralizing cultures emphasizing the significance of 
ECM composition for proper mineralization. Time course studies identified several 
novel direct GC target genes and genes that were under control of the osteoblast 
differentiation program. To extend our observation beyond skeletal development, a 
vascular smooth muscle cell (VSMC)-based model for arteriosclerosis was used. This 
showed that GC-treatment also enhanced matrix mineralization in VSMC cultures. 
Moreover, we showed that a large subset of genes was similarly regulated in VSMCs 
and osteoblasts, demonstrating similarities between bone and vascular mineralization. 
In conclusion, differential expression profiling of mineralizing and nonmineralizing 
cultures proved to be a powerful tool to unravel the molecular mechanisms underlying 
GC-induced matrix mineralization in bone and arteriosclerosis. Several novel direct GC 
targets and targets to control bone formation were identified.
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4.1 Introduction
Osteoblasts play a pivotal role in the regulation of bone quality as they are the bone forming cells and the directors of bone resorption by osteoclasts. Osteoblasts are 
derived from mesenchymal stem cells and undergo a complex differentiation process 
regulated by many endocrine and autocrine factors 1. 
Glucocorticoid steroids (GCs) such as cortisol are crucial initiators of human 
osteoblast differentiation 2, 3. At the molecular level GC signaling is mediated via the GC 
receptor (GR). The GR is expressed in various cell-types including osteoblasts 4, where 
it regulates gene expression by binding to GC responsive elements in the regulatory 
regions of target genes. Despite clear stimulation of bone formation by GCs in vitro, 
GCs are still regarded as negative regulators of bone formation. This is mainly based on 
clinical use of GCs, which frequently results in bone loss and increased risk of fractures 
(GC-induced osteoporosis) 5. It should, however, be considered that this negative effect 
on bone is caused by high pharmacological levels of GCs for longer periods and might not 
reflect the physiological role of GCs in bone. Furthermore, most in vitro studies on GC-
induced osteoporosis are performed using mouse osteoblasts that lack the need for GC-
treatment to induce differentiation and mineralization 6. This latter is in great contrast 
to human osteoblasts for which GCs are a prerequisite for proper differentiation.
In human osteoblasts cortisol triggers the production of a mature extracellular 
matrix (ECM) that eventually becomes mineralized. Initiation of mineralization requires 
the precipitation and attachment of hydroxyapatite crystals (Ca10[PO4]6[OH]2) to the 
ECM 7. However, the exact mechanism is poorly understood. The osteoblast marker 
alkaline phosphatase (ALPL) is suggested to play a role in matrix mineralization, where 
it hydrolyzes organic phosphatase to release free inorganic phosphate 8. Osteoblasts 
produce numerous ECM proteins including the most abundant, such as collagen type-I, 
osteopontin and osteocalcin. This results in a complex mixture of proteins constituting 
the ECM of which the composition acts as an important determinant of initiation and 
progression of mineralization 7, 9. 
Matrix mineralization is not unique for bone tissue demonstrated by ectopic 
mineralization in pathological conditions. Vascular smooth muscle cells (VSMCs) are 
believed to be primarily involved in vascular mineralization. These cells can undergo 
an osteoblast-like differentiation process expressing osteoblastic factors including ALPL 
and runt-related transcription factor 2 (RUNX2) 10, 11.
 Despite the established requirement of GCs for osteoblast differentiation, little 
is known about the genes and molecular networks underlying GC-induced osteoblast 
differentiation and mineralization. Only a few GC target genes are described that 
are involved in osteoblast function and differentiation. New insights into GC-induced 
osteoblast differentiation and matrix mineralization might lead to additional bone-
building reagents. To identify novel targets to control bone formation and bone quality 
we generated genome-wide expression profiles of mineralizing cultures and compared it 
with that of nonmineralizing cultures. 
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4.2 Results
Glucocorticoids are essential for ECM mineralization 
GC-induced osteoblast differentiation and mineralization was studied in detail by using 
the human pre-osteoblast model SV-HFO, which is a well-characterized osteoblast cell-
line showing a controlled GC-induced differentiation process in a 3-week period. In the 
presence of 10-7 M dexamethasone (DEX) or cortisol, an ECM is formed and the process 
of mineralization is initiated around day 12 12. Besides induction of mineralization 
(Fig. 4.1 A), GC-treatment also strongly induced the osteoblast differentiation marker 
alkaline phosphatase (ALPL) in SV-HFO osteoblasts (Fig. 4.1 B).
In addition to SV-HFO cultures, GC-induced differentiation and mineralization was 
studied using primary NHOst osteoblasts. These cells reflected more mature staged 
Fig. 4.1. Glucocorticoid-induced osteoblast differentiation and matrix mineralization. Calcium staining (A) and ALPL 
mRNA levels (B) of control and mineralizing (GC-treated) SV-HFO (day 19) and NHOst (day 14) cultures. Calcium 
was stained using Alizarin Red. ***p<0.001 compared to control cultures.
Fig. 4.2. Gene profile correlation plot of control and mineralizing cultures. Correlation plots of Affymetrix HG-U133 
Plus 2.0 expression data of control and mineralizing osteoblasts (SV-HFO) at six time-points of culture. Red color 
indicate positive correlation, blue color indicates negative correlation.
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osteoblasts compared to SV-HFO pre-osteoblasts. NHOst had higher basal ALPL mRNA 
levels compared to non-treated SV-HFO cultures. In contrast to SV-HFO, basal ALPL 
levels in NHOst were not further enhanced by GC-treatment (10-7 M DEX) (Fig. 4.1 B). 
But importantly, GC-treatment was still essential for the induction of mineralization in 
NHOst cultures (Fig. 4.1 A). These findings show that GC-treatment triggers a series of 
molecular events in human osteoblasts that eventually lead to mineralization of the 
ECM. During the remainder of this study GC-treated and non-GC-treated cultures are 
designated as mineralizing and control cultures, respectively.
Gene profiling in control and mineralizing osteoblasts
Gene expression profiling experiments were performed to assess the difference in 
gene expression between osteoblasts that are capable of matrix mineralization and 
nonmineralizing control osteoblasts. Affymetrix GeneChips were used to analyze both 
mineralizing and control cultures (SV-HFO) throughout the culture period (days 3, 5, 7, 
12, 14, and 19).
These gene expression profiles of control and mineralizing cultures of each analyzed 
day were compared and ordered based on their correlation (Fig. 4.2). In Figure 4.2 a red 
color indicates high correlation between samples and a blue color low correlation. Two 
major blocks can be identified representing control and mineralizing cultures (dotted 
squares in Fig. 4.2). This demonstrated that control and mineralizing cultures have 
strongly different gene profiles. 
In this paper we focused on the genes that distinguish these mineralizing cultures 
from control cultures. Relevant genes were identified by selecting probe sets (Affymetrix 
IDs) that had throughout culture time on average >2-fold higher or lower intensities 
in mineralizing cultures compared to control cultures. In other words, the average 
intensities of day 3 to day 19 in mineralizing cultures divided by the average intensities 
of day 3 to day 19 in control cultures should differ more then 2-fold. By doing this we 
included genes that were always up- or down-regulated throughout culture time but 
also genes that were specifically up- or down-regulated in the early or later stages but 
that reach overall an average a 2-fold difference. This selection query resulted in the 
identification of 740 probe sets, representing 489 unique genes and 64 non-annotated 
probe sets. From the 740 selected probe sets, 364 probe sets were up- and 376 probe 
sets were down-regulated in mineralizing cultures compared to control cultures (data 
not shown).
Validity of the GeneChip analysis
Validity of the GeneChip data was assessed by comparative quantitative PCR (qPCR) 
analyses of 34 genes. For this we analyzed RNA isolated from independent experiments 
not used for the initial GeneChip analysis. The difference in gene expression was assessed 
as fold-difference (average day 3 to day 19) between control and mineralizing cultures. 
This fold-difference was calculated following both GeneChip and qPCR analysis and this 
revealed that a 2-fold change is a robust cut-off. In general, the fold-difference found by 
qPCR was higher compared to the fold-difference calculated by GeneChip (Fig. 4.3).
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Fig. 4.3 Validity of the GeneChip data. mRNA expression of 34 genes was quantified in control and mineralizing 
cultures following qPCR and GeneChip. Fold-difference (log2 transformed) between control (average expression 
of d3 to d19) and mineralizing cultures (average expression of d3 to d19) is plotted. Grey line indicates 100 % 
correlation between qPCR and GeneChip.
Regulation of bone-related genes
Within the 489 genes being up- or down-regulated in mineralizing cultures compared to 
control cultures, numerous genes were identified with already known functions in bone 
biology or which are involved in bone metabolism related pathways or processes. In 
Table 4.1 a selection of these bone-related genes is presented. The strongest regulated 
osteoblast-related gene in this list was zinc finger and BTB domain containing 16 
(ZBTB16). ZBTB16 was recently identified as a stimulator of osteoblast differentiation 
and mineralization acting upstream of RUNX2 13. qPCR in SV-HFO and NHOst cultures 
confirmed the GeneChip data and showed that this gene was undetectable in non-
mineralizing control cultures. GC-treatment, however, strongly increased ZBTB16 
mRNA expression. Moreover, during osteoblast differentiation and mineralization the 
expression progressively increased (Fig. 4.4 A).
Novel osteoblast-related genes
To identify novel genes involved in osteoblast differentiation and mineralization we 
selected genes having similar expression profiles as ZBTB16 and had an unknown function 
in osteoblasts. Six other genes were selected that showed stable low expression in control 
osteoblasts and, like ZBTB16, were strongly induced in mineralizing osteoblasts. These 
genes were 1] transmembrane and tetratricopeptide repeat containing 1 (TMTC1), 2] 
glycoprotein M6B (GPM6B), 3] zinc finger protein 36 (ZFP36 also known as TTP or GOS24), 
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Table 4.1. Genes differentially expressed in control and mineralizing osteoblasts cultures. Selection of 
genes, which have to our knowledge known functions in bone biology or which are involved in bone 
related pathways or processes. Fold difference indicates average intensities of mineralizing cultures 
(d3 to d19) over average intensities of control cultures (d3 to d19). Genes are presented with their 
affymetrix ID by which they were identified. (*) The direction of regulation was analyzed and confirmed 
by qPCR. 
Gene
Symbol
Fold 
Difference
Osteoblast markers  
Alkaline phosphatase, liver/bone/kidney [215783_s_at; 1557924_s_at]
Runt-related transcription factor 2 [232231_at]
Osteopontin [209875_s_at]
ALPL*
RUNX2*
SPP1*
Û 3.7
Û  2.1
0.49 Ü
Extracellular matrix regulation
Matrix metalloproteinase 1 [204475_at]
Matrix metalloproteinase 2 [201069_at]
Matrix metalloproteinase 3 [205828_at]
Matrix metalloproteinase 14 [217279_x_at; 202827_s_at]
Matrix metalloproteinase 19 [204575_s_at]
ADAM metallopeptidase with thrombospondin type 1 motif 2 [236901_at; 214454_at]
Tissue inhibitor of metalloproteinase 3 [201149_s_at]
Tissue inhibitor of metalloproteinase 4 [206243_at]
MMP1*
MMP2
MMP3
MMP14
MMP19
ADAMTS2
TIMP3
TIMP4*
0.032 Ü
0.27 Ü
0.053 Ü
0.39 Ü
Û  2.2
Û  2.5
0.42 Ü
Û 28
Growth factor related
Insulin-like growth factor binding protein 2 [202718_at]
Insulin-like growth factor binding protein 5 [211958_at; 203425_s_at; 1555997_s_at; 211959_at]
Transforming growth factor, beta 2 [228121_at; 209909_s_at; 220407_s_at]
BMP-binding endothelial regulator precursor protein [241986_at]
Noggin [231798_at]
Interleukin 1, alpha [210118_s_at]
Interleukin 1, beta [205067_at; 39402_at]
Interleukin 6 (interferon, beta 2) [205207_at]
IGFBP2
IGFBP5
TGFB2
BMPER
NOG
IL1A
IL1B
IL6
Û  5.2
0.20 Ü
Û  2.6
0.37 Ü
0.34 Ü
0.074 Ü
0.053 Ü
0.076 Ü
Wnt signaling
Low density lipoprotein receptor-related protein 6 [205606_at]
Frizzled homolog 8  [227405_s_at; 224325_at]
Secreted frizzled-related protein 1 [202037_s_at; 202035_s_at; 202036_s_at]
LRP6
FZD8*
SFRP1*
Û  2.2
0.26 Ü
0.21 Ü
Prostaglandin related
Prostaglandin E receptor 2 [206631_at]
Prostaglandin E receptor 4 [204896_s_at; 204897_at]
Prostaglandin-endoperoxide synthase 2 (COX-2) [204748_at; 1554997_a_at]
Prostaglandin E synthase [207388_s_at; 210367_s_at]
Prostaglandin D2 synthase [211748_x_at]
PTGER2*
PTGER4*
PTGS2*
PTGES*
PTGDS*
Û  5.3
Û  4.5
0.15 Ü
0.22 Ü
Û  3.51
Others
Leptin receptor [209894_at; 227095_at; 211354_s_at; 211356_x_at; 211355_x_at]
Natriuretic peptide receptor C/guanylate cyclase C [219790_s_at; 219789_at]
Zinc finger and BTB domain containing 16 [205883_at]
Hydroxysteroid (11-beta) dehydrogenase [205404_at]
LEPR
NPR3
ZBTB16*
HSD11B1*
Û  2.7
Û  9.5
Û  15
0.26 Ü
4] eyes absent homolog 2 (EYA2), 5] dishevelled associated activator of morphogenesis 
2 (DAAM2) and 6] the cannabinoid receptor 1 (CNR1). Next, mRNA expression was 
quantified by qPCR in control and mineralizing osteoblast cultures (SV-HFO and NHOst). 
This showed that TMTC1 and GPM6B had similar expression profiles as ZBTB16 in both 
osteoblast models (Figs. 4.4 B and 4.4 C). The ZFP36 expression pattern was less clear, 
but it was increased at all time points compared to the control cultures (Fig. 4.4 D). 
Expression of EYA2 and DAAM2 increased strongly in mineralizing SV-HFO cultures; 
however, in the NHOst cultures no induction was observed (Figs.4.4 E and 4.4 F). The 
expression pattern of CNR1 could be confirmed in both osteoblast models. This gene 
was specifically up regulated during stages of mineralization, whereas the expression 
was low and stable in control osteoblasts (Fig. 4.5 A). Since several reports recently 
indicated a role of cannabinoid receptors 1 and 2 in bone 17-19, this gene was studied in 
more detail in human osteoblasts.
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Fig. 4.4. Expression pattern of ZBTB16 and novel osteoblast genes during osteoblast differentiation. (A) ZBTB16 
mRNA expression in control and mineralizing cultures of SV-HFO and NHOst. In addition, 5 other genes with similar 
expression patterns as ZBTB16 were analyzed in control and mineralizing cultures of SV-HFO and NHOst (B-F). 
Graphs show relative mRNA expression compared to day 3 of control cultures determined by qPCR.
Fig. 4.5. CNR1 expression and functionality in human osteoblasts. (A) CNR1 mRNA expression in control and 
mineralizing osteoblasts cultures determined by qPCR. *p<0.05; **p<0.01; ***p<0.001 compared to control cultures 
at indicated time points. (B) Quantification of mineralization (day 16) in osteoblasts cultures that were continuously 
treated with various concentrations of the specific CNR1 agonist ACEA. *p<0.05; **p<0.01; ***p<0.001 compared 
to vehicle.
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Table 4.2. List of networks derived using Ingenuity Pathway Knowledge database. Input genes 
were 98 genes that were differentially expressed in control and mineralizing osteoblast cultures and 
were annotated with the GO term development. Score: indicates the enrichment of the network. 
Top functions: indicates the kind of processes these genes have been shown to be involved in. 
Data based on ingenuity version 4.0. á > 2.0-fold up-regulated, â > 2.0-fold down-regulated in 
mineralizing cultures compared to control cultures. 
Genes Score Top functions
1
ANGPT1á, ANKHâ, CCL2â, COL8A1á, CSF2â, 
DCNá, ENGâ, FOXC2á, FZD8â, HTRA1á, IL6â, IL8â, 
IL11â, INHBAâ, JAG1á, KLF6á, LIFâ, LRP6á, NOGâ, 
NRP2â, PPARGá, PTGS2â, RUNX2á, SEMA3Câ, 
SFRP1â, SMTNâ, SNAI2á, SPP1â, TGFB2á, 
THBS1á, TIE1â, TLR4á, VEGFâ, WISP1â, ZBTB16á
75
Cellular 
Movement, Tissue 
Development, 
Organismal 
Development
2
ADAM10á, AFP, ALOX5AP, ALPLá, ANGPTL4á, 
ARG1, CCR7, CTNNB1, EDIL3á, ESM1â, F2, FCGR1A, 
FGF18, FOXE1â, FPRL1, HAS1, IL32, IL23A, IL3RA, 
INDO, KRT34â, LAMA4â, LAMB3â, LEPRá, LRP6á, 
MEOX1â, NLK, NRCAMá, SEMA3Câ, SMTNâ 
SOCS4á, STAT3, TGFB1, TNF, TNFAIP2â
26
Cellular Movement, 
Connective 
Tissue Disorders, 
Inflammatory 
Disease
3
ALOX5, ANG, AQP4, BHLHB3â, CLEC3Bá, COL11A1á, 
COL12A1á, DAD1, DMDá, EYA2á, G3BP, HMGA1â, 
IDI1, IER3â, IGFBP2á, KCNJ4, KLF6á, KRT19, LDB2â, 
LIMK2, MBOAT5, MMP2, MYOD1, NRG1â, PCSK6, PLG, 
RNF4, SIM1, SIX1á, SLC2A3, SP1, SPOCK1â, TGFB1, 
THBS2, VEGFCâ
22
Cancer, 
Cardiovascular 
System 
Development and 
Function, Tumor 
Morphology
4
ADARB1á, ARHGDIBâ, CCNB2, CDC42, CDC42EP3á, 
CEACAM5, COL5A1, COL5A3á, CSDA, CXCL1â, EBFá, 
EP300, FBN2á, FN1, GART, HMGN2, ICKá, ISGF3G, 
LY6A, MAFBâ, MFAP2, MMP19á, MYC, NDRG1â, 
NFYB, NOSIP, PPP1R15A, PTTG1, RRM2, SOX9â, 
TOP2A, TP53, UBE2C, YY2, ZIC2â
18
Cell Cycle, DNA 
Replication, 
Recombination, and 
Repair, Cancer
5
ADAM12â, AGT, CCR7, CD38, CSF3â, EHFâ, EPHB2â, 
FGD4á, FPR1, GPM6Bá, HDC, HTRA2, IL4, IL25, 
ITGA2â, KCNMA1â, LTB, LY96, MAPK1, MAPK8, 
NCF1, NOTCH3á, NOVâ, NPR3á, PLA2G10, PLSCR1, 
PTPRRâ, SH3PXD2A, SPHK1â, SRC, ST5, TFF3, 
TIMP1, TNFRSF11A, TPSD1
18
Cellular Movement, 
Cellular Growth 
and Proliferation, 
Immune Response
Cannabinoid receptor 1
The functionality of CNR1 in osteoblasts was tested using the specific CNR1 agonist 
ACEA (Arachidonyl-2’-chloroethylamide) 20. SV-HFO and NHOst osteoblasts were cultured 
in the presence of 5, 50, 500 and 5000 nM ACEA. Mineralization and ALPL activity was 
measured at day 16 of culture. ACEA-treatment stimulated matrix mineralization in 
osteoblasts cultures at concentrations higher than 5 nM (Fig. 4.5 B). ALPL activity and 
cell number (DNA content) remained unchanged after treatment (data not shown).
Gene Ontology and gene network analysis
The biological relevance of the 489 selected genes was examined by Gene Ontology 
(GO) enrichment analysis. The 489 genes were categorized for: GO Biological 
Process (Fig. 4.6 A), GO Molecular Function (Fig. 4.6 B), and GO Cellular Component 
(Fig. 4.6 C) 21. In total, we identified 106 biological processes, 28 molecular functions, 
and 9 cellular components being significantly over-represented compared to what would 
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Fig. 4.6. Gene Ontology (GO) enrichment analysis. Enriched GO terms found within the set of 489 differentially 
expressed genes (between control and mineralizing cultures) for GO Biological Process (A), GO Molecular Function 
(B), and GO Cellular Component (C). The z-score indicates the standardized enrichment score. Numbers inside 
the bars indicate number of genes from the set of 489 differentially expressed genes determining the GO terms. 
#  Number of GO terms was reduced by exclusion of several overlapping GO terms. *p<0.05; **p<0.01; ***p<0.001 
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Fig. 4.7. Developmental genes regulated by GC-induced differentiation. Hierarchical clustering of 98 genes 
annotated with the GO-term development that were differentially expressed in control and mineralizing cultures. Red 
color indicates increased expression and green color indicates decreased expression compared to the geometric 
mean. Genes are annotated with their gene symbol, gene name and probe sets by which they were identified. 
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Fig. 4.8.  Gene network 1 identified by Ingenuity Pathway Analysis based on the 98 development genes (annotated 
with GO biological process term development) differentially expressed in control andmineralizing cultures. All 
genes within this gene-network are differentially expressed indicated by their red (up in mineralizing cultures) or 
green (down in mineralizing cultures) color. Solid lines = direct interaction. Dotted lines = indirect interaction. A = 
activation / deactivation; RB = regulation of binding; PR = protein mRNA binding; PD = protein DNA binding; B = 
binding; E = expression; I =inhibition; L = proteolysis; M= biochemical modification; O = other; P= phosphorylation 
/desphosphorylation; T = transcription; LO = localization
be expected if 489 randomly selected genes were analyzed.
The identification of differentiation-related processes including development, 
morphogenesis, angiogenesis and cell differentiation are intuitively logical considering 
the cell models used as are the processes calcium ion homeostasis and phosphate 
transport (Fig. 4.6 A). They are of great interest as these processes might contain novel 
important regulatory genes for osteoblast differentiation. Within the 489 differentially 
expressed genes 98 genes were annotated with the GO term development, which are 
depicted in Fig. 4.7 The relationship and interaction between the 98 development 
genes was analyzed and visualized using Ingenuity Pathway analysis. This software 
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tool generates gene networks based on known gene-to-gene interactions. Analysis of 
the 98 development genes resulted in de identification of five enriched gene networks 
that are shown in Table 4.2. Gene network 1 was strongly enriched since all 35 genes 
in this network were differentially expressed in control and mineralizing cultures. This 
gene network is demonstrated in Fig. 4.8 and contains genes such as RUNX2, ZBTB16, 
interleukin 6 and 8 (IL6/8), vascular endothelial growth factor (VEGF), low density 
lipoprotein receptor-related protein 6 (LRP6), decorin (DCN), and transforming growth 
factor beta 2 (TGFB2) in interaction with other known but also many novel bone-related 
genes. In addition to these developmental genes, the complete data set of 489 genes 
was used to generate interacting gene networks. In total, eight strongly enriched gene 
networks were identified which are shown in Table 4.3. 
The GO Molecular Function analysis identified several enriched functions intuitively 
logical and of interest for bone formation such as collagen binding, hyaluronan synthase 
activity, metalloendopeptidase activity, extracellular matrix structural constituent, 
and glycosaminoglycan binding (Fig. 4.6 B). Following this the analysis for GO Cellular 
Component showed that, genes located in the extracellular region, space or matrix 
were significantly enriched (Fig. 4.6 C). In total, 36 genes annotated with ECM were 
differentially expressed in control and mineralizing cultures (Fig. 4.9 A).
Regulation of ECM genes
We analyzed 5 up-regulated and 5 down-regulated ECM genes in more detail by qPCR in 
control and mineralizing cultures of SV-HFO and NHOst (Fig. 4.9 B). First, this showed 
that the expression of ECM genes like; metallopeptidase inhibitor 4 (TIMP4); C-type 
lectin domain family 3, member B (CLEC3B, also known as tetranectin), laminin beta 3 
(LAMB3) and matrix metallopeptidase 1, 2 and 3 (MMP1/2/3) were strongly regulated 
(> 10-fold) in mineralizing osteoblasts.  Secondly, it showed that the majority of the 
ECM genes were similarly regulated in NHOst and SV-HFO osteoblasts. The regulation of 
matrix metallopeptidase 3 (MMP3) and hyaluronan synthase 1 (HAS1), however, showed 
discrepancies between SV-HFO and NHOst cultures. This might be explained by the 
already low expression of HAS1 and MMP3 in control NHOst cultures, whereas in SV-HFO 
the basal expression was higher but strongly decreased by GC-treatment (Fig. 4.9 C). 
This supports the notion of a more mature phenotype of NHOst compared to SV-HFO, 
which is in line with our conclusion on basis of difference in basal ALPL activity.
Direct DEX gene regulation
All genes discussed in this paper were identified according to their differential expression 
between control and mineralizing cultures upon continuous treatment with DEX. Using 
this selection, the difference in gene expression might be caused by two processes; 
1] direct gene regulation by DEX-treatment or 2] indirect as a consequence of the GC-
induced osteoblast differentiation program. It is difficult to discriminate between these 
two processes since continuous presence of DEX is necessary to induce differentiation 
and mineralization. Nevertheless, several culture conditions were created in which 
we aimed to reveal whether a gene is directly regulated by DEX or indirectly as a 
consequence of GC-induced differentiation (Fig 4.10 A).
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Table 4.3. List of networks derived using Ingenuity Pathway Knowledge database. Input genes were 
the 489 genes that were differentially expressed in control and mineralizing osteoblast cultures. 
Score: indicates the enrichment of the network. Top functions: indicates the kind of processes these 
genes have been shown to be involved in. Data based on ingenuity version 4.0. á > 2.0-fold up-
regulated, â > 2.0-fold down-regulated in mineralizing cultures compared to control cultures. 
Genes Score Top functions
1
CCL2â, CCL3â, CCL7â, CCL8â, CTSSâ, CXCL3â, 
CXCL5â, CXCL6â, EDG7â, F2RL1â, FZD8â, GBP2â, 
HTRA1á, IGFBP2á, IGFBP5â, IL6â, IL1Aâ, IL1RNâ, 
LIFRá, LRP6á, MMP1â, MMP2â, MMP3â, MMP14â, 
NFKBIZâ, PAPPAá, PROS1á, PTGESâ, SAA1á, 
SOD2â, SPP1â, STOMá, THBS2â, TIMP3â, TIMP4á
53
Immune Response, 
Cell-To-Cell Signaling 
and Interaction, 
Hematological 
System Development 
and Function
2
AMPD3â, ANGPT1á, AREGá, BDKRB1â, BDKRB2â, 
CCL20â, CD44â, CSF3â, EDN1â, ESM1â, FOXC2á, 
G0S2â, GCNT1á, H19á, HAS1â, HSD11B1â, ICAM1â, 
IL8â, IL24â, IL1Bâ, IL1RAPá, KLF2â, ODC1â, 
PBEF1â, PTGDSá, PTGER2á, PTGER4á, PTGS2â, 
PTPRBâ, SERPINB2â, SPINT1â, TEKâ, TIE1â, 
TNFAIP2â, VEGFCâ
53
Cardiovascular 
System Development 
and Function, 
Organismal Injury and 
Abnormalities, Cell-
To-Cell Signaling and 
Interaction
3
C5ORF13á, DCNá, DPP4â, EDNRAá, ENGâ, FAPâ, 
FBLN1á, FN1á, INHBAâ, ITGB8â, JAG1á, KLF6á, 
LAMA4â, MMP19á, NID2á, NOGâ, NOVâ, NRP2â, 
PDGFRBá, PLAUâ, PLAURâ, RUNX2á, SEMA3Câ, 
SFRP1â, SMTNâ, SNAI2á, STC1â, TFPI2â, TGFB2á, 
TGFBIâ THBS1á, TNCâ, TNFAIP6â, VEGFâ, WISP1â
53
Cellular Movement, 
Cellular Development, 
Cellular Growth and 
Proliferation
4
ANGPTL4á, BCL2A1â, BHLHB3â, CCND1â, 
CDCP1â, CDKN2Bá, COL8A1á, CSF2â, F2RL2â, 
FGF7â, HAS2â, HIPK2á, HMGA1, IER3â, IL11â, 
KITá, KITLGá, KLF9á, KLHL24á, LAMB3â, MGLLâ, 
NF1á, NRG1â, PER1á, PODXLâ, PPARGá, PRKG2â, 
PTPRRâ, RPS6KA2á, SDC1â, SOX9â, TNFSF15â, 
TSC22D3á, ZFP36á, ZFP36L2á
53
Cellular Growth and 
Proliferation, Cancer, 
Cell Cycle
5
ABTB1â, ALPLá, ANGPT1á, CASP3, CASP4, CDH1, 
COL11A1á, CSRP1â, DNAJB4á, DRAP1, DSG1, 
FKBP5á, G3BP, GCLC, IER3â, ITGAE, JAG1á, 
KCNIP3á, KRT19, MT2A, NEU3, PBEF1â, PKP2á, 
PLOD1, PTEN, SEPT4á, SFRS2IPá, SLC20A1, 
SLC7A11á, SNRP70, STARD10â, TCF8á, TGFB1, 
TNFRSF10A, TP73L
16
Cancer, Cell Death, 
Hepatic System 
Disease
6
CLEC3Bá, CXCL1â, CXCL2â, CXCL12â, CYP3A5, 
DIO1, DPP4â, áEBF, EP300, ETV1, FPRL1, GPM6Bá, 
HCLS1â, HGF, IL4, ISG20â, KLKB1, LAMA3, MAOAá, 
MMP2â, MMP10, MN1, NCOA3á, NCOA6IP, NR4A3, 
PCMT1, PIGR, PKIBâ, PLG, PPARBPá, PRNPâ, 
S100A9, SPOCK1â, SPSB1â, TXK
16
Cell-To-Cell Signaling 
and Interaction, 
Cellular Movement, 
Hematological 
System Development 
and Function
7
ADAM12â, AKT1, ARHGDIA, C21ORF7â, CCL19, 
CDC42, CDC42EP3á, CFL1, CTSL2, CXCL1â, CYBB, 
DOCK9á, FGD4á, FLJ20701â, FNBP1Lá, GAS6, 
HOMER2, IL13, IL8RB, ITGA10á, ITGB1, ITGB1BP1, 
LGALS3, MUC5AC, NEDD4Lâ, NEXNá, PLEK2â, 
RGS3â, SEPT7, SEPT11á, SLC16A6â, SLC3A2, TEKâ, 
TGM2â, YWHAZ
16
Cellular Movement, 
Cell-To-Cell Signaling 
and Interaction, 
Tissue Development
8
ADCYAP1, ANXA2, AREGá, CA12â, CFL1, CNN1â, 
CORO2Bâ, CTSL2, DACH1, DYSFâ, EFEMP1á, FOS, 
FOXD1â, GAS1á, GPX1, IER3â, IL11â, INSR, MKL1, 
MYOCDâ, NDRG1â, NMI, PSG2â, RGC32á, RHOB, 
RPS9, S100A10, SMAD4, TERT, TK1, TNCâ, VHL, XBP1, 
ZFP36á, ZNF33Aá
16
Cell Death, Gene 
Expression, Cellular 
Development
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Gene expression was measured at day 14 in control cultures that were treated with 
DEX for 3, 6, or 24 h and at day 14 in cultures that were continuously treated with 
DEX (Figs. 4.10 B-E). In addition, gene expression was measured in cultures that were 
treated with DEX for 10 days to induce differentiation followed by exclusion of DEX 
for the final 4 days before RNA isolation at day 14 of culture (Fig. 4.10 F). This showed 
that several genes were direct DEX target genes showing up-regulation already after 
Fig. 4.9. ECM genes differentially expressed in control and mineralizing osteoblasts. (A) Hierarchical clustering 
of 35 genes annotated with ECM, which were differentially expressed in control and mineralizing cultures (SV-
HFO). Red color indicates increased expression and green color indicates decreased expression compared to the 
geometric mean. Color intensities indicate the magnitude of regulation. Genes are annotated with their gene symbol, 
gene name and probe sets by which they were identified. (B) mRNA expression of a selection of ECM genes 
shown in Fig. 4.9 A.Gene expression was quantified by qPCR in control and mineralizing cultures of SV-HFO and 
NHOst. Difference in gene expression is presented as the fold-difference (log2 transformed) between mineralizing 
and control cultures (average expression of d5 to d19). (C) mRNA expression of HAS1 and MMP3 in control and 
mineralizing osteoblasts (SV-HFO and NHOst). *p<0.05; **p<0.01 compared to control cultures. 
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Fig. 4.10. mRNA expression after short and long term DEX-treatment. Gene expression at day 14 of osteoblast 
culture (SV-HFO) after DEX treatment quantified by qPCR. (A) DEX incubation scheme for figures 4.10 B-F. 
Cultures were treated for (B) 3 hours (3h), (C) 6 hours (6h), (D) 24 hours (24h) and (E) continuously with DEX at 
day 14 of culture. In addition, cultures were treated with DEX for 10 days to induce differentiation and subsequently 
DEX was excluded for 4 days before RNA isolation at day 14 (F). *p<0.05; **p<0.01; ***p<0.001 compared to control 
cultures. 
3h of DEX-treatment. The most sensitive gene for DEX was ZBTB16, which showed a 
83-fold increase after 3h of DEX-treatment increasing up to 2000-fold after 24h. Other 
genes were only significantly regulated after 6h or 24h of DEX-treatment. Excluding 
DEX for the final 4 days showed that the expression of the majority of genes was still 
changed compared to control cultures even in the absence of DEX. Together, these data 
demonstrated that we identified direct DEX target-genes (e.g., ZBTB16, ZFP36 and 
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TIMP4), genes that were primarily regulated in a differentiation dependent manner 
(e.g., ALPL, EYA2 and MMP2) and genes that are probably regulated by combination of 
both processes (e.g., HAS1). 
Vascular smooth muscle cell induced ECM mineralization
To extend the observations beyond skeletal development we used a vascular smooth 
muscle cell-based model for vascular calcification 22, 23. Human VSMCs were cultured in an 
Fig. 4.11. Comparative analysis of osteoblast and VSMC induced matrix mineralization. (A) VSMCs were cultured in 
osteogenic medium with and without DEX. After three weeks of culture cells were stained for calcium using Alizarin 
Red. (B-C) Gene regulation in control and mineralizing osteoblast (SV-HFO) and VSMC cultures. Difference in gene 
expression is presented as the folddifference (log2 transformed) between mineralizing (average expression of d3 
to d19) and control cultures (average expression of d3 to d19). *p<0.05; **p<0.01; ***p<0.001 compared to control 
cultures.
osteogenic medium containing DEX (10-7 M). Using this osteogenic medium mineralization 
of the ECM could be detected in the third or fourth week of culture (Fig. 4.11 A). 
Importantly, if DEX was excluded from the culture medium no mineralization of the 
ECM was observed. This suggest that matrix mineralization in VSMC is triggered via 
a similar mechanism as observed in osteoblasts. To reveal if a similar set of genes 
was differentially expressed in VSMC compared to osteoblasts, we quantified mRNA 
expression in control and mineralizing VSMCs (Fig. 4.11 C). In total, the mRNA expression 
of 18 genes was quantified using qPCR. This revealed a large overlap in gene regulation 
between osteoblasts and VSMCs. However, there were also some discrepancies in gene 
regulation between VSMCs and osteoblasts (e.g., DAAM2, FBNL1, LAMB3 and MMP2).
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4.3 Discussion
The current study identified processes, molecular networks and novel targets in the control of osteoblast differentiation and bone formation and identified novel 
GC target genes in osteoblasts. Comparative analyses demonstrated overlap and 
discrepancies between bone and atherosclerosis-related mineralization. Although 
GCs are crucial for human osteoblast differentiation and mineralization surprisingly 
little is known about the mechanism behind these processes. In relation to osteoblast 
differentiation several microarray studies have been performed, however, mainly in 
rodent models 21-24. Murine osteoblast models are frequently used to study the effects of 
GCs in relation to GC-induced osteoporosis and data about GCs are therefore interpreted 
from a totally different point of view 25. Only a limited number of microarray studies have 
been performed using human cells, which do not focus on GC-induced differentiation 
13, 26. The human pre-osteoblast SV-HFO model proved to be a good model to identify 
regulatory genes involved in bone formation. In order to confirm data found with SV-
HFO cultures, human NHOst cultures were used. These osteoblasts represent a more 
mature staged osteoblast, exemplified by high basal ALPL activity. Nevertheless, GC-
treatment was still necessary to induce matrix mineralization in these NHOst cultures. 
This indicates that GC-treatment triggers early osteoblast differentiation (SV-HFO) but is 
still required for matrix synthesis and mineralization by more mature staged osteoblasts 
(NHOst).
The presented study is unique in that it compares gene profiles of human osteoblast 
cultures induced by GCs to differentiate and mineralize with that of nonmineralizing 
control cultures. These two extreme conditions were exploited to select relevant 
genes involved in bone formation. This proved to be a powerful tool in selecting genes 
of biological relevance, as demonstrated by the identification of numerous known 
osteoblast-related genes such as RUNX2, ALPL and ZBTB16. ZBTB16 is a transcriptional 
repressor involved in cell cycle control and has been shown to have pleiotropic functions 
including limb development 27-29. The identification of ZBTB16 was interesting since it was 
recently identified as a crucial factor for matrix mineralization in human mesenchymal 
stem cell cultures acting upstream of RUNX2 13. In lymphoblastic leukemia and in human 
stromal and smooth muscle cells ZBTB16 was shown to be a direct target of GCs 30, 31. We 
showed that in human osteoblasts this gene is also a direct GC-target and might be an 
important mediator of GC-induced differentiation and mineralization.
Several genes that paralleled the expression pattern of ZBTB16 and that were so far 
unknown to be expressed in osteoblasts or to have a function in osteoblasts were studied 
in more detail. The expression patterns of TMTC1, GPM6B and ZFP36 in the SV-HFO 
model were also found in the more mature NHOst differentiation model, i.e. increase 
during differentiation and mineralization. Currently no data on expression of TMTC1 in 
other cells or on function of TMTC1 are available. GPM6B is only characterized regarding 
its expression in neurons and glia 32. ZFP36 is a transcriptional regulator involved in 
the development of various organs and tissues. Mice deficient for ZFP36 have been 
generated and showed an autoimmunity phenotype including severe arthritis but no 
other clear skeletal phenotype 33. For EYA2 and DAAM2 the expression pattern in NHOst 
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cells was different from that in SV-HFO. No increase in expression during mineralization 
was observed. Whether this is related to the initial difference in maturity between these 
osteoblast differentiation models is not clear. For DAAM2 no expression or functional data 
are available yet. EYA2 is a transcriptional regulator highly homologous to EYA1 which 
appears to be a part of the group of developmental genes such as PAX6, GLI3, SOX9 and 
sonic Hedgehog (SHH) that in case of disturbed expression levels lead to several clinical 
symptoms 34, 35. Interestingly, disturbed expression of GLI3, SOX9 and SSH in mice leads 
to various disturbances in skeletal development and mineralization 36-38. Based on this it 
is tempting to postulate that EYA2 plays an important role in skeletal development and 
bone formation. Despite that so far little direct information on the function of these 
genes in bone is present, their strong up-regulation during stages of mineralization 
makes them interesting novel candidates for the control of bone formation. Proof of 
principle is given by targeting CNR1 which activation increased matrix mineralization. 
The role of CNR1 in bone is currently confined to osteoclasts 14. Our data now implicate 
also a significant role of CNR1 in bone formation. Together with the data on CNR2 15, 16 it 
substantiates a role for cannabinoid-related ligands in bone metabolism.
The biological relevance of the 489 identified genes was further substantiated by GO 
en gene network enrichment analysis. Identification of GO biological process terms like 
development, morphogenesis and cell differentiation is in line with the experimental 
setup of GC-induced osteoblast differentiation. In the GO cellular component analyses 
ECM genes were identified as strongly enriched, which emphasized the importance of 
matrix composition for matrix mineralization. Currently, little is known about the role 
of the majority of these ECM genes in matrix mineralization, which makes it yet difficult 
to interpret the significance of these ECM genes. Nevertheless, the observed direction 
of regulation coupled to the mineralization phenotype may already hint at the function 
of these ECM genes. In addition, as shown in Figure 4.6, numerous other GO terms were 
identified as strongly enriched, however, most of these processes are still unknown in 
relation to osteoblast differentiation and bone metabolism. Presently it is too premature 
to discuss these processes extensively but their identification opens up the opportunity 
to unravel these processes in osteoblast differentiation.
Together, the current approach of a differential screen of mineralizing and 
nonmineralizing cultures delivered a relatively small set of 489 genes which, aside 
already known bone-related genes, will contain other novel osteoblast regulatory genes. 
The identified gene networks are good leads to select appropriate candidate genes for 
the control of bone formation. In these networks genes with unknown function in bone 
co-localize and interact with genes known to be functional in bone, indicating the 
potential importance for the novel bone related genes. However, to pinpoint precisely 
their functional role elaborate studies are needed. This is a major challenge, as these 
genes should not only be studied independently but importantly also in interaction with 
each other. This latter is directly related to the fact that metabolic bone diseases such 
as osteoporosis are complex diseases in which not a single gene but a multitude of 
interacting genes are at the basis of the disease.
To extend the observations beyond skeletal development and mineralization 
we studied VSMCs as a model of atherosclerosis. GCs also triggered VSMC-induced 
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matrix mineralization and regulated a similarly subset of genes in VSMCs compared to 
osteoblasts. Using this model and the comparative analyses, genes can be identified that 
are specifically involved in the mineralization process in a cell type independent manner, 
while on the other hand genes can be identified which are specific for either bone or 
vascular mineralization. This approach and the currently identified genes are therefore 
also of great importance for cardiovascular disease, since vascular mineralization is a 
risk factor for cardiovascular failure 39, 40.
In conclusion, a unique aspect of this study was that we compared mineralizing 
human osteoblast cultures with their nonmineralizing counterparts. This led to the 
identification of numerous potential targets to control bone formation and bone quality. 
Novel genes were identified that are either directly or indirectly regulated by GCs 
including ZBTB16, CNR1 and multiple ECM genes. Together these data substantially add 
to the understanding of cellular processes, molecular networks and genes in osteoblast 
differentiation and mineralization and form a solid start to further unravel the molecular 
mechanism behind human osteoblast differentiation and bone formation.
4.4 Materials and Methods
Cell culture
SV-HFO cells were cultured as previously described 12. After seeding, cells were incubated 
for two days before they were put on mineralizing or nonmineralizing medium (indicated 
as day 0). Medium was supplemented with freshly added 10 mM b-glycerophosphate 
(Sigma), 100 nM dexamethasone (DEX) (Sigma) or other additives and replaced every 2-3 
days. The CNR1 agonist ACEA was purchased from Tocris.
Normal human osteoblasts (NHOst) (Cambrex Bio Science; CC-2538) and vascular 
smooth muscle cells  (Coronary artery smooth muscle cells; Cambrex Bio Science; CC-
2583) were cultured similar as SV-HFO cells only with the following adjustments. NHOst 
were used between passage 3 and 6 and were seeded in a density of 5 x 103 vital cells 
per cm2. NHOst cultures were induced to mineralize in similar medium as SV-HFO, 
except that 10 % charcoal-treated heat-inactivated FCS (Gibco BRL) was used. VSMCs 
were used between passage 3 and 7 and seeded in a density of 5 x 103 vital cells per 
cm2.  Expansion of VSMCs was performed in smooth muscle cell medium (Cambrex Bio 
Science) supplemented with Clonetics Sm-GM-2 Bulletkit (Cambrex Bio Science). VSMCs 
were induced to mineralize in DMEM (Gibco BRL; with 4500 mg/l glucose, L-glutamine 
and pyruvate) supplemented with 100 nM DEX, 0.1 mM ascorbic acid (Sigma), 10 mg/ml 
insulin (Sigma), 1 mM CaCl2 (final concentration of 2.8 mM), 10 mM b-glycerophosphate 
and 10 % FCS (Gibco BRL).
DNA, alkaline phosphatase activity, and mineralization assays
At the end of cultures cells were scraped in PBS-Triton X-100 and stored at -80° 
until analysis. ALPL, DNA and calcium measurements were performed as previously 
described 41. Shortly, DNA content was measured fluorimetrically using ethidium bromide 
solution. Alkaline phosphatase activity was measured by determining the release of 
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Table 4.4. Primer and probe sequences and concentration used for qPCR analysis. Primer sets without 
a fluorescence probe were used in combination with the SYBR green QPCR kit (Eurogentec).
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paranitrophenol from paranitrophenylphosphate. Calcium content was colorimetrically 
determined after addition of 1M ethanolamine buffer (pH 10.6) 0.35 mM o-cresolphtalein 
complexone, 19.8 mM 8-hydroxyquinoline and 0.6 mM hydrochloric acid at 595 nm. For 
Alizarin Red S staining cell cultures were fixed for 60 min with 70 % ethanol on ice. After 
fixation, cells were washed twice with PBS and stained for 10 min with Alizarin Red S 
solution (saturated Alizarin Red S in demineralized water adjusted to pH 4.2 using 0.5 
ammonium hydroxide). Alizarin Red solution was removed and cultures were washed 
with demineralized water.
Quantitative PCR analysis (qPCR)
RNA isolation, cDNA synthesis and QPCR were performed as described previously 12. 
Primer and probes sequences and concentrations are shown in Table 4.4. The expression 
of genes for which no probe sequence is given are analyzed using the SYBR green I or 
qPCR core kit (Eurogentec)
Affymetrix GeneChip-based gene expression
Purity and quality of isolated RNA was assessed by RNA 6000 Nano assay on a 2100 
Bioanalyzer (Agilent Technologies). Per analyzed condition total RNA of 3 different 
biological samples was pooled. Synthesis of first and second strand cDNA from total RNA 
was performed according to the One-Cycle Target Labeling protocol (Affymetrix; 701024 
Rev. 3). In total, 4.0 μg of total RNA was reverse transcribed using Superscript ds-cDNA 
Synthesis Kit according to the manufacturer’s description (Invitrogen). Subsequently, 
double-stranded cDNA was purified using GeneChip Sample Cleanup Module (Affymetrix) 
and served as a template in the in vitro transcription reaction using BioArray 
HighYield RNA Transcript Labeling Kit (Affymetrix). Next, the RNA (cRNA) was purified 
using GeneChip Sample Cleanup Module. In total, 20 μg of biotin-labeled cRNA was 
fragmentized by metal-induced hydrolysis at a final concentration of 0.5 μg/μL for 35 
minutes at 94°C. Fragmentation was checked on an Agilent 2100 Bioanalyzer confirming 
an average size of approximately 100 nt. In total, 15 μg fragmented biotinylated cRNA 
was hybridized to GeneChip Human Genome U133 Plus 2.0 oligonucleotide GeneChips 
(Affymetrix) according to the manufacturer’s protocol (Affymetrix, 701025 Rev 5). 
Staining, washing and scanning procedures were carried out as described in the GeneChip 
Expression Analysis technical manual (Affymetrix). Data acquisition was performed using 
the GeneChip Scanner 3000.
GeneChip data analysis
In order to examine the quality of the different arrays, measured intensity values were 
analyzed using the GeneChip Operating Software (GCOS, Affymetrix). The percentage 
of present calls (about 40 %), noise, background, and ratio of GAPDH 3’ to 5’ (<1.4) all 
indicated high quality of the samples and an overall comparability. Probe sets that were 
never present (according to Affymetrix MAS5.0 software) in any of the GeneChips were 
omitted from further analysis. Raw intensities of the remaining probe sets (30336) of 
each chip were log2 transformed and normalized using quantile normalization. After 
normalization the data was back transformed to normal intensity values. Data analysis 
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and visualization were done using the OmniViz package, version 3.6.0. For each probe 
set, the geometric mean of the hybridization intensities of all samples was calculated. 
The Pearson’s correlation and visualization tool of OmniViz was used to study the results 
of unsupervised clustering of the samples (based on the log2 geometric mean values). 
In the correlation plot samples are ordered by correlation (samples with high positive 
correlations or high negative correlations are putted into separate blocks) and the cells 
are color-coded by correlation coefficient values. For the correlation plots analysis 
genes were used that were differentially expressed (>2-fold difference from geometric 
mean) at one of the analyzed days.
To select differentially expressed probe sets the average intensity value of all 6 
time-points was calculated for both control and mineralizing cultures using an cut off of 
30 (intensity value). Probe sets were selected that showed at least a 2.0-fold difference 
between control and mineralizing cultures. 
For GO enrichment analysis the 740 selected probe sets were analyzed using 
Ontology Transfer 14. Ingenuity Pathways Analysis 4.0 was used to identify gene 
networks. The 740 probe sets with corresponding fold differences (log2 transformed) 
were uploaded into the application. Each Affymetrix ID was mapped to its corresponding 
gene object in the Ingenuity Pathways Knowledge Base. These genes were overlaid onto 
a global molecular network developed from information contained in the Ingenuity 
Pathways Knowledge Base. Networks of these focus genes were then algorithmically 
generated based on their connectivity.
Gene nomenclature
Gene names and gene symbols were used as provided by HUGO Gene Nomenclature 
Committee 43.
Statistics
Data were only presented if multiple independent experiments showed similar results. 
Experiments were performed at least in triplicate. Values are the means ± SEM. 
Significance was calculated using the Student’s t-Test. To calculate significance for GO 
analyses Benjamini and Hochberg false discovery rate was used 42.
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Abstract
Bone quality is an important determinant of osteoporosis, and proper osteoblast 
differentiation plays an important role in the control and maintenance of bone quality. 
We investigated the impact of activin signaling on human osteoblast differentiation, 
extracellular matrix formation, and mineralization. Activins belong to the transforming 
growth factor-β superfamily and activin A treatment strongly inhibited mineralization in 
osteoblast cultures, whereas the activin antagonist follistatin increased mineralization. 
Osteoblasts produced activin A and follistatin in a differentiation-dependent manner, 
leading to autocrine regulation of extracellular matrix formation and mineralization. In 
addition, mineralization in a vascular smooth muscle cell-based model for pathological 
calcification was inhibited. Comparative activin A and follistatin gene expression profiling 
showed that activin signaling changes the expression of a specific range of extracellular 
matrix proteins prior to the onset of mineralization, leading to a matrix composition 
with reduced or no mineralizing capacity. These findings demonstrate the regulation of 
osteoblast differentiation and matrix mineralization by the activin A-follistatin system, 
providing the possibility to control bone quality as well as pathological calcifications 
such as atherosclerosis by using activin A, follistatin, or analogs thereof.
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5.1 Introduction
Decreased bone quality is an important determinant of osteoporosis. Bone quality is determined largely by a combination of protein composition and mineralization of 
the extracellular matrix (ECM) 1. Osteoblasts play a pivotal role in regulating bone quality, 
as they are the bone-forming cells and the directors of bone resorption by osteoclasts. 
Osteoblasts are of mesenchymal origin and undergo a complex differentiation process 
regulated by multiple endocrine, paracrine, and autocrine factors. During differentiation 
and bone formation, osteoblasts produce a complex ECM that eventually starts to 
mineralize. Initiation of mineralization requires the precipitation and attachment 
of calcium phosphate crystals to the ECM, although the exact mechanism is poorly 
understood 2. The process of mineralization is not unique for bone cells demonstrated by 
ectopic mineralization in pathological conditions. Vascular smooth muscle cells (VSMCs) 
are thought to be primarily involved in vascular mineralization. These cells undergo an 
osteoblast-like differentiation process expressing osteoblastic factors, including alkaline 
phosphatase (ALPL) and runt-related transcription factor 2 3-5.
Several members of the transforming growth factor-β (TGFβ) superfamily, 
including TGFβ and bone morphogenic proteins (BMPs), are well-known regulators of 
bone formation. Both TGFβ and BMPs promote bone development by stimulating the 
differentiation of osteoblast progenitors 6, 7. In addition, TGFβ seems to inhibit later 
phases of osteoblast differentiation and mineralization 8-10. Activins belong to the 
TGFβ superfamily, but their precise role in bone formation is unknown. The structure 
of activins is closely related to that of TGFβ, and activins act via similar intracellular 
signaling molecules 11. Activins and their relatives, inhibins, were initially purified from 
gonadal fluids and characterized on the basis of their ability to modulate FSH secretion 
from pituitary gonadotropes 12, 13. Besides this classical role of activins, activins can 
affect the function of other cell types and tissues (e.g., the adrenal gland, liver, 
neurons, pancreas, and bone) 14-18.
Activins and inhibins are composed of the inhibit subunits α, βA, and βB. 
Heterodimerization of the α and βA, or βB subunit forms inhibin A or inhibin B. Homo- and 
heterodimerization of the βA, and βB subunits result in formation of activin A, activin AB, 
or activin B 12. Activins need type I and type II activin receptors for signal transduction. 
Activins bind to the activin type IIA or type IIB receptors, leading to recruitment and 
phosphorylation of the activin type IB receptor (ALK4). The phosphorylated type I 
receptor, in turn, phosphorylates intracellular signaling proteins known as Smads. Smad2 
or 3 are phosphorylated by activins and TGFβ, whereas Smad1, 5, or 8 are phosphorylated 
by the BMP-like ligands 11. Activin signaling is inhibited by the extracellular action of 
inhibins or follistatin 19. Follistatin is a soluble protein that functions as an activin 
binding protein preventing activin from interacting with its receptor 20. Inhibins need the 
presence of a coreceptor, betaglycan, to inhibit activin signaling via competitive binding 
to the activin type II receptor, preventing  recruitment of the activin type I receptor 21, 22.
Several studies demonstrated a role for activins in bone metabolism. Large quantities 
of activin are found in the ECM of bovine bone 23. Activin A enhances osteoclast-like cell 
formation in murine bone marrow cultures 24, 25. Activin A promotes osteoblastogenesis 
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in murine bone marrow cultures 25 and, in vivo, promotes bone formation and fracture 
healing in rodents 23-27. However, other reports demonstrated an inhibitory effect of 
activin on osteoblast differentiation in rat and murine osteoblasts 28, 29.
The aim of this study was to assess the impact of activin signaling on osteoblast 
differentiation related to human bone formation and bone quality. The effect of activin 
A on matrix mineralization was measured together with the endogenous production of 
activin A and activin antagonists during osteoblast differentiation. Moreover, genome-
wide expression profiling in osteoblasts was performed to reveal downstream mediators 
of activin signaling in relation to matrix mineralization. 
5.2 Results
Activin A inhibits matrix mineralization in human osteoblast cultures
Activin signaling in osteoblasts was studied in detail using the SV-HFO osteoblast 
differentiation model. This human osteoblast model produces an ECM in culture, which 
eventually is mineralized in a 2 to 3 wk period 30. Activin A treatment strongly inhibited the 
mineralization process (Fig. 5.1 A) (up to 50 – 100 %). Three other mineralization models 
were treated with activin A to demonstrate that inhibition of matrix mineralization by 
activin A is not unique for the SV-HFO osteoblast model. Activin A was tested in another 
human osteoblast model (NHOst) and in human mesenchymal stem cell (MSC) cultures 
that were induced to differentiate toward osteoblasts (Fig. 5.1 B, C). Similar to SV-
HFO cells, mineralization in both human osteoblast models was inhibited by activin A. 
In addition, human VSMCs were treated with activin A. VSMCs can be used as a model 
for vascular mineralization since they can form a mineralized ECM in vitro 31. Activin A 
treatment strongly inhibited matrix mineralization in these VSMC cultures (Fig. 5.1 D).
The effect on matrix mineralization was dose dependent, showing significant 
inhibition after treatment with activin A concentrations of 5 ng/ml and higher (Fig. 
5.1 E). Together with decreased matrix mineralization, activin A also decreased the 
activity of the osteoblast differentiation marker ALPL dose dependently, although the 
magnitude of inhibition (10–30 %) was smaller than that of mineralization (data not 
shown).
Osteoblasts produce activin A in a differentiation dependent manner
To reveal whether activin can act in an autocrine manner, we measured mRNA levels of 
the activin subunits inhibin-βA (INHBA) and inhibin-βB (INHBB) together with activin A 
protein production in human osteoblast cultures. QPCR demonstrated that INHBA was 
expressed abundantly compared with the INHBB subunit. In contrast, inhibin-α (INHA) 
mRNA was almost undetectable (Fig. 5.2 A). This suggests that osteoblasts mainly 
produce activin A. In addition, Fig. 5.2 A shows mRNA expression of the activin type I 
receptor (ACVR1B) and the activin type II receptors (ACVR2A/2B) in osteoblasts.
Quantification of activin A protein showed that osteoblast cultures secrete 
biologically relevant amounts of activin A (up to 5 ng/ml), whereas inhibin A protein 
could not be detected (data not shown). Activin A production corrected for cell number 
(DNA content) was measured at different stages of differentiation (days 5, 12, and 19). 
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Figure 5.1. Activin A inhibits matrix minerali-
zation. Three different human osteoblast (OB) 
differen-tiation models (A–C) and human 
vascular smooth muscle cells (D) were 
induced to mineralize in the absence and 
continuous presence of activin A (20 ng/ml). 
Mineralization was visualized by Alizarin Red 
staining on day 14 for SV-HFO and NHOst 
cultures, on day 20 for MSC cultures, and on 
day 30 for VSMC cultures. (E) Osteoblasts 
(SV-HFO) were cultured in the presence of 
indicated concentration activin A. Calcium 
content was quantified after 19 days of 
culture. Values means ± SEM. **P < 0.01 
compared with vehicle cultures.
Figure 5.2. Production and localization of activin A in human bone. (A) mRNA expression of inhibin/activin subunits 
(INHA, INHBA, INHBB) and activin type I (ACVR1B) and type II receptors (ACVR2A, ACVR2B) in osteoblast 
cultures (SV-HFO). Values means ± SEM. (B) Production of activin A protein by human osteoblasts (SV-HFO). 
Activin A levels were measured in control osteoblast cultures (open bars) and osteoblast cultures that were induced 
to mineralize (gray bars). Production was corrected for the culture DNA content. Values means ± SEM. **P < 0.01 
compared with control osteoblasts; #P < 0.01 compared with day 5 of mineralizing cultures. (C) Immunohistological 
staining of inhibin-βA subunit (left panels) and inhibin-α subunit (center panels) in human bone tissue. Mouse IgG2b 
was used as a negative control (right panels).
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Figure 5.3. Follistatin action and expression 
in human osteoblasts. (A) Activin signaling 
was measured using a luciferase reporter 
plasmid for activin signaling (CAGA-
luciferase). Osteoblast cultures (SV-HFO) 
were treated with activin A and coincubated 
with follistatin, then luciferase activity was 
measured after 24 h. Values means ± SEM. 
*P < 0.05; **P < 0.01 compared with vehicle. 
(B) Similar to panel A, only a BMP-responsive 
reporter construct was used (BRE luciferase) 
and cultures were treated with BMP2a. 
(C) Osteoblast cultures were treated with follistatin or activin A for 19 days. Calcium content was measured on day 
19. Values means  se. *P < 0.05; **P < 0.01 compared with vehicle. (D) Follistatin production by human osteoblasts 
(SV-HFO) on days 5, 12, and 19 in control and mineralizing conditions. Values means ± SEM. **P < 0.01 compared 
with control osteoblasts, ##P < 0.01 compared with day 5. (E) The molar ratio between activin A and follistatin of 
control and mineralizing osteoblast cultures on days 5, 12, and 19. Values means ± SEM. *P < 0.05; **P < 0.01 
compared with control osteoblasts. 
Activin A production decreased during differentiation and was lowest during stages of 
matrix mineralization (days 12 and 19) (Fig. 5.2 B, mineralizing osteoblasts). To explore 
this differentiation-dependent regulation, activin A production was also measured in 
preosteoblast cultures (SV-HFO) that did not undergo differentiation into fully functional 
and mineralizing osteoblasts. Nonmineralizing osteoblasts (control osteoblasts) 
were created by excluding glucocorticoids (DEX) from the culture medium. These 
osteoblast cultures had low ALP activity and did not show in vitro mineralization 32. 
Control osteoblasts had significantly higher activin A production than their mineralizing 
counterparts (Fig. 5.2 B), demonstrating that, in differentiated osteoblasts, activin A 
production is suppressed during mineralization.
In addition, immunohistology on human bone biopsies showed that human bone 
tissue contained high levels of activin A. The inhibin-βA subunit was detected in 
mineralized bone matrix, but inhibin-α subunit could not be detected (Fig. 5.2 C).
Activin A inhibits mineralization in an autocrine manner
The impact of endogenously produced activins on osteoblast function was measured by 
neutralizing activin signaling by the addition of the activin binding protein follistatin. 
First we measured whether follistatin was able to neutralize activin signaling in 
osteoblast cultures. An activin-signaling luciferase reporter construct (CAGA-Luc) was 
used to measure activin signaling. Activin A treatment increased CAGA-Luc activity 
dose-dependently, which could be inhibited by coincubation with follistatin (Fig. 5.3 A). 
Follistatin also reduced basal CAGA-Luc signaling, which further supports endogenous 
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production of activin and activation of activin signaling in osteoblasts. It has been 
suggested that follistatin also neutralizes BMP action 33, 34. To study this in osteoblasts, a 
BMP-responsive luciferase reporter construct was used (BRE-Luc). Addition of 10 and 100 
ng/ml BMP2a strongly induced BRE-Luc activity. In contrast to activin signaling, addition 
of follistatin had no effect on either basal or BMP2a-induced BMP signaling (Fig. 5.3 B). 
This suggests that, under these conditions, follistatin specifically neutralizes activin 
signaling in osteoblasts.
Neutralization of endogenous activins by follistatin treatment (100 and 500 ng/ml) 
clearly increased matrix mineralization (Fig. 5.3 C) together with a minor increase in 
ALPL activity (data not shown). This shows that osteoblasts secrete activin A, which 
inhibits mineralization and ALPL activity in a paracrine and/or autocrine way. In these 
experiments, osteoblasts were also treated with activin A to compare the impact of 
activin A with that of follistatin. These incubations demonstrated a dose-dependent 
effect of activin signaling on mineralization, where follistatin- (500 ng/ml), vehicle-, 
and activin A-treated cultures (50 ng/ml) represent neutralized, endogenous, and high 
activin signaling, respectively (Fig. 5.3 C).
Activin A-to-follistatin ratio is decreased in mineralizing cultures
Besides activin A production by osteoblasts, we demonstrated that osteoblasts secrete 
biologically relevant amounts of follistatin. On day 12 of culture, maximum levels 
of follistatin (up to 1–3 ng/ml) could be measured in the culture supernatants. This 
indicates that, in osteoblasts, endogenous activin signaling is regulated by the expression 
of activin A as well as by expression of follistatin. The production of follistatin was 
measured (corrected for DNA content) throughout culture in mineralizing and control 
osteoblasts (Fig. 5.3 D). Follistatin production was higher at the beginning of culture 
(day 5) in mineralizing osteoblast compared with control osteoblasts and decreased 
during culture in both conditions. For the eventual action of activin A, it is important 
to take into account the molar ratio of activin A and follistatin. This demonstrated that 
mineralizing cultures have a lower activin A-to-follistatin ratio compared with control 
cultures, indicating suppressed activin signaling in mineralizing conditions (Fig. 5.3 E).
Activin signaling is most effective prior to the onset of mineralization
We investigated whether activin signaling inhibits mineralization in a specific time 
window of osteoblast differentiation by treating cultures with activin A during specific 
periods. First, cultures were treated in the premineralization period (up to day 10 of 
culture) or during the mineralization period (from day 10 of culture onward) with a 
moderate dose of activin A (20 ng/ml). Subsequently, mineralization was measured on 
day 19 (Fig. 5.4 A). Treatment preceding the mineralization period most effectively 
inhibited mineralization, whereas treatment in the period when mineralization was 
ongoing appeared to be ineffective. To zoom in on this premineralization period, more 
specific incubations were performed, as depicted in Fig. 5.4 B. Activin A was most 
effective when present in the final 7 days before the onset of mineralization. Even when 
activin A was present only during the final 2 days (days 10–12) before mineralization, a 
significant decrease in mineralization was measured (Fig. 5.4 B).
94
C
ha
pt
er
 5
A
ctivin signaling inhibits m
atrix m
ineralization
95
Figure 5.4. Activin A treatment during different stages of differentiation. (A) Osteoblasts (SV-HFO) were treated 
with activin A before the onset of mineralization (day 0 to 10), after the onset of mineralization (day 10 to 19), or 
during the whole culture period (day 0 to day 19). Calcium content was measured at the end of culture (day 19). (B) 
Osteoblasts (SV-HFO) were treated with activin A in a specific period before the onset of mineralization. Calcium 
content was measured on day 12. (C) Osteoblast cultures (SV-HFO) were cultured for 10 days in the presence or 
absence of activin A. On day 10, cultures were devitalized and subsequently cultured in normal culture medium. 
Calcium content was measured at the moment of devitalization (day 0) and 3 and 5 days after devitalization. Values 
means ± SEM. *P < 0.05; **P < 0.01 compared with vehicle cultures.
We hypothesized that activin signaling in this premineralization phase leads to an 
altered matrix composition, keeping it in an immature state not able to mineralize. To 
prove this, we exploited the fact that osteoblast cultures produce an ECM within the first 
10 days of culture that is mature and can subsequently mineralize independent of the 
presence of additional living osteoblasts 35. This effect was achieved by freezing osteoblast 
cultures to -20°C at the onset of mineralization (day 10). These cultures containing 
nonliving cells but an intact ECM were subsequently incubated for an additional 3 or 
5 days with culture medium. Mineralization was quantified at the moment of fixation 
(day 10 living cultures=day 0 devitalized cultures) and after 3 and 5 days of additional 
incubation (see incubation scheme Fig. 5.4 C). No mineralization was measured on day 0 
of devitalized cultures. However, after 3 and 5 days, mineralization of the ECM could 
be measured (Fig. 5.4 C, vehicle). In cultures that had been pretreated with activin A 
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prior to devitalization, no mineralization of the ECM could be detected. These findings 
support our hypothesis that the major impact of activin A occurs before the onset of 
mineralization and suggest an effect on matrix composition and maturation.
Gene profile analysis of follistatin- and activin A-treated osteoblast cultures
Gene profile experiments were performed to gain insight into the molecular action of 
activin A in osteoblasts using Affymetrix HG U133 Plus 2.0 Genechips. Gene expression 
profiles of follistatin- (500 ng/ml), vehicle-, and activin A- (50 ng/ml) treated osteoblasts 
were compared. These treatments created cultures having low, moderate (endogenous), 
and high activin signaling, resulting in three different levels of matrix mineralization as 
demonstrated in Fig. 5.3 C. 
A phenotype-based query was designed to identify genes regulated by activin signaling 
in the premineralization period (days 5 and 12), which was shown to be important for 
inhibition of mineralization by activin A (Fig. 5.4 B). An important aspect in the selection 
query was that we searched for genes that were regulated in follistatin- and activin A-
treated cells, since both conditions affected mineralization. Genes were selected that 
were up-regulated in activin A-treated cultures (low mineralization) and down-regulated 
in follistatintreated cultures (high mineralization) compared with vehicle cultures, or 
vice versa, on days 5 and 12 In addition, the difference in gene expression between 
activin A- and follistatin-treated cultures should be at least 2-fold on one of these 2 
days (Fig. 5.5 A). In total, 520 Affymetrix IDs were selected representing 397 unique 
genes and 62 nonannotated Affymetrix IDs. The selected Affymetrix IDs are presented as 
a hierarchical clustering in Fig. 5.5 A; red and green indicate up- and down-regulation 
compared with vehicle cultures, respectively.
Gene ontology analysis
Next, GO enrichment analysis was used to categorize the 397 selected genes for the GO 
categories: biological process (Fig. 5.5 B), molecular function (Fig. 5.5 C), and cellular 
component (Fig. 5.5 D). In total, we identified 47 biological processes, 13 molecular 
functions, and 4 cellular components as significantly over-represented compared with 
what would be expected if 397 random genes were analyzed. Several GO terms for 
biological process shared high similarity and were identified by similar groups of genes. 
In Fig. 5.5 B, we reduced the number of biological process terms to 20 by excluding 
these overlapping GO terms.
QPCR showed that mRNA expression of osteoblast differentiation markers like 
RUNX2, collagen type-I, secreted phosphoprotein 1 (osteopontin), and bone gamma-
carboxyglutamate gla protein (osteocalcin) were unchanged by activin signaling (data not 
shown), suggesting no direct effect on the osteoblast differentiation process. However, 
GO biological process analysis demonstrated that differentiation-related processes like 
development and morphogenesis were strongly enriched by activin signaling (Fig. 5.5 B), 
including the osteoblast transcription factor MSX2 36. QPCR confirmed GeneChip analyses 
that MSX2 mRNA expression was significantly inhibited by activin A in osteoblasts (SV-
HFO) as well as in VSMCs (Fig. 5.5 E).
The GO enrichment analysis for cellular component showed that genes related to 
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Figure 5.5. Gene ontology (GO) enrichment analysis of activin signaling-regulated genes. (A) Phenotype-based 
selection query based on Affymetrix Genechip data of vehicle-, activin A- (50 ng/ml), and follistatin- (500 ng/ml) 
treated osteoblast cultures (SV-HFO). In total, 520 affymetrix probe sets matched this selection query, representing 
397 unique genes and 62 nonannotated probe sets. Affymetrix probe sets are hierarchically clustered; red indicates 
up-regulation and green indicates down-regulation compared with vehicle cultures. Color intensities indicate the 
magnitude of regulation. (B–D) Enriched GO terms within the set of 397-regulated genes for GO biological process (B), 
GO molecular function (C), and GO cellular component (D). Enriched categories are those identified as significantly 
enriched (P < 0.05) after multiple testing. Numbers inside the bars indicate the number of genes from the set of 
397 selected genes determining the GO term. #Number of presented biological processes is reduced by exclusion 
of several overlapping GO terms. *P <  0.05; **P  <  0.01; ***P  <  0.001. (E) QPCR analysis of MSX2 expression 
in osteoblast (SV-HFO, day 7) and VSMC (day12) cultures after activin A (50 ng/ml) and follistatin (500 ng/ml) 
treatment. Values means  ± SEM. **P < 0.01 compared with vehicle. #P  <  0.05; ##P  <  0.01 compared with follistatin.
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localization in the extracellular region, space, or matrix were significantly enriched 
(Fig. 5.5 D). This result is in line with our hypothesis that activin A affects extracellular 
matrix formation and maturation (see Fig. 5.4 C). Although expression of the well-known 
and abundant ECM proteins in bone, collagen type-I, osteopontin, and osteocalcin was 
Figure 5.6. ECM genes regulated by activin signaling. (A) Hierarchical clustering of genes that matched the 
selection query (Fig. 5.5 A) and were annotated with the GO term ECM. Genes are annotated with their gene 
symbol, gene name, and Affymetrix IDs. Green indicates down-regulation and red indicates up-regulation compared 
with vehicle cultures. Color intensities indicate the magnitude of regulation (Genechip data). (B) QPCR analysis of 
nine selected ECM genes together with ALPL as a positive control. Expression was measured in follistatin-, vehicle-, 
and activin A-treated osteoblasts (SV-HFO, day 7) and VSMC cultures (day 12). The mRNA expression in vehicle 
cultures was set to 1 and used as a reference. Values means ± SE. *P < 0.05; **P < 0.01 compared with vehicle. 
#P < 0.05; ##P < 0.01 compared with follistatin.
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unchanged by activin signaling, these GeneChip analyses identified numerous ECM genes 
that were regulated by activin signaling (Fig. 5.6 A).
Activin signaling alters ECM composition in osteoblasts as well in VSMCs
A selection of ECM genes was analyzed in more detail using QPCR in follistatin-, vehicle-, 
and activin-treated osteoblasts and VSMCs (Fig. 5.6 B). The expression of ALPL was also 
quantified as a positive control. This experiment showed that CLEC3B, COL5A3, TIMP4, 
NID2, and ALPL, which were suppressed by activin A (upper 5 panels) in osteoblasts, were 
also suppressed by activin A in VSMC cultures. Activin signaling in osteoblasts increased 
POSTN and MMP2 expression, which was also demonstrated in VSMCs. In contrast, activin 
A increased FBLN5 and CSPG2 expression in osteoblasts, but the expression of these 
genes was unchanged in VSMCs.
Follistatin treatment did not alter gene expression in VSMCs. This result agrees with 
the expression data of INHBA and INHBB (mRNA) in VSMC, both of which had a low level 
compared with levels in osteoblasts (data not shown). Moreover, activin A production by 
VSMCs cultures was much lower than the production by osteoblasts (data not shown). In 
VSMCs, only POSTN mRNA expression was regulated by follistatin (0.5-fold). This gene 
was strongly induced by activin signaling and is probably already activated by a low 
concentration of activins (Fig. 5.6 B).
5.3 Discussion
This study shows that activin signaling controls human osteoblast differentiation and function, and inhibits matrix mineralization through mechanisms that include 
altered ECM composition and maturation. The presence and production of activin 
A in bone together with the strong effects of activin A on mineralization in vitro 
demonstrate a physiological impact of activin A on human osteoblast differentiation 
and bone metabolism. As a consequence, the control of activin signaling in bone might 
be crucial for proper bone formation. We showed that activin signaling in osteoblasts 
is tightly controlled in a differentiation-dependent manner. Mineralizing osteoblast 
cultures showed decreased activin A production and expression of the activin antagonist 
follistatin, resulting in a decreased activin A-tofollistatin ratio in mature osteoblasts. 
This indicates that osteoblasts autoinhibit matrix mineralization via expression of activin 
A, which in turn is controlled by its inhibitor follistatin. These control mechanisms have 
been shown for other regulatory growth factors in bone (e.g., activities for both BMPs 
and insulin-like growth factors are regulated by various binding proteins in bone) 6, 37. 
We demonstrated that, in osteoblasts, follistatin acts as a specific inhibitor of activin 
A and not of BMP2. This is in line with other data showing that follistatin does not 
inhibit BMP2 38. It is tempting to speculate that the function of the activin-follistatin 
mechanism is to control the extent of mineralization and, for example, to prevent 
overmineralization of bone tissue, which can result in brittle bones that are too stiff and 
unable to reform during loading 1. 
Suppression of osteogenesis by activins was also found by others using murine and 
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rat osteoblasts 28, 29. Other studies performed in rodent models showed stimulation 
of osteogenesis, bone formation, and fracture healing by activins 25-27, 39, 40. Mice 
deficient for the inhibin-A subunit and follistatin have been generated and have shown 
abnormal tooth and craniofacial development after birth, but no other peculiar skeletal 
phenotypes 41, 42. Unfortunately, both of these available systemic knockout mouse models 
die within 24 h of birth, making it impossible to study postnatal bone development and 
bone remodeling. Follistatin-overexpressing transgenic mice are viable, but no skeletal 
phenotype has yet been described in these mice 43. Whether the lack of effects or 
opposite effects in murine models reflect yet-unexplained species differences is not 
clear. However, these studies lack detailed analysis of bone tissue (e.g., bone mineral 
content, bone mineralization rate, and bone microarchitecture).
It has been shown that TGFβ, a structural relative of activin, can inhibit matrix 
mineralization in osteoblast cultures 8-10. At the signal transduction level, activins 
and TGFβ both stimulate Smad2/3 phosphorylation 11, which might explain the 
overlapping effects of activin and TGFβ in vitro. Even though the effects of TGFβ 
on matrix mineralization are similar to the effects we describe for activin A, the 
physiology might differ. TGFβ is present as a latent complex in the bone matrix, and 
accumulated TGFβ is activated only during bone resorption by osteoclasts 44, 45. In 
contrast, activins are produced and released directly in an active form. Therefore, 
activin and TGFβ differ in bioavailability during osteoblast development in vivo. TGFβ 
may activate osteoblasts (precursors) during bone resorption when inactive TGFβ 
becomes activated, whereas activin and follistatin control osteoblast differentiation 
and mineralization in a mechanism independent of a direct coupling to resorption.
The current mineralization data demonstrate that, in osteoblasts, activin treatment 
before the initiation of mineralization is crucial for strong inhibition of mineralization. 
On the basis of these data, it can be hypothesized that activin causes an altered ECM 
composition in such a way that the mineralization potential of the ECM is strongly 
inhibited. This hypothesis is substantiated by gene expression studies. The unbiased 
gene expression profiling approach demonstrated an altered expression of numerous 
ECM genes by activin signaling. Little is known about the role of the majority of these 
ECM proteins in matrix mineralization, which makes it difficult to interpret the full 
extent and significance of these ECM proteins alone or in combination. Only a limited 
number of deficient mice have been generated for these ECM genes, of which the 
majority lack a bone phenotype. Although for functional matrix protein analysis, 
knocking out or changing the expression of only a single ECM might not be sufficient 
to alter matrix mineralization. The combination of matrix proteins (i.e., the ECM 
composition) might be of greater importance for the eventual matrix quality and 
mineralization capacity. Nevertheless, the observed direction of regulation coupled 
to the mineralization phenotype may hint at the function of these ECM genes. ECM 
genes that are up-regulated by activin signaling (low mineralization) may act negatively 
on mineralization, whereas ECM genes that are downregulated may act positively. In 
support of this is the observation that C-type lectin domain family 3 member B (CLEC3B, 
also known as tetranectin), down-regulated by activin signaling, has been shown to 
be positively involved in mineralization 46, whereas periostin (POSTN) and chondroitin 
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sulfate proteoglycan 2 (CSPG2), up-regulated by activin signaling, are negatively 
implicated in mineralization 47-49. The direction of the regulation of genes involved 
in ECM turnover (MMP2, ADAMTS3, and TIMP4) is also in line with this hypothesis.
To extend the observation beyond skeletal development and mineralization, we 
showed that in a VSMCbased model for vascular mineralization, matrix mineralization 
was also inhibited by activin A treatment. This indicates that, besides osteoporosis, 
these findings can also be of great importance for vascular mineralization, which 
is a major risk factor for cardiovascular failure 50, 51. Other studies have shown that 
activin A is expressed in VSMC cultures and in atherosclerotic lesions 52, 53. Moreover, 
it was demonstrated that activin A promotes the contractile phenotypes of VSMC 52. 
Promotion of this VSMC phenotype might simultaneously inhibit VSMC osteogenesis 
and matrix mineralization. On the other hand, activin A might inhibit VSMC-
induced matrix mineralization via a mechanism similar to that in osteoblasts. This 
is supported by our observations that several ECM genes were similarly regulated by 
activin A in VSMCs and osteoblasts. Shao and colleagues showed that Msx2 promotes 
cardiovascular calcification by activating paracrine Wnt signaling 54. We showed 
that activin signaling suppressed MSX2 expression in VSMCs as well as osteoblasts. 
According to GeneChip data, paracrine Wnt signaling seemed to be unaffected, with the 
exception of WNT2B. QPCR analyses demonstrated that activin signaling significantly 
decreased WNT2B mRNA expression in osteoblast and VSMC cultures (data not shown).
In summary, the key findings are 1) osteoblasts express activin A and its natural 
inhibitor follistatin to control activin signaling in a differentiation-dependent 
manner, 2) activin inhibits mineralization in a human bone formation model as well 
as in a model for vascular mineralization, and 3) activin does so by changing the 
expression of a wide range of matrix proteins before the onset of mineralization 
leading to a matrix composition with no or reduced mineralizing capacity. This 
led to the conclusion that activin signaling is a potent regulator of bone matrix 
formation and mineralization, and thereby an interesting mechanism in the control 
and maintenance of bone quality. Mineralization can be controlled in two directions 
using activin A, follistatin, or analogs of these compounds. As a consequence, activin 
signaling and activin target genes are important therapeutic targets for controlling 
matrix mineralization in bone as well as mineralization in pathological conditions.
5.4 Materials and methods
Cell culture
SV-HFO cells were cultured as described previously 30. Medium was supplemented 
with freshly added 10 mM β-glycerophosphate (Sigma, St. Louis, MO, USA), 100 
nM dexamethasone (DEX) (Sigma), or other additives (activin and follistatin) and 
replaced every 2 or 3 days. Follistatin was purchased from PeproTech and activin 
A from R&D Systems (Minneapolis, MN, USA). Normal human osteoblasts (NHOst) 
(Cambrex Bio Science CC-2538; East Rutherford, NJ, USA), vascular smooth muscle 
cells (coronary artery smooth muscle cells; Cambrex Bio Science; CC-2583), and human 
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Table 5.1. Primer and probe sequences and concentration used for qPCR analysis. Primer sets without 
a fluorescence probe were used in combination with the SYBR green QPCR kit (Eurogentec).
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mesenchymal stem cells (Cambrex Bio Science) were cultured in a manner similar to 
that of SV-HFO cells, with only the following adjustments. NHOsts and hMSCs were 
used between passages 3 and 6 and seeded in a density of 5 x 103 and 10 x 103 vital 
cells per cm2, respectively. NHOst and hMSC cultures were induced to mineralize 
in a medium similar to SV-HFO, except that 10 % charcoal-treated, heatinactivated 
FCS (Gibco BRL, Carlsbad, CA, USA) was used. VSMCs were used between passages 
3 and 7 and seeded in a density of 5 x 103 vital cells/cm2. Expansion of VSMCs was 
performed in smooth muscle cell medium (Cambrex Bio Science) supplemented 
with Clonetics Sm-GM-2 Bulletkit (Cambrex Bio Science). VSMCs were induced to 
mineralize in DMEM (Gibco BRL; with 4500 mg/l glucose, l-glutamine, and pyruvate) 
supplemented with 100 nM DEX, 0.1 mM ascorbic acid (Sigma), 10 μg/ml insulin (Sigma), 
1 mM CaCl2 (final concentration of 2.8 mM), 10 mM β-glycerophosphate, and 10 % FCS.
DNA, alkaline phosphatase activity, and mineralization assays
ALPL, DNA, and calcium measurements were performed as described previously 32.
Quantitative PCR analysis (QPCR)
RNA isolation, cDNA synthesis, and QPCR were performed as described previously 30. 
Primer and probe sequences and concentrations used for QPCR are listed in Table 5.1.
Quantification of activin A, follistatin, and inhibin A
At various days during culture, medium was collected for activin A and follistatin 
measurements. Medium was collected from the cultures after 48 h incubation. Medium 
was centrifuged (5 min, 500 g) and stored at -20°C for further analysis. Cell lysates were 
also prepared so as to analyze DNA content of the corresponding cultures. Activin A was 
measured using 50–100 μl medium and the activin A DuoSet ELISA kit. Follistatin was 
measured using 100 μl medium and the follistatin quantikine ELISA  kit (R&D Systems). Inhibin 
A was measured using the inhibin A ELISA kit purchased from Serotec (Raleigh, NC, USA).
Immunohistology
Plastified bone sections were deacrylated in a 1:1 mixture of xylene and chloroform for 
30 min, then dipped in xylene, rehydrated, and rinsed twice with distilled water. Slides 
were pretreated with Tris-EDTA buffer, pH 9.0, for 15 min at 100°C and cooled down for 
15 min, followed by rinsing in tap water. Endogenous peroxidase activity was inhibited 
by a 10:1 mixture of PBS and H2O2 for 10 min, followed by two water washes and one Tris-
HCl pH 8.0 wash. The following steps were carried out in a humidified chamber at room 
temperature. Primary antibodies were diluted 1:50 in normal antibody diluent (Skytek 
Laboratories, Logan UT, USA; code ABB999) and incubated for 60 min. Inhibin-βA, 
inhibin-α, and IgG2b negative control antibodies were purchased from Serotec (MCA950 
ST, MSA951S, MCA691). Slides were rinsed twice in Tris-HCl, pH 8.0. Immunoreactivity 
was detected with the Dako REALtm Envisiontm Detection System, peroxidase/ DAB +, 
rabbit/mouse (Dako, Carpinteria, CA, USA; code K5007). After DAB detection, slides 
were rinsed in tap water and counterstained in Harris hematoxylin for 1 min, rinsed 
in tap water for 2 min, dehydrated in ascending ethanol steps, rinsed in xylene, and 
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coverslipped with Pertex mounting medium (Histolab, Västra Frölunda, Sweden).
Luciferase reporter assays
On day 5 of culture, cells were transfected with 200 ng reporter plasmids per well (12-
well plate) using Fugene6 (Roche, Nutley, NJ, USA). After 24 h, medium was replaced 
by fresh medium containing low serum (0.2 % FCS) and incubated for 3 h. After 3 h the 
medium was refreshed for the second time with medium containing low serum, but 
this time supplemented with additives as described in Results. After 24 h, cells were 
lysed by incubating for 20 min in 100–200 μl lysis buffer (Promega, Madison, WI, USA). 
Luciferase activity was measured using 25 μl cell lysate and the Steady-Glo Luciferase 
Assay System (Promega). Activin signaling was measured using pGL3(CAGA)12-lux 
(CAGA-Luc) 55 and BMP signaling was measured using pGL3-BRE-luc (BRE-Luc) 56.
Devitalization of osteoblast cultures
On day 10 of culture, medium was removed and the cultures were washed once 
with PBS (Gibco BRL). Cultures were air dried and frozen overnight at -20°C. Next, 
devitalized cultures were incubated normally as described in the cell culture methods
(indicated as day 0 for devitalized cultures).
Affymetrix Genechip-based gene expression
Purity and quality of isolated RNA were assessed by RNA 6000 Nano assay on a 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The RNA of three different 
biological samples was pooled per condition analyzed. Synthesis of first strand second 
strand cDNA from total RNA was performed according to the One-Cycle Target Labeling 
protocol (Affymetrix, Santa Clara, CA, USA; 701024 Rev. 3). In total, 4.0 μg of total 
RNA was reverse transcribed using a Superscript ds-cDNA Synthesis Kit according to 
the manufacturer’s description (Invitrogen, Carlsbad, CA, USA). Subsequently, double-
stranded cDNA was purified using GeneChip Sample Cleanup Module (Affymetrix) and 
served as a template in the in vitro transcription reaction using BioArray HighYield 
RNA Transcript Labeling Kit (Affymetrix). The amplified biotinylated complementary 
RNA (cRNA) was purified using a GeneChip Sample Cleanup Module. In total, 20 μg 
of biotinlabeled cRNA was fragmentized by metal-induced hydrolysis at a final 
concentration of 0.5 μg/μl for 35 min at 94°C. Fragmentation was checked on an 
Agilent 2100 Bioanalyzer, confirming an average size of ≈100 nt. Fifteen micrograms 
of fragmented biotinylated cRNA was hybridized to GeneChip Human Genome U133 
Plus 2.0 oligonucleotide Genechips (Affymetrix) according to the manufacturer’s 
protocol (Affymetrix, 701025 Rev 5). Staining, washing, and scanning procedures 
were carried out as described in the GeneChip Expression Analysis technical manual 
(Affymetrix). Data acquisition was performed using the GeneChip Scanner 3000.
Genechip data analysis
To examine the quality of the various arrays, measured intensity values were analyzed 
using GeneChip Operating Software (Affymetrix). The percentage of present calls 
(≈40 %), noise, background, and ratio of GAPDH 3’ to 5’ (1.4) all indicated a high quality 
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of samples and an overall comparability. Probe sets that were not present (according 
to Affymetrix MAS5.0 software) in any of the Genechips were omitted from further 
analysis. Raw intensities of the remaining probe sets of each chip were log2 transformed 
and normalized using quantile normalization. After normalization, the data were back-
transformed to normal intensity values. Data analysis was carried out using OmniViz 
software, version 3.6.0. For gene ontology (GO) analysis, the 520 selected affymetrix IDs 
were analyzed using OntologyTraverser 57.
Gene nomenclature
Gene names and gene symbols were used as provided by HUGO Gene Nomenclature
Committee 58.
Statistics
Data were presented only if multiple independent experiments showed similar results. 
Experiments were performed at least in triplicate. Values are the means ± SEM. Significance 
was calculated using the Student’s t test. The Benjamini and Hochberg false discovery
rate was used to calculate significance for the GO analyses 57.
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Abstract
The Wnt signaling pathway is an important regulator of cellular differentiation in a 
variety of cell types including osteoblasts. In this study we investigated the impact 
of Wnt signaling on the function of human osteoblasts in relation to the stage of 
differentiation. Differentiating osteoblasts were created upon glucocorticoid (GC) 
treatment, whereas nondifferentiating osteoblasts were created by excluding GC from 
the culture medium. GC-induced differentiation caused suppression of endogenous 
β-catenin levels and transcriptional activity. During glucocorticoid (GC)-induced 
osteoblast differentiation Wnt signaling activity slightly decreased alkaline phosphatase 
activity in differentiating osteoblasts, but strongly suppressed matrix mineralization. In 
addition, mRNA expression of several Wnt signaling genes was strongly regulated during 
GC-induced osteoblast differentiation, including frizzled homolog 8, dickkopf homolog 
1 and secreted frizzled-related protein 1. In contrast, in the absence of GC-induced 
differentiation, Wnt signaling acted positively by stimulating basal alkaline phosphatase 
activity. Interestingly, pre-stimulation of Wnt-signaling in osteoblasts enhanced their 
differentiation capacity later on during the GC-induced differentiation process. In 
conclusion, we showed a differentiation-dependent effect of Wnt signaling in osteoblasts. 
Wnt signaling stimulated early osteoblasts in their capacity to differentiate, whereas 
mature osteoblasts were strongly inhibited in their capacity to induce mineralization. 
Moreover, osteoblast differentiation suppressed endogenous Wnt signaling and changed 
expression of multiple Wnt signaling genes.
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6.1 Introduction
The Wnt signaling pathway is an important regulator of cellular differentiation in a variety of cell types 1. It plays a widespread role in skeletogenesis from embryonic 
skeletal patterning, through fetal skeletal development, and bone remodeling in 
adults 2, 3. 
In humans 19 different Wnt proteins have been identified. Wnt proteins activate 
Wnt/β-catenin signaling upon binding to the frizzled receptor and a co-receptor LRP 5 
or 6. During activation of Wnt signaling degradation of β-catenin is prevented, which 
results in β-catenin accumulation, its nuclear transport and regulation of several 
target genes. In the absence of Wnt signal, the level of β-catenin is kept low through 
degradation of cytoplasmic β-catenin.  A multiprotein complex containing glycogen 
synthase kinase 3β and scaffolding proteins axin and adenomatosis polyposis coli 
(APC) mediate the degradation of β-catenin by phosphorylation of specific amino acid 
residues. Wnt signaling is under the control of several extracellular factors that inhibit 
Wnt signaling.  Secreted frizzled related proteins (SFRPs) and Wnt inhibitory factor 
(WIF) bind directly to Wnt proteins thereby preventing receptor activation. Dickkopf 
(Dkk) proteins inhibit Wnt signaling via binding to LRP5 or 6 and the associated protein 
Kremen, which dissociates LRP5 or 6 from frizzled preventing formation of an active Wnt 
receptor complex 1, 4.
Multiple skeletal defects have been described in mice deficient for distinct Wnt 
signaling genes 5-11. In humans, loss-of-function mutations in LRP5 are associated with 
osteoporosis-pseudoglioma syndrome, which is characterized by low bone mass and 
skeletal fragility 12. In contrast, gain of function mutations in LRP5 are associated with a 
high bone mass phenotype 13, 14. Moreover, various genetic variants of LRP5 are associated 
with BMD and risk of fractures in humans 15-18. Despite all these data, the precise 
mechanism of Wnt signaling in bone biology remains unclear. The skeletal defects are 
at least partially accomplished by regulating osteoblast differentiation. Several reports 
show that Wnt signaling contributes to osteoblast differentiation 19-21, whereas other 
reports show the ability of Wnt signaling to inhibit osteoblast differentiation 22-24.
The conflicting data on whether Wnt signaling is stimulating or inhibiting osteoblast 
differentiation is likely to reflect the diverse function of Wnt signaling at different stages 
of osteoblast development. To address this we exploited a human pre-osteoblast cell line, 
SV-HFO, that dependent on the presence or absence of GCs either differentiates in a full 
active bone forming osteoblast or does not differentiate, respectively. We studied the 
endogenous Wnt signal and expression of Wnt signaling related genes in differentiating 
and nondifferentiating osteoblasts. In addition, the impact of Wnt signaling was studied 
on osteoblast function in both differentiation conditions.
6.2 Results
Glucocorticoid induced human osteoblast differentiation 
Wnt signaling was studied in human osteoblasts representing two functionally different 
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stages of differentiation. To create these two different staged osteoblasts the human 
pre-osteoblast cell line SV-HFO was treated with or without 100 nM dexamethasone 
(DEX). DEX treatment induced osteoblast differentiation and created cultures having 
high alkaline phosphates activity (ALPL) that initiated matrix mineralization after 2 
weeks of culture. Cultures that were not treated with DEX showed low ALPL activity 
and showed no matrix mineralization 25. Throughout the remainder of the study non-
DEX-treated and DEX-treated cultures will be referred as nondifferentiating and 
differentiating cultures, respectively.
Figure 6.1. Endogenous Wnt signaling in differentiating and nondifferentiating osteoblast cultures. (A) β-catenin 
levels (cytosolic fraction) at day 5, 12 and 19 of culture. (B) Quantification of β-Catenin in the cytosolic and nuclear 
fraction in nondifferentiating and differentiating osteoblast cultures at day 5, 12 and 19 of culture. (C) β-Catenin 
levels (cytosolic fraction, day 12) of nondifferentiating cultures, nondifferentiating cultures that were treated for 24 
h with DEX and differentiating osteoblast cultures. (D) Wnt signaling measured by a Wnt responsive luciferase 
reporter construct in nondifferentiating and differentiating cultures at day 7.  * p<0.05, ** p<0.01 compared to 
nondifferentiating OBs.
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Endogenous Wnt signaling is reduced in differentiating osteoblasts
To explore the relationship between differentiation and Wnt signaling, endogenous 
Wnt signaling was measured in differentiating and nondifferentiating osteoblasts. 
β-catenin levels were measured in both the cytosolic and nuclear fraction of osteoblast 
cultures at days 5, 12 and 19 of culture. This showed that differentiated osteoblasts 
had clearly lower β-catenin levels compared to their nondifferentiating counterparts 
in both cellular fractions. Quantification of multiple independent Western blot assays 
showed that β-catenin was significant reduced in differentiating cultures in both the 
cytosolic and the nuclear fraction at day 12 and 19 (Fig. 6.1 B). In addition, short-term 
DEX treatment (10-7M, 24 h) did not change β-catenin levels (Fig. 6.1 C), demonstrating 
that the difference found in β-catenin levels is a consequence of the DEX-induced 
differentiation program.
Reduced β-catenin levels suggest reduced endogenous Wnt signaling. A Wnt 
signaling luciferase reporter construct was used (WRE-Luc) to measure Wnt signaling 
in osteoblasts. Indeed, this showed that differentiating osteoblasts had lower WRE-
promoter activity compared to nondifferentiating cultures (Fig. 6.1 D).
Figure 6.2. Gene expression of various Wnt signaling genes during osteoblast differentiation. (A-I) qPCR data 
of 9 Wnt signaling related genes that were differentially expressed between nondifferentiating and differentiating 
osteoblast cultures. * p<0.05, ** p<0.01 compared to nondifferentiating osteoblasts.
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Regulation of Wnt related genes during osteoblasts differentiation
Affymetrix GeneChips were used to identify the expression of a broad range of Wnt 
signaling related genes in human osteoblasts. A gene was selected as a Wnt signaling 
gene on basis of data on http://www.stanford.edu/~rnusse/wntwindow.html. First, 
genes were identified as expressed in human osteoblast if they were detected by multiple 
independent GeneChip experiments. An overview of the presence of various Wnt signaling 
related genes in human osteoblasts is shown in Table 6.1. Secondly, Wnt signaling genes 
were selected that showed differential expression between nondifferentiating and 
differentiating osteoblasts. Genes were selected if the expression was 1.6 fold-different 
between nondifferentiating and differentiating cultures at at least one of the time 
points analyzed. Since a 1.6-fold difference is a relative mild cut-off, these genes were 
Table 6.1. Wnt signaling related genes expressed in human osteoblast identified by Affymetrix GeneChips. 
# According to GeneChip data using a cut off value of 1.6-fold difference. * No probeset was present on the 
GeneChip to detect these genes.
 Gene Detected by Regulated qPCR Gene Detected by Regulated qPCR
 symbol GeneChip #  symbol GeneChip #
Wnt proteins    Inhibitors  
WNT1 N -  DKK1 Y Y Fig. 6.2 F
WNT2 N -  DKK2 Y N 
WNT2B Y N  DKK3 Y N 
WNT3 Y N  DKK4 N - 
WNT3A* -* -*  SFRP1 Y Y Fig. 6.2 G
WNT4 N -  SFRP2 N - 
WNT5A Y N  FRZB Y N 
WNT5B Y -  SFRP4 Y N 
WNT6 Y Y  SFRP5 N - 
WNT7A N -  WIF N - 
WNT7B N -   Nuclear regulators 
WNT8A Y N  CTNNB1 Y N 
WNT8B N -  JUP Y Y Fig. 6.2 I
WNT9A Y N  LEF1 Y N 
WNT9B N -  TCF7 Y N 
WNT10A N -  TCF7L1 Y N 
WNT10B N -  TCF7L2 Y N 
WNT11 N -  Cytoplasmic regulators 
WNT16 Y N  GSK3A Y N 
Receptors    GSK3B Y N 
FZD1 Y Y Fig. 6.2 A APC Y Y Fig. 6.2 H
FZD2 Y Y Fig. 6.2 B APC2 Y N 
FZD3 Y N  DVL1 Y N 
FZD4 Y N  DVL2 Y N 
FZD5 N -  DVL3 Y N 
FZD6 Y Y Fig. 6.2 C DVL1L1* -* -* 
FZD7 Y N  AXIN1 N - 
FZD8 Y Y Fig. 6.2 D AXIN2 Y N 
FZD9 N -  FRAT1 Y N 
FZD10 N -  FRAT2 Y N 
KREMEN1 Y N  NKD1 N - 
KREMEN2 N -  NKD2 N - 
LRP5 Y N  PORCN N - 
LRP6 Y Y Fig. 6.2 E    
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only identified as potentially regulated. Quantitative real time PCR (qPCR) was used to 
confirm the differential mRNA expression of these genes.
The following 10 Wnt signaling related genes were identified as potentially regulated 
and analyzed using qPCR (Fig. 6.2); wingless-type MMTV integration site family member 
6 (WNT6), frizzled homolog 1/2/6 and 8 (FZD1/2/6/8), low density lipoprotein receptor-
related protein 6 (LRP6), dickkopf homolog 1 (DKK1), secreted frizzled-related protein 1 
(SFRP1), adenomatosis polyposis coli (APC) and junction plakoglobin (JUP).
In total, 5 Wnt receptors were differentially expressed by GC-induced differentiation. 
FZD1, 2 and 8 were all suppressed by GC-induced differentiation, whereas FZD6 together 
with LRP6 were up regulated during GC-induced differentiation. The Wnt inhibitor DKK1 
was stimulated by GC-induced differentiation at all days of culture, whereas another 
inhibitor of Wnt signaling SFRP1 was strongly suppressed by GC-induced differentiation. 
APC, which also acts negative on Wnt signal increased during the final stages of GC-
induced differentiation. The β-catenin homolog  JUP 26 was decreased by GC-induced 
differentiation. Differential expression of WNT6 could not be confirmed using qPCR 
(data not shown).
Figure 6.3. Effect of Wnt signaling on osteoblast differentiation. (A) Nondifferentiating osteoblasts were continuously 
treated with LiCl or Wnt3a to induce Wnt signaling, subsequently ALPL activity was measured at day 5, 12 and 19. 
(B) Differentiating osteoblasts (DEX treated) were continuously treated with LiCl or Wnt3a to induce Wnt signaling, 
subsequently ALPL activity was measured at day 5, 12 and 19. * p<0.05, ** p<0.01 compared to vehicle.
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Figure 6.4. Effect of Wnt signaling on matrix mineralization. Differentiating osteoblasts  (DEX treated) were 
continuously treated with LiCl or Wnt3a to induce Wnt signaling, subsequently matrix mineralization was measured 
at day 19. * p<0.05, ** p<0.01 compared to vehicle.
Wnt signaling controls osteoblast differentiation and function
Together these data show that during GC osteoblast differentiation, osteoblast lower 
their endogenous Wnt signal and change the expression of several genes involved in 
Wnt signaling. To reveal the impact of enhanced Wnt signaling in both differentiating 
and nondifferentiating osteoblasts Wnt signaling was activated in both conditions. 
Wnt signaling was induced by culturing SV-HFO cells in the presence of recombinant 
Wnt3a or lithium chloride (LiCl), which stimulates Wnt signaling by inhibiting β-catenin 
degradation 27. First, Wnt signaling was activated in nondifferentiating pre-osteoblast 
cultures. These cultures were continuously treated with LiCl (4 and 8 mM LiCl) or Wnt3a 
(2 and 10 ng/ml), and subsequently ALPL activity was measured at days 5, 12 and 19 of 
culture. This showed that activation of Wnt signaling significantly induced basal ALPL 
activity with the most prominent effect after 19 days of culture (Fig. 6.3 A). Although 
ALPL activation was increased, this stimulation of ALPL in the absence of DEX was not 
sufficient to induced mineralization (data not shown). Secondly, Wnt signaling was 
activated in differentiating osteoblast cultures. Remarkably, in these differentiating 
cultures an opposite effect was observed. LiCl and Wnt3a treatment slightly decreased 
ALPL activity (Fig. 6.3 B). Moreover, in this condition we measured the effects of Wnt 
signaling on matrix mineralization. This showed that Wnt signaling in differentiating 
osteoblasts strongly inhibited matrix mineralization (day 19, Fig. 6.4).
In order to exclude any discrepancy in β-catenin activation between nondifferentiating 
and differentiating osteoblasts, β-catenin activation by LiCl treatment was measured in 
both differentiating conditions. This showed that 8 mM of LiCl clearly induced β-catenin 
levels in both differentiation conditions (data not shown).  Moreover, in all experiments 
NaCl (4 and 8 mM) was used as a negative control for LiCl, which showed no effect on 
β-catenin levels, ALPL activity, and mineralization irrespective of the differentiation 
condition.
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Wnt signaling controls osteoblast function in an differentiation dependent manner 
independent of glucocorticoids
Differentiating osteoblasts were created upon continuous treatment with DEX. Using this 
method the observed differentiation dependent effects of Wnt signaling on ALPL activity 
might be caused by two different processes; 1] direct interaction with glucocorticoid 
signaling or 2] as a consequence of the osteoblast differentiation program.
In order to study the role of DEX in more detail, experiments were performed in 
which LiCl treated cultures were co-incubated with DEX for 48 hours (Fig. 6.5). This 
should reveal whether the presence of DEX results in a direct inhibitory effect of Wnt 
signaling as observed during DEX-induced differentiation. SV-HFO cultures were cultured 
for 10 days in nondifferentiating conditions. Subsequently, these cultures were treated 
for 48 hours with LiCl (8 mM), DEX (100 nM) or a combination of both. DEX and LiCl 
treatment independently stimulated ALPL activity. Importantly, Wnt signaling-stimulated 
ALPL activity was independent of the presence or absence of DEX (Fig. 6.5). This proves 
that the different effects of Wnt signaling as shown in Figures  6.3 A and B are due to 
differences in osteoblast differentiation between the two conditions. In other words, 
Wnt signaling enhances ALPL activity when pre-osteoblasts are still undifferentiated, 
whereas Wnt signaling inhibits ALPL activity in differentiated osteoblasts.
Figure 6.5. Short term LiCl and DEX treatment in nondifferentiating osteoblast cultures. Nondifferentiating 
osteoblasts were cultured until day 10. Subsequently, these cultures were treated for 48 hours with LiCl (8 mM), 
DEX (100 nM) or a combination of both. ** p<0.01
These data led to the hypothesis that activation of Wnt signaling in the early stages 
of osteoblast differentiation will enhance differentiation later on. In order, to test this 
hypothesis we activated Wnt signaling in nondifferentiating osteoblasts before they 
were induced to differentiate. This was achieved by pre-treating the cultures with LiCl 
(8 mM) for 5 days. After these 5 days the cultures were induced to differentiate by DEX 
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Figure 6.6. Activation of Wnt signaling in early osteoblasts. Nondifferentiating cultures were pre-treated with 8 mM 
LiCl for 5 days (II). After these 5 days differentiation was initiated by DEX treatment. In contrast, osteoblast cultures 
were treated with 8 mM LiCl only during DEX-induced differentiation from day 5 onwards (III). ALPL activity was 
measured at day 19 of culture.  ** p<0.01compared to control (I).
treatment (Fig. 6.6 condition II). As a control, pre-osteoblast cultures were treated 
with LiCl (8 mM) only during DEX-induced differentiation from day 5 onwards (Fig. 
6.6 condition III). At day 19 we quantified the level of differentiation by measuring ALPL 
activity. This revealed that pre-treatment with LiCl until day 5 enhanced ALPL activity 
at day 19 compared to the non pre-treated controls (Fig. 6.6 condition I). In contrast, 
cultures that were treated with LiCl only during DEX-induced differentiation had slightly 
reduced ALPL activity (Fig. 6.6 condition III).
6.3 Discussion
Conflicting data have been published whether Wnt signaling acts stimulatory or inhibitory on osteoblast differentiation. Using human pre-osteoblasts we 
showed that Wnt signaling acts either negative or positive on osteoblast function. 
Most importantly, these effects were dependent on the differentiation stage of the 
osteoblast. In human osteoblasts, differentiation can be initiated after exposure to 
GCs. During this GC-induced osteoblast differentiation process Wnt signaling strongly 
inhibited matrix mineralization. This negative effect of Wnt signaling on osteoblast 
differentiation and matrix mineralization was also demonstrated by other studies 
using osteoblasts from various origin 22-24. In contrast, Wnt signaling acted positive on 
osteoblasts when, in the absence of GCs, they were not induced to differentiate. Smith 
and colleagues demonstrated that GCs can directly influence Wnt signaling by inhibiting 
the transcriptional activity of LEF/TCF in differentiating murine osteoblasts 28. However, 
we showed that the effects of Wnt signaling in differentiating osteoblasts are not due to 
a direct effect of GCs on Wnt signaling but the result of an altered cellular response to 
Wnt signaling as a consequence of the GC-induced differentiation program.
We hypothesized that Wnt signaling stimulates early osteoblasts in their capacity to 
differentiate and subsequently to progress to mature matrix synthesizing osteoblasts. 
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This is proven by our pre-treatment studies in which Wnt signaling was induced for 
5 days in the early stage of culture and next induced to differentiate by GCs. The 
differentiation capacity of the Wnt signaling pre-treated cells was higher than the 
non-pretreated cells. However, other additional signals, i.e., GCs were still necessary 
to induce full differentiation. This positive property of Wnt signaling on osteoblast 
differentiation capacity is supported by LRP5 deficient mice that showed a reduced 
number of osteoblasts and by reports showing stimulation of osteoblast differentiation 
by Wnt signaling in vitro 5, 19-21. These early effects together with the observations 
of a controlling or limiting effect on the final differentiation and mineralization of 
osteoblasts shows a dual control mechanism of osteoblast differentiation by Wnt 
signalling. Such a dual control mechanism might act as an elegant feedback mechanism 
to control proper bone formation by controlling the number of osteoblast precursors 
that will become mature osteoblasts and at the same time controlling the activity of the 
mature osteoblasts. In case this control mechanism is strongly out of balance this results 
in impaired bone formation, as demonstrated by various mice models that are deficient 
for distinct Wnt signaling genes 5, 7-11.
The diverse function of Wnt signaling at different stages of osteoblast development 
makes the control of Wnt signaling during these different stages of great importance 
to ensure proper osteoblast function. Suppressed β−catenin levels in differentiating 
osteoblasts points to such a control mechanism. In mouse ES cells β−catenin levels 
are correlated with the differentiation capacity of these cells 29. Suppressed β−catenin 
levels in differentiating osteoblasts might help to facilitate osteoblast differentiation 
and matrix mineralization. One candidate to suppress Wnt signaling during human 
osteoblast differentiation is the Wnt signaling inhibitor DKK1. DKK1 was significantly 
up-regulated during GC-induced differentiation and is a well-known inhibitor of Wnt 
signaling. A functional role of Dkk proteins in osteoblasts has been described for Dkk2 
in murine osteoblasts. Dkk2 expression is strongly increased during murine osteoblast 
differentiation and silencing of Dkk2 clearly reduced matrix mineralization 24. Moreover, 
Dkk2 deficient mice show reduced matrix mineralization, supporting the negative effects 
of Wnt signaling on mature osteoblasts in vivo 11. However, it is likely that several other 
regulators are involved as well in suppressing Wnt signaling in mature osteoblasts.
The fact that there are multiple Wnt proteins, Wnt inhibitors and Wnt receptors 
makes it yet difficult to unravel the role, regulation and function of Wnt signaling in 
osteoblasts. More information about which Wnt signaling genes are expressed and 
functional in osteoblasts is important for better understanding the role and complexity 
of Wnt signaling in bone. One challenge is to reveal the impact of endogenous expression 
of Wnt proteins, e.g., which Wnt proteins activate early differentiation and which Wnt 
proteins inhibit later stages of differentiation and via which Frizzled or LRP receptors 
these actions take place.
Our data show that several Wnt signaling genes were differentially expressed 
between nondifferentiating and differentiating osteoblasts. A similar kind of study was 
performed by Boland and colleagues in human mesenchymal stem cells (MSCs) focusing 
on FZD on WNT genes 23. They found differential mRNA expression of FZD6, FZD7, WNT11 
and WNT9A during osteoblast differentiation. We found differential expression of four 
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Frizzled receptors, LRP6, and the Wnt signaling inhibitors DKK1 and SFRP1. SFRP1 was 
the most strongly regulated Wnt signaling gene found in our study. Interestingly, in 
mice this Wnt antagonist has been shown to be a negative regulator of trabecular bone 
formation 10. Although we cannot explain the precise consequence of all the differentially 
expressed genes for osteoblast function we can correlate them with decreased β−catenin 
levels and decreased Wnt signal. Moreover, it might well be that due to the differentially 
expressed Wnt receptors and Wnt antagonists osteoblasts have a changed sensitivity and 
specificity for the various Wnt proteins during differentiation.
It is still unclear, however, how the differentiation dependent effects of Wnt 
signaling are mediated. In this paper we excluded a direct interaction of GCs. Moreover, 
LiCl experiments showed that the differentiation dependent effects were independent 
of any Wnt signaling receptor, Wnt protein, or Wnt antagonist. Therefore, it is tempting 
to speculate that differentiation-dependent epigenetic activation and silencing of 
Wnt signaling-regulated genes takes place. However, to answer this question detailed 
target gene promoter analyses should be performed in Wnt activated early and mature 
osteoblast cultures.
In conclusion, we showed that Wnt signaling stimulates the early steps of osteoblast 
differentiation and inhibits more mature osteoblasts. Importantly, we demonstrated 
these contradicting findings within the same osteoblast differentiation model, precluding 
possible cell dependent or species dependent effects. Furthermore, we found that 
differentiating osteoblasts have suppressed Wnt signal and changed expression of various 
Wnt signaling genes, which might help facilitate the differentiation and mineralization 
process in osteoblasts.
6.4 Materials and methods
Cell Culture
SV-HFO cells were cultured in αMEM (Gibco BRL, Paisley, U.K) supplemented with 20 mM 
HEPES, pH 7.5 (Sigma, St.Louis, MO); streptomycin/penicillin; 1.8 mM CaCl2 (Sigma); and 
heat-inactivated FCS (GIBCO) at 37°C and 5 % CO2 in a humidified atmosphere. Thawed 
cells were precultured for 1 week in the presence of 10 % FCS. In this preculture, cells 
were seeded in a density of 5 x 103 vital cells per cm2 and were subcultured every 
week. During this preculture, SV-HFO cells remained in an undifferentiated stage. After 
preculturing, cells were seeded in a density of 10 x 103 vital cells per cm2 in 6- or 12-
wells plates (Corning, NY, USA). After seeding, cells were incubated for two days before 
they were put on differentiating medium (indicated as day 0). Medium was supplemented 
freshly with 10 mM β−glycerophosphate (Sigma), 100 nM dexamethasone (DEX) (Sigma) or 
other additives and replaced every 2-3 days. Nondifferentiating cultures were similarly 
cultured as differentiating cultures, however DEX was excluded. LiCl and Wnt3a were 
purchased from Sigma and R&D systems (Minneapolis, MN, USA), respectively. For 
analysis, medium was collected and stored at -20°C and cells were harvested from the 
culture dish in PBS containing 0.1 % Triton X-100 and stored at -80°C. Cell lysates were 
sonicated on ice in a sonifier cell disrupter for 2 x 15 sec before analysis.
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Alkaline phosphatase activity and mineralization assays 
For DNA measurements, 100 µl SV-HFO cell lysates were treated with 200 µl heparin 
(8 IU/ml in PBS) and 100 µl ribonuclease A (50 mg/ml in PBS) for 30 min at 37°C. This was 
followed by adding 100 ml ethidium bromide solution (25 µg/ml in PBS). Samples were 
analyzed on the Wallac 1420 victor2 (PerkinElmer, Wellesley, MA) using an extinction 
filter of 340 nm and an emission filter of 590 nm. For standards, calf thymus DNA (Sigma) 
was used.
ALPL activity was assayed by determining the release of paranitrophenol from 
paranitrophenylphosphate (20 mM in 1 M diethanolamine buffer supplemented with 1 
mM MgCl2 at pH 9.8) in the SV-HFO cell lysates for 10 min at 37°C. The reaction was 
stopped by adding 0.06 M NaOH and measured at 405 nm. Results were adjusted for DNA 
content of the cell-lysates.
For quantification of the mineral content cell lysates were incubated overnight in 
0.24 M HCl at 4°C. Calcium content was colorimetrically determined after addition of 
1M ethanolamine buffer (pH 10.6) 0.35 mM o-cresolphtalein complexone, 19.8 mM 8-
hydroxyquinoline and 0.6 mM hydrochloric acid at 595 nm. Results were adjusted for 
DNA content of the cell-lysates.
β-catenin westernblot
From SV-HFO cultures, nuclear and cytoplasm fractions were isolated using NE-PER 
isolation kit (Pierce, Rockford, IL, USA) according to the manufacturer’s description 
and stored at –80ºC. Before analysis, total protein concentration was measured using 
BCA protein assay reagent (Pierce) according to the manufacturer’s description. Next, 
10 µg protein was separated on a 10 % SDS-PAGE gel, followed by blotting on Hybond 
nitrocellulose membranes (Amersham Pharmacia Biotech, Piscataway, NJ, USA). After 
blotting, membranes were blocked for 2 hours in TBST (20 mM Tris, 137 mM NaCl, 0.1 % 
Tween-20, pH 7.6) containing 5 % milk powder. Next, membranes were incubated over-
night at 4º C with monoclonal anti-β-Catenin antibody (1:2000; Cell signaling, Beverly, 
MA, USA) in TBST containing 5 % bovine serum albumin (Sigma). For detection, membranes 
were incubated for 2 hours with goat-α-rabbit-HRP (1:1000; DAKO, Carpinteria, CA, 
USA) in TBST containing 5 % milk powder. Next, the ECL detection system (Amersham 
Pharmacia Biotech) was used and immunoreactive bands were quantified using Quantity 
One software (Bio-Rad Hercules, CA, USA)
Luciferase reporter assays
At day 5 of culture cells were transfected with 200 ng Wnt signaling WRE-Luciferase 
reporter plasmid (TOPFLASH, 30) (12 wells plate) using Fugene6 (Roche, Basel, 
Switzerland) according to the manufacturer’s description. After 24 hours cells were lysed 
by incubating for 20 minutes in 100-200 µl lysis buffer (Promega, Madison, WI). Luciferase 
activity was measured using 25 µl cell-lysate and the Steady-Glo Luciferase Assay 
System (Promega). To correct for transfection efficiency between nondifferentiating 
and differentiating luciferase values were corrected for the luciferase activity of the 
pGL3-control vector (Promega).
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RNA isolation and cDNA synthesis
Total RNA was isolated using RNA-Bee solution (Tel-Test, Friendwood, TX) according to 
the manufacturer’s protocol. To remove calcium (derived from the extracellular matrix), 
RNA was precipitated by overnight incubation with 4 M LiCl and 50 mM EDTA at -20°C. 
After precipitation and centrifugation for 30 min at 14,000 rpm and 4°C, the RNA pellet 
was washed four times with 70 % EtOH and subsequently dissolved in H2O. The total 
amount of RNA was quantified using the RiboGreen RNA Quantitation Kit (Molecular 
Probes, Eugene, OR). One microgram total RNA was reverse transcribed into cDNA using 
a cDNA synthesis kit and according to the protocol of the manufacturer (MBI Fermentas, 
St. Leon-Rot, Germany), using 0.5 µg oligo(dT)18 and 0.2 µg random hexamer primers. 
When purified mRNA was used in the cDNA synthesis, 10 µg of total RNA was purified using 
a oliotex mRNA mini kit (Qiagen, Stanford, CA, USA) according to the manufacturer’s 
protocol. RNA was eluted in 60 µl form which 10 µl was used in the cDNA synthesis.
Quantitative real time PCR (qPCR)
qPCR was carried out using an ABI 7700 sequence detection system (Applied Biosystems, 
Foster City, CA). Reactions were performed in 25 µl volumes using a qPCR core kit 
(for assays using a probe) and qPCR kit for SYBR green I (for assays using SYBR green) 
(Eurogentec, Seraing, Belgium). Primer and probe sets were designed, using the Primer 
Express software (version 2.0; Applied Biosystems), amplicons overlapped at least 
one exon-exon boundary. Since the FZD1, 2 and 8 genes consist of a single exon these 
genes were also analyzed on cDNA derived from purified mRNA to avoid genomic DNA 
contamination. Cycling conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 min. Primer and probe concentrations are listed 
in Table 6.2. Genes consisting of a single exon were quantified using cDNA derived from 
purified mRNA.
Affymetrix GeneChip-based gene expression
Purity and quality of isolated RNA was assessed by RNA 6000 Nano assay on a 2100 
Bioanalyzer (Agilent Technologies). Per analyzed condition total RNA of 3 different 
biological samples was pooled. Synthesis of first and second strand cDNA from total RNA 
was performed according to the One-Cycle Target Labeling protocol (Affymetrix; 701024 
Rev. 3). In total, 4.0 µg of total RNA was reverse transcribed using Superscript ds-cDNA 
Synthesis Kit according to the manufacturer’s description (Invitrogen). Subsequently, 
double-stranded cDNA was purified using GeneChip Sample Cleanup Module (Affymetrix) 
and served as a template in the in vitro transcription reaction using BioArray 
HighYield RNA Transcript Labeling Kit (Affymetrix). Next, the RNA (cRNA) was purified 
using GeneChip Sample Cleanup Module. In total, 20 µg of biotin-labeled cRNA was 
fragmentized by metal-induced hydrolysis at a final concentration of 0.5 µg/µl for 35 
minutes at 94°C. Fragmentation was checked on an Agilent 2100 Bioanalyzer confirming 
an average size of approximately 100 nt. In total, 15 µg fragmented biotinylated cRNA 
was hybridized to GeneChip Human Genome U133 Plus 2.0 oligonucleotide GeneChips 
(Affymetrix) according to the manufacturer’s protocol (Affymetrix, 701025 Rev 5). 
Staining, washing and scanning procedures were carried out as described in the GeneChip 
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Table 6.2. Primer and probe sequences and concentration used for qPCR analysis. Primer sets without a 
fluorescence probe were used in combination with the SYBR green QPCR kit (Eurogentec)
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Expression Analysis technical manual (Affymetrix). Data acquisition was performed using 
the GeneChip Scanner 3000. 
In order to examine the quality of the different arrays, measured intensity 
values were analyzed using the GeneChip Operating Software (GCOS, Affymetrix). 
The percentage of present calls (about 40 %), noise, background, and ratio of GAPDH 
3’ to 5’ (<1.4) all indicated high quality of the samples and an overall comparability. 
Probe sets that were never present (according to Affymetrix MAS5.0 software) in any 
of the GeneChips were omitted from further analysis. Raw intensities of the remaining 
probe sets (30336) of each chip were log2 transformed and normalized using quantile 
normalization. After normalization the data was back transformed to normal intensity 
values.
Gene nomenclature
Gene names and gene symbols were used as provided by HUGO Gene Nomenclature 
Committee 31.
Statistics
Data were only presented if multiple independent experiments showed similar results. 
Experiments were performed at least in triplicate. Values are indicated as means ± SEM. 
Significance was calculated using the Student’s t-Test.
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7.1 The use of in vitro bone formation models
In the treatment of osteoporosis additional therapies that promote bone formation are highly desirable. To develop novel drugs that enhance bone formation, more 
knowledge about the biology of osteoblasts is required. To study complex processes 
such as osteoblast differentiation and matrix mineralization we used several in vitro 
osteoblast-based models of bone formation. In the presented studies three different 
human derived osteoblast models were used; 1] bone marrow derived mesenchymal 
stem cells (MSCs), 2] immortalized fetal pre-osteoblasts (SV-HFOs), and 3] primary 
committed osteoblasts (NHOsts). The SV-HFO osteoblast model was frequently used 
since it has been shown to be a robust model in timing of differentiation and formation 
of a mineralized extracellular matrix (ECM). This in contrast to the MSC and NHOst 
osteoblast models that showed much greater variations in timing of differentiation and 
mineralization. Nevertheless, the MSC and NHOst models are of great use for validation 
purposes. Moreover, using these three osteoblast models a broad window of the 
osteoblast differentiation process was covered.
7.2 Complexity in the control of osteoblast differentiation
In this thesis three signaling pathways were investigated in relation to bone formation; 
1] glucocorticoid (GC) signaling, 2] activin signaling and, 3] Wnt signaling. GC signaling 
was shown to be essential for the initiation of human osteoblast differentiation, 
whereas the activin and Wnt signaling pathways strongly inhibited in vitro bone 
formation. Despite their negative effects, the Wnt and activin signaling pathways were 
shown to be endogenously active in osteoblasts. Although this seems illogical, it might 
function as a continuously break to control differentiation and (over) mineralization. 
Interestingly, in osteoblast cultures in which differentiation and mineralization were 
initiated the break was weakened as demonstrated by suppressed activin and Wnt 
activity (Chapter 5, Fig. 5.3 E; Chapter 6, Fig. 6.1). An opposite mechanism was 
observed for GC signaling, which was enhanced via expression of 11β-HSD1 in case 
of delayed differentiation (Chapter 3, Fig. 3.3). Together this demonstrates that 
osteoblasts intrinsically control multiple signaling pathways to facilitate and control 
their differentiation and mineralization in an optimal manner.
Despite the fact that the GC, activin, and Wnt signaling pathways were able to 
regulate osteoblasts, they are not the unique regulators of osteoblasts. Many other factors 
are known that regulate osteoblast differentiation and activity such as 1,25α(OH)2D3, 
parathyroid hormone, TGFβ ,insulin growth factor I and several BMPs 1-7. It is likely that 
this high variety of endocrine, paracrine and autocrine factors regulating osteoblast 
differentiation is necessary to control the multiple steps involved in osteoblastogenesis 
(Chapter 1; Fig. 1.4). This indicates that during in vitro studies a certain hormone can be 
inactive in early stages of differentiation, whereas it has a major impact later on during 
differentiation and vice versa. This is emphasized by our findings, which showed that the 
GC, activin, and Wnt signaling all acted in a differentiation dependent manner.
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It is likely that the steps in osteoblastogenesis are not controlled by one single 
factor but by a specific set of regulatory factors. Moreover, these various factors 
probably interact with each other in order to control osteoblast differentiation. The 
big challenge is now to map all factors that control human osteoblast function and 
differentiation. In addition, more knowledge is necessary about how, when and together 
with what these factors act on osteoblasts. Therefore, the following points should be 
addressed when studying regulatory factors in osteoblast cultures; 1] at which stage of 
osteoblast differentiation do these factors act, 2] do these factors interact with each 
other, 3] is there a certain hierarchy among the factors, 4] do they act in an endocrine, 
paracrine or autocrine manner, 5] are these factors controlled by osteoblasts, i.e., can 
they be inhibited or activated by osteoblast themselves, and 6] can these factors be of 
physiological relevance, in other words can the factors reach an osteoblast in vivo?
7.3 Mouse, rat and human osteoblasts models are not one 
and the same
The studies concerning activin signaling in Chapter 5 were initiated because work done 
by Gaddy-Kurten and colleagues who showed that activins stimulated osteoblastogenesis 
in mice 8. To our surprise we found a strong suppression of matrix mineralization in the 
human osteoblast models. This discrepancy between the two species is not a unique 
observation since various discrepancies have been described between murine and 
human osteoblasts. An example is given by GCs. In this thesis the importance of GCs 
for human osteoblast differentiation was emphasized (Chapters 2, 3 and 4). However, 
in murine osteoblast cultures, GCs are non-essential for initiation of differentiation 9, 10. 
The osteocalcin gene is a good example of species dependent regulation of gene 
transcription. Osteocalcin is an important protein in bone and is used in the clinic as 
a serum marker for bone turnover. Remarkably, production of this protein in mice and 
humans is regulated in opposites ways by 1,25α(OH)2D3, which is a well-known hormone 
controlling calcium homeostasis and bone metabolism. 1,25α(OH)2D3 clearly enhances 
osteocalcin production in human (Chapter 2, Fig. 4) and rat osteoblasts 11, whereas it 
suppresses osteocalcin production in murine osteoblasts 12, 13. Although rats are closely 
related to mice, rat osteoblasts show several discrepancies with murine osteoblasts, 
regarding 1,25α(OH)2D3 regulation of osteocalcin 
11, the impact of activin A 14 and the 
requirement of GC for their differentiation 15, 16. In these respects, rat osteoblasts show 
more similarities with human osteoblasts.
The combination of differentiation- and species-specific effects in osteoblasts 
complicates the comparison of distinct observations generated in different osteoblast 
models. For example, we believe that the discrepancies we found between murine and 
human osteoblasts are due to species-specific effects. However, since we compared 
two different osteoblast models we cannot completely exclude other factors explaining 
the contradicting effects of activin A. The stimulatory effects of activin A in the murine 
osteoblasts were based on directly isolated and cultured bone marrow cells. In these 
experiments adherent bone marrow cells were cultured and treated with activin A. In 
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our experiments, using human cells, we cultured only the MSC fraction of human bone 
marrow that was free from hematopoietic cells. Although unlikely, activin A might act 
differently in total bone marrow cultures compared to isolated MSC cultures.
7.4 Paradoxical effects of glucocorticoids in bone
Glucocorticiods are nowadays well-established factors that stimulate human osteoblasts 
in vitro. However, long term GC treatment frequently results in bone loss and increased 
risk of fractures 17-19. These negative side effects of GC treatment on bone are still poorly 
understood, but are believed to be partially induced by reduced bone formation 18, 20, 21. 
In the past murine osteoblast models were studied to unravel the mechanism underlying 
the negative side effects of GCs. These cells, however, do not require GCs to initiate their 
differentiation program in vitro 9, 10, which is in great contrast to human osteoblasts for 
which GCs are a prerequisite for proper differentiation. Using these murine osteoblast 
models, it was shown that GCs mediate their negative side effects directly via osteoblast 
by inducing apoptosis and inhibiting proliferation 20, 22, 23. Nowadays, human osteoblast 
models are more frequently used, which lack the described negative side effects of GCs 
described in murine osteoblasts (Chapter 2, Fig. 2.1) 24.
Although GCs are essential for proper human osteoblast development, little was 
known about the molecular mechanism underlying GC-induced osteoblast differentiation 
and mineralization. Chapter 4 is the first study that describes the molecular consequence 
of GC-induced differentiation in human osteoblasts. In this study genome-wide gene 
expression microarrays were used to identify numerous genes that are under the 
control of the GC-induced differentiation program. Several transcription regulators 
were identified including ZBTB16 and ZFP36, which were shown to be direct GC target 
genes (Chapter 4, Fig. 4.10). RUNX2 was also found to be up-regulated during GC-
induced differentiation (Chapter 2, Fig. 2.3). Although this gene is crucial for osteoblast 
differentiation and function 25, 26 it is not a direct target gene of GCs. Recently, ZBTB16 
was found to be a crucial transcription factor for human osteoblast differentiation and 
matrix mineralization acting upstream of RUNX2. Therefore it was interesting to identify 
ZBTB16 as the strongest regulated gene in our human osteoblast models. Its expression 
was over 80-fold up-regulated after 3h of GC treatment and more than 20000-fold 
after 2 weeks of differentiation. It is tempting to speculate that ZBTB16 is the first 
transcriptional responder of GCs during GC-induced differentiation, activating many 
other secondary genes such as RUNX2 that initiate osteoblast differentiation.
The essential role of GCs for human osteoblast differentiation is emphasized by 
11β-HSD1 activity in bone 27. Why should such an enzyme, which converts inactive 
cortisone into cortisol, be expressed in bone if cortisol is detrimental for bone? In 
Chapter 3 (Figs. 3.3 and 3.4) we describe that 11β-HSD1 activity acts as a feedback 
mechanism for delayed osteoblast differentiation caused by low cortisol concentrations. 
Most of the cortisol in the circulation is bound to cortisol binding globulin (CBG) 28, which 
might limit the access of cortisol to the osteoblast microenvironment. In contrast, the 
11β-HSD1 substrate cortisone has an approximately 10-fold lower affinity for CBG than 
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cortisol 29, resulting in relatively high levels of free cortisone, which can easily diffuse to 
the osteoblast microenvironment. In the latter situation 11β-HSD1 acts as a continuously 
paracrine activator of cortisol. Such a mechanism in bone is not unique for cortisol, 
paracrine activation of estrogens and 1,25α(OH)2D3 has also been demonstrated 
30-32.
Although numerous studies show that GCs are non-essential for murine osteoblast 
differentiation, other studies show that physiological GC concentrations in vitro can 
be beneficial for murine osteoblast differentiation or activity 33-36. These findings are 
supported by in vivo studies performed by Sher et al. 37 who demonstrated an anabolic 
effect of physiological levels of GCs on bone. They developed transgenic mice that have 
locally abolished corticosterone action in bone, achieved by specifically overexpressing 
11β-HSD2 in osteoblasts. This enzyme converts corticosterone into inactive 11-
dehydrocorticosterone to reduce active GC levels locally. These 11β-HSD2 transgenic 
mice showed reduced trabecular bone and lower basal collagen synthesis supporting the 
anabolic role of physiological GC concentrations in bone tissue.
All in all, it is valid to conclude that physiological concentrations of GCs are 
beneficial for bone, whereas high doses GCs initiate several secondary effects (e.g., at 
the intestine, kidney, parathyroid glands) that act negatively on bone.
7.5 Microarray generated data
The microarray technology was used to find regulatory genes that control the process 
of differentiation and mineralization in osteoblasts. Gene profiles were generated in 
relation to; 1] GC-induced osteoblast differentiation and matrix mineralization (Chapter 
4), 2] activin A suppression of matrix mineralization (Chapter 5), and 3] 1,25α(OH)2D3-
enhanced osteoblast differentiation and matrix mineralization (data not shown in this 
thesis 38). An important aspect of these studies was that we directly linked the microarray 
data to the phenotypic effects on the osteoblast (=matrix mineralization).
This approach identified many known osteoblast-related genes but also many genes 
were identified yet unknown to be expressed in osteoblasts. The identified genes were 
strongly enriched in specific Gene Ontology (GO) categories, like development, cell 
differentiation and skeletal development (Chapter 4, Fig. 4.6 A; Chapter 5, Fig. 5.5 B). 
The identification of these kinds of processes is in line with our experimental setup 
(osteoblast differentiation) and would be unlikely to happen if a biological incoherent set 
of genes had been selected. Moreover, this suggests that other expressed genes with yet 
unknown function have skeletal developmental-like functions. GO enrichment analyses 
are also of great use to confirm the biological validity of the selected genes. Technical 
validity of the microarrays was assessed by qPCR, which showed that the data obtained 
by our microarrays were reliable (Chapter 4, Fig. 4.3; and Chapter 5, Fig. 5.6 B).
Based on the findings described above, the set of genes found in our human SV-HFO 
osteoblast model is of great interest as the data is robust and contains many potential 
osteoblast regulatory genes. A great challenge will now be to study these genes in 
interaction with each other. A drawback of the gene profile studies is that despite 
the strict phenotype-based selection criteria we identified still too much genes. In 
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total, several hundreds of genes were identified, which cannot all be studied in detail. 
Publication of the identified genes, gene-networks and biological processes identified by 
our microarray approach in public databases will open up the functional scrutiny of the 
wide range of novel identified osteoblast genes by contributions of other researchers in 
the field. 
To limit the number of identified genes, data obtained from distinct microarray 
experiments could be integrated. Using such an approach, genes are only selected if 
their expression is regulated by more than one osteoblast regulatory factor. In our case, 
we can merge the genes regulated by GC induced differentiation (Chapter 4) with the 
genes regulated by the activin-follistatin system (Chapter 5). This will drastically limit 
the number of genes and we believe that be doing this the most significant and relevant 
genes in osteoblasts are selected. An important aspect again, is to correlate the direction 
of gene regulation with the phenotype of the osteoblast cultures. In other words, if a 
gene is up-regulated by GC-induced differentiation (stimulator of mineralization) 
this gene should be down-regulated by activin A (inhibitor of mineralization) or the 
other way around. Optimally, more conditions can be included in such an approach. 
Preliminary analyses show that we indeed can select genes that are under control of 
more than two different osteoblast regulatory factors. Genes can be selected that 
are regulated by 1] GC-induced osteoblast differentiation, 2] the activin A-follistatin 
system, and 3] 1,25α(OH)2D3 (all potent regulators of mineralization). These genes have 
great potential and are of primary interest in our further studies.
7.6 Screening for potential therapeutic targets
To confirm whether we indeed successfully identified osteoblast regulatory genes in 
our microarray experiments the selected genes should be functionally characterized 
in relation to osteoblast function. Activating or inactivating target genes in osteoblasts 
is one way to reveal their functional role in bone formation. Genes representing a 
receptor-like protein are easy to target since most often various agonists or antagonists 
are available. Therefore, receptor-like genes are currently our primary targets to 
test in relation to bone formation. This approach already resulted in novel findings 
demonstrated by the proof of function of the cannabinoid receptor (CNR1) (Chapter 4, 
Fig. 4.5).
Nevertheless, the number of identified receptors is limited and other protein families 
are of equal interest. In order, to functionally screen a broad range of target genes an 
RNA interference (RNAi) approach should be used. This technique makes it possible to 
silence the mRNA expression of any gene in a cell 39-41 . In the past years various attempts 
have been made within our research group to develop RNAi-based gene silencing in 
human osteoblast cultures. Using plasmid based transient RNAi several target genes 
were successfully silenced (data not shown in this thesis), however, only for a limited 
period of time (several days). To mediate long-term gene silencing a lentiviral-based 
RNAi is currently under development 42, which will make it possible to characterize gene 
function during the entire osteoblast differentiation period.
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To translate in vitro findings to physiological significance several approaches can 
be used. Population based association studies  (e.g., the Rotterdam study) 43 can be 
performed to reveal if gene-variants of the identified genes are associated with certain 
bone characteristics such as bone mineral density and fractures. To study genes in more 
detail, mice models can be developed that are deficient for certain genes. Subsequently, 
detailed micro CT bone analysis can be performed to analyze the phenotype of the 
bone 44. Alternatively, the zebrafish model could act as an useful tool to screen 
gene function by using antisense RNA molecules (morpholinos). Zebrafish develop a 
mineralized skeleton in a 6 days period, which makes it possible to screen target genes 
in a high throughput manner in vivo 45.
Together, these screening methods should identify novel genes that regulate bone 
metabolism and act as novel targets for therapeutic intervention. In Figure 7.1 the 
process from in vitro bone formation to therapeutic drug envisaged by the Calcium 
and Bone research group of the Department of Internal Medicine, Erasmus MC is 
schematically depicted.
7.7 Extracellular matrix composition
In our studies we used human osteoblasts that produce a mineralized ECM. Interestingly, 
in Chapter 5 (Fig. 5.4 C) we showed that after 10 days of ECM synthesis the ECM seemed 
completely finished and ready for mineral deposition in the presence of Ca2+, PO4
3-, and 
a proper pH (pH 7.5). Importantly, mineralization could take place independent of the 
further presence of living osteoblasts. This phenomenon actually opened up the way 
to study the impact of ECM composition in more detail.  We showed that treatment of 
osteoblasts with activin A only during ECM synthesis (treatment up to 10 day of culture) 
drastically decreased the mineralization capacity of the ECM in the subsequent period 
(the culture period from day 10) (Chapter 5, Fig 5.4 C). In contrast, GC treatment 
during this same period strongly enhanced the mineralization capacity of the ECM 
(Chapter 2, Fig. 2.2). Unfortunately, the effect of Wnt signaling on matrix composition 
was not studied in this way yet. Although activin A and GC treatment strongly influenced 
the mineralization capacity of the ECM, no major changes were found in the expression 
of the most abundant ECM proteins (e.g., collagen I, osteocalcin and osteopontin). This 
proves that other ECM proteins expressed by osteoblasts control the mineralization 
capacity of the ECM as well.
In the microarray studies many ECM genes were found as differentially expressed, 
which emphasizes the importance of ECM composition for matrix mineralization. In 
total, 36 ECM genes were regulated during GC-induced differentiation (Chapter 4, 
Fig. 4.9 A), and 24 ECM genes by the activin-follistatin system (Chapter 5, Fig 5.6 A). 
Yet we do not know the optimal composition of the ECM and the functions of the 
majority of ECM proteins in bone are still unknown. Nevertheless, the observed 
direction of regulation of the ECM genes identified by our microarray studies coupled 
to the mineralization phenotype may hint at the function of these ECM genes. In other 
words, ECM genes that are up-regulated by activin signaling (low mineralization) may 
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Figure 7.1: Schematic picture of generating novel therapeutic targets that stimulate bone formation. First, gene 
profiles are generated by microarray experiments in human in vitro bone formation models. Genes are selected 
that correlate with the phenotype of the cultures (mineralization of the ECM). Secondly, the identified genes are 
functionally characterized upon activation or inactivation. Genes that show an anabolic effect in vitro will be further 
characterized in several in vivo models. Finally, a small subset of genes will be leftover that control bone metabolism 
and act as novel therapeutic targets
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act negatively on mineralization, whereas ECM genes that are down-regulated may act 
positively. In case of GC-induced differentiation, genes up-regulated by this process may 
act positively on mineralization, whereas the down-regulated ones may act negatively 
on mineralization.
If we focus on the genes that are regulated by GC-induced differentiation and by the 
activin-follistatin system, we find seven ECM genes that are controlled by both processes 
(Table 7.1). Interestingly, six out of these seven ECM genes were regulated in opposing 
ways by the two conditions, which make them of great interest. COL5A3, CLEC3B, NID2 
and TIMP4 were up-regulated by GC-induced differentiation and down-regulated by 
activin signaling, which makes them potential stimulators of matrix mineralization. 
MMP2 and SPOCK are down-regulated by GC-induced osteoblast differentiation and 
up-regulated by activin signaling, which make them potential inhibitors of matrix 
mineralization.
Nevertheless, we should take into account that a function of a gene is not always 
correlated with the phenotype of the osteoblasts. For example, 1,25α(OH)2D3 enhances 
matrix mineralization 1 but at the same moment it induces proteins like osteocalcin and 
osteopontin, which have been negatively implicated in mineralization 46-51. Moreover, it 
should be considered that not only one single ECM protein determines the mineralization 
capacity of the ECM. Changing the expression of one single ECM gene will probably 
not result in a major change in mineralization. The total ECM composition might be of 
greater importance in the control of matrix mineralization and eventually the quality 
of bone.
7.8 Control of extracellular matrix mineralization
We hypothesize that there are two distinct phases in the process of bone formation 
where the extent of mineralization can be influenced (Fig. 7.2). Phase 1 covers the 
period in which the ECM is produced and matured. At this phase regulatory factors 
(e.g., hormones and growth factors) can directly or indirectly change the composition 
of the ECM. Altering ECM composition in phase 1 will eventually influence the extent 
of mineralization later on. After the ECM is completely synthesized and matured, 
Table 7.1: ECM genes regulated by GC-induced differentiation and by the activin-follistatin system is human 
osteoblasts.
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hydroxyapatite mineral is deposited to the ECM (= Phase 2). At this phase the 
mineralization can be controlled by factors that directly control mineral formation and 
deposition, e.g., pH 52, (pyro)phosphate, calcium ions and alkaline phosphatase 53-56. 
At the same moment osteoblast activity can still control the rate of mineralization. 
Osteoblasts secrete proteins like osteocalcin and osteopontin that are suggested to 
directly inhibit crystal formation 46-48, 50, 51. Expression of other ECM proteins, ion channels 
or enzymes at this phase may also directly influence the mineralization rate.
Other compounds such as inorganic phosphate (PO4
3-) act in both phase 1 and 
phase 2. Inorganic phosphate is a necessary compound of the mineral in bone, but 
several studies also demonstrate its effect on osteoblast differentiation, activity and 
apoptosis 54, 57.
ECM synthesis ECM maturation ECM maintenance
Phase 1: ECM synthesis & composition Phase 2: Control of mineral deposition
Cortisol �
Activin A �
1,25�(OH)2D3�
PO43-�
Other hormones � �?
Alkaline phosphatase �
Ca2+�
PO43-�
pH [low � , high �]
Osteocalcin �
Other ECM proteins � �?
Enzymes � �?
Ion channels � �?
ECM produced by osteoblasts
Osteoblast culture (time)
ECM ready for mineral deposition
~day 10
Figure 7.2: The control of extracellular matrix (ECM) mineralization. During the formation, maturation and 
mineralization of the ECM two phases exist where the extent of mineralization can be influenced. Within 10-days of 
osteoblast culture an ECM is produced that is ready for mineral deposition (Phase 1). In this phase several factors 
can influence the mineralization capacity of the ECM by influencing ECM composition. During mineral deposition 
(Phase 2), factors that directly regulate mineral deposition can regulate the extent of ECM mineralization. In 
Figure 7.2 mineralization of osteoblast cultures is indicated by the red color (Alizarin red staining) of the culture 
dishes.
7.9 Activin signaling as a novel therapeutic target to 
modulate mineralization of the ECM
In Chapter 5 we demonstrated that osteoblasts auto-inhibit mineralization of the ECM 
by endogenous expression of activin A. This auto-inhibition opens the way to use activin 
signaling in a therapeutic manner. Recently, Pearsall and colleagues demonstrated 
that treatment with an activin antagonist stimulated bone formation in mice 58, which 
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substantiates the therapeutic potential of activin signaling. The use of activin signaling 
to control mineralization is of particular interest since it can control mineralization in 
two directions. Inhibition of endogenous activin signaling will enhance mineralization, 
whereas stimulation of activin signaling will suppress mineralization. The latter gives 
activin signaling also potential in the control of pathological calcifications. In vitro, we 
already showed that activin inhibits the mineralization process in a vascular smooth 
muscle cell (VSMC)-based model for arteriosclerosis (Chapter 5, Fig 5.1 D).
To modulate activin signaling in vivo there are multiple potential targets for 
therapeutic intervention. At the cell surface level, activin receptors can be activated 
by activins or derivatives/analogues. Local inhibition or neutralization of follistatin will 
enhance free levels of activin, which would be an elegant method to enhance activin 
signaling locally. To inhibit activin signaling similar methods could be used, addition of 
follistatin or other activin binding proteins can be used to neutralize activin signaling. 
Activin receptors or other signaling molecules such as Smad2 and Smad3 can directly 
be targeted to inhibit activin activity. In addition, modulation of specific activin target 
genes, like the identified ECM genes, is a good alternative for therapeutic intervention. 
For the latter application the function of the target genes should be characterize 
first. Both up-regulated and down-regulated activin target genes are of interest since 
they potentially inhibit or stimulate the mineralization, respectively. The functional 
consequences of stimulating or inhibiting the actions of activins and activin signaling as 
described above are summarized in Table 7.2.
Since activin and TGFβ signaling show a large overlap in their signaling it might be 
difficult to modulate activin signaling without influencing TGFβ signaling. The challenge 
will be to characterize all the players in the activin and TGFβ signaling pathways and 
to assess the overlap, but importantly, also the differences between these signaling 
pathways. Another challenge will be to specifically target mineralization in bone or 
pathological calcifications. 
As an alternative for in vivo applications, activin signaling can be employed in tissue 
engineering. Bone explants can be produced ex vivo in which follistatin or derivatives 
are added to enhance the bone formation process. In contrast, for other applications 
extracellular matrices can be produced ex vivo that do not mineralize in vivo upon 
activin treatment.
Table 7.2. Functional consequence on matrix mineralization after manipulating components of the activin-follistatin 
system. *  Modulation of activin signaling can be achieved by modulation of type I or type II activin receptors or 
Smad signaling molecules.
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7.10 Wnt signaling
The described loss-of-function and gain-of-function mutations in the Wnt co-receptor 
LRP5 leading to a very high or very low bone mass in humans indicate an important role 
of Wnt signaling in bone metabolism 59-61. After these findings several in vivo and in vitro 
studies were published that indeed showed a stimulatory role of Wnt signaling on bone 
formation caused by enhanced osteoblastic activity 62-64. These findings, however, might 
be publication biased since the mutation in LRP5 strongly suggested a positive role of 
Wnt signaling in osteoblasts. Remarkably, these publications were followed by studies 
showing a contradicting effect in terms of inhibition of osteoblast differentiation and 
mineralization by Wnt signaling 65-67. The conflicting data on whether Wnt signaling acts 
stimulatory or inhibitory on osteoblast differentiation is likely to reflect diverse function 
of Wnt signaling at different stages of osteoblast development.
In Chapter 6 we showed that within one cell model the Wnt signaling pathway 
stimulates early differentiation but strongly inhibits matrix mineralization later on during 
differentiation. This knowledge is crucial for the interpretation and comprehensibility of 
the complex Wnt signaling pathway in relation to bone formation. The therapeutic use 
of such a pathway to control bone formation will be difficult since it is almost impossible 
to target a specific stage of osteoblast differentiation in vivo. The complexity of the Wnt 
signaling 68, however, could open the way to target Wnt signaling in a differentiation 
dependent manner. It is likely that multiple ligands and receptors control Wnt signaling 
in the osteoblast. We showed that several Wnt signaling components are differentially 
expressed during osteoblast differentiation and are therefore interesting targets to 
control in a differentiation dependent manner.
7.11 Final remarks & Conclusion
In conclusion, many aspects of human osteoblast differentiation were studied in this 
thesis. The studies regarding GCs, Wnt signaling and the activin A-follistatin system 
resulted in a significant increase in knowledge about the role of these signaling pathways 
in the control of osteoblast differentiation and bone formation. We demonstrated that 
the actions of these signaling pathways are dependent on the stage of osteoblast 
differentiation, demonstrating that proper timing is essential to control osteoblast 
differentiation and function in vitro and in vivo. Regarding the role of GCs in bone, 
we showed that in normal osteoblast physiology GCs are of great importance and do 
not mediate negative effects directly on osteoblasts. The negative side effects of GCs 
on bone formation are probably mediated by other processes that indirectly affect 
osteoblasts and bone formation. 
The novel findings concerning the potent effects of the activin A-follistatin system on 
matrix mineralization are of particular interest since we identified a novel therapeutic 
target to control bone matrix formation and subsequent mineralization. Follow-up 
research is needed to precisely pinpoint the mechanism of action of action and to clarify 
the full therapeutic potential of regulating activin in skeletal diseases or diseases of 
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pathological calcification. The use of activin signaling to control matrix formation and 
mineralization in an ex vivo manner (e.g., tissue engineering) seems already applicable 
and this will be tested in the near future.
We believe that the microarray data, generated by unique phenotype-based 
selection queries, has great potential to discover other novel therapeutic targets that 
control bone formation. The generated gene expression profiles will lead researchers 
within the bone field to better understand the complex processes of osteoblast 
differentiation and bone formation. The complete microarray dataset, however, is not 
fully exploited yet and might be strengthened by the addition and integration of other 
data sets and further data mining. A good start was made by the experiments described 
in this thesis. It is anticipated that these genes encompass important novel regulators 
of osteoblast differentiation and bone formation. The functional characterization of the 
identified and phenotype-based selected genes is a major challenge and unfortunately 
beyond the time frame of this thesis. Currently, these functional analyses are in progress 
among others by lentiviral siRNA studies and zebrafish-based screens.
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8.1 Samenvatting
Osteoporose is de meest voorkomende botziekte die wordt gekenmerkt door lage 
botmassa en een verhoogd risico op fracturen. In het lichaam zijn osteoblasten 
verantwoordelijk voor de productie van nieuw bot en hebben daarom een belangrijke 
taak in het reguleren van de botmassa. Osteoblasten zijn afkomstig van mesenchymale 
stamcellen die zich onder andere in het beenmerg bevinden. Het ontwikkelingsproces 
van mesenchymale stamcel naar volwassen osteoblast is zeer complex en wordt 
gecontroleerd door verscheidene endocriene en autocriene factoren (beschreven in 
Hoofdstuk 1). Het doel van het in dit proefschrift beschreven onderzoek was om meer 
kennis te verkrijgen van het ontwikkelingsproces van humane osteoblasten, zodat deze 
als basis gebruikt kan worden om nieuwe therapieën te ontwikkelen die de botvorming 
kunnen stimuleren. Binnen dit onderzoek is gebruik gemaakt van humane osteoblast 
modellen die het botvormingsproces in vitro nabootsen, waarbij er voornamelijk 
geconcentreerd is op het bestuderen van glucocorticoïden, 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), Wnt signaaltransductie en activine signaaltransductie 
in relatie tot osteoblast ontwikkeling en botvorming.   
Ondanks het feit dat glucocorticoïden de botvorming in vitro stimuleren, staan 
glucocorticoïden vooral bekend als factoren die de botvorming negatief beïnvloeden. 
Deze aanname is voornamelijk gebaseerd op de negatieve bijeffecten tijdens 
glucocorticoïden gebruik, zoals verlies van botmassa en verhoogd risico op fracturen. 
In Hoofdstuk 2 wordt juist de essentiële rol van glucocorticoïd hormonen zoals 
cortisol voor de correcte differentiatie van humane osteoblasten benadrukt. Er werd 
aangetoond dat glucocorticoïden tijdens het vroege levensstadium van osteoblasten 
verdere differentiatie en mineralisatie van de extra-cellulaire matrix (ECM) initiëren. 
Tevens is aangetoond dat glucocorticoïden de expressie van meerdere genen die positief 
betrokken zijn tijdens osteoblast differentiatie verhogen. Van andere genen zoals 
osteopontine en osteocalcine, die negatief betrokken zijn bij de mineralisatie, werd 
aangetoond dat de expressie juist onderdrukt wordt door glucocorticoïden. Tenslotte 
toonden we aan dat glucocorticoïden de proliferatie van osteoblasten verhogen terwijl 
de mate van celdood gelijk bleef. Concluderend laat hoofdstuk 2 zien dat de negatieve 
bijeffecten van glucocorticoïden niet verklaard worden door directe effecten op 
osteoblasten maar door andere mechanismen die waarschijnlijk indirect de botvorming 
onderdrukken.
Op cellulair en weefsel niveau wordt de activiteit van glucocorticoïden verhoogd door 
de aanwezigheid van het enzym 11β-HSD1. Dit enzym zet het inactieve glucocorticoid 
cortison om in het biologisch actieve cortisol. In Hoofdstuk 3 is de regulatie van 11β-
HSD1 expressie tijdens het differentiatieproces van humane osteoblasten bestudeerd. 
Er is aangetoond dat de activiteit van 11β-HSD1 omgekeerd gerelateerd is aan de 
differentiatie stadia van humane osteoblasten. Met andere woorden, wanneer 
osteoblasten in de aanwezigheid van glucocorticoiden differentiëren naar volwassen 
osteoblasten, wordt er weinig cortisol geproduceerd. Daarentegen, in osteoblasten die 
niet door glucocorticoïden gestimuleerd worden en dus niet verder differentiëren, is 
de cortisol productie hoog. Om het moleculaire mechanisme van deze differentiatie 
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afhankelijke expressie te achterhalen is de promotor van het 11β-HSD1 gen bestudeerd. 
Dit resulteerde in de identificatie van specifieke regio’s binnen de 11β-HSD1 promotor 
die betrokken zijn bij de differentiatie afhankelijke expressie van het 11β-HSD1 gen. Tot 
slot is de functionaliteit van 11β-HSD1 in osteoblasten aangetoond door osteoblasten te 
laten differentiëren in de aanwezigheid van het nog inactieve cortison. Dit liet zien dat 
osteoblasten hun eigen differentiatie kunnen initiëren door cortison om te zetten in het 
actieve glucocorticoïd cortisol. 
Ofschoon glucocorticoïden essentieel zijn voor de correcte ontwikkeling van 
osteoblasten, is de moleculaire kennis omtrent dit proces beperkt. In Hoofdstuk 4 
is het proces van glucocorticoïden- geïnduceerde osteoblast differentiatie op een 
moleculair niveau bestudeerd door gebruik te maken van genexpressie microarrays die 
het hele genoom omvatten. De genexpressie profielen van mineraliserende (behandeld 
met glucocorticoïden) en niet mineraliserende osteoblasten (niet behandeld met 
glucocorticoïden) zijn met elkaar vergeleken om regulatoire genen te identificeren 
die betrokken zijn bij het differentiatie en mineralisatie proces van osteoblasten.  Dit 
leverde een variëteit aan genen, processen en gen-netwerken op die differentieel tot 
expressie kwamen tussen mineraliserende en niet mineraliserende osteoblasten. Verdere 
bewijsvoering voor dit concept werd geleverd door de identificatie van de cannabinoid 
receptor 1. Deze receptor kwam tijdens de mineralisatie specifiek tot expressie en 
activatie van deze receptor verhoogde de mineralisatie van de ECM. Tevens werden in 
Hoofdstuk 4 de processen van osteoblast- en vasculaire gladde spiercel-geïnduceerde 
mineralisatie met elkaar vergeleken. Dit toonde aan dat glucocorticoïden voor beide 
celtypen essentieel zijn om de mineralisatie van de ECM te induceren. Het vergelijken 
van genexpressie tussen de beide celtypen gaf aan dat een grote groep genen op dezelfde 
manier gereguleerd werden in zowel osteoblasten als vasculaire gladde spiercellen. 
Deze resultaten wezen dan ook op een grote overlap tussen het mineralisatie proces in 
bot en mineralisatie van de vaatwand tijdens het proces van arteriosclerose. 
Verscheidene leden van de transforming growth factor-β (TGFβ) superfamilie staan 
bekend om hun effect op het botmetabolisme. Activines behoren ook tot de TGFβ 
superfamilie maar over hun functie in bot is nog weinig bekend. Hoofdstuk 5 beschrijft 
ons werk omtrent de functie van activine A in osteoblasten. Er werd aangetoond dat 
activine A de mineralisatie van de ECM in osteoblasten zeer sterk remt. Daarentegen, 
als de endogene activine A activiteit juist onderdrukt werd door gebruik te maken 
van het activine A bindend eiwit follistatine, werd de mineralisatie juist verhoogd. 
Deze bevindingen laten zien dat door gebruik te maken van activine of follistatine, 
de mineralisatie in tegenovergestelde richting gestuurd kan worden. Verder wordt in 
hoofdstuk 5 aangetoond dat activine A in de periode van ECM synthese de samenstelling 
van de ECM zo verandert dat deze niet of nauwelijks meer kan mineraliseren. Dit 
werd bevestigd door genexpressie microarrays uitgevoerd op activine A en follistatine 
behandelde osteoblast-kweken. Deze studies identificeerden een bepaalde groep ECM 
genen die onder controle staan van de activine signaaltransductie. Als laatste lieten we 
zien dat activine A ook vasculaire gladde spiercellen-geïnduceerde mineralisatie van 
de ECM kan remmen. Deze studies geven aan dat naast osteoporose, de bevindingen 
omtrent activine ook belangrijk kunnen zijn voor aandoeningen zoals arteriosclerose.   
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Wnt signaaltransductie heeft een belangrijke functie in het controleren van 
celdifferentiatie van verscheidene celtypen waaronder osteoblasten. Tegenstrijdige data 
zijn gepubliceerd die zowel positieve als negatieve effecten van Wnt signaaltransductie 
op osteoblasten laten zien. In Hoofdstuk 6 wordt aangetoond dat het effect van Wnt 
signaaltransductie afhankelijk is van het differentiatiestadium van osteoblasten. Wnt 
signaaltransductie stimuleerde vroege osteoblasten in hun capaciteit om zich verder te 
differentiëren, terwijl volwassen osteoblasten sterk geremd werden in hun vermogen 
om te mineraliseren. Tevens is in hoofdstuk 5 de endogene activiteit van de Wnt 
signaaltransductie bestudeerd. Dit werk gaf aan dat tijdens osteoblast differentiatie de 
activiteit van Wnt signaaltransductie wordt onderdrukt en de expressie van verscheidene 
Wnt signaaltransductie-gerelateerde genen sterk wordt gereguleerd. 
Samenvattend zijn verscheidene aspecten van humane osteoblast differentiatie 
bestudeerd in dit proefschrift. De experimenten betreffende glucocorticoїden, Wnt 
signaaltransductie en het activine A-follistatine systeem heeft aanzienlijk meer kennis 
opgeleverd omtrent de functie van deze factoren in het osteoblast differentiatie proces 
(bediscussieerd in Hoofdstuk 7). De nieuwe bevindingen aangaande de sterke effecten 
van het activine A-follistatine systeem op de mineralisatie van de ECM heeft momenteel 
onze primaire interesse aangezien we een nieuw therapeutisch doelwit geїdentificeerd 
hebben met betrekking tot botvorming en arteriosclerose. Tevens vermoeden we 
dat binnen de microarray data, beschreven in hoofdstuk 4 en 5, nog vele nieuwe 
therapeutische doeleiwitten te vinden zijn die de botvorming kunnen controleren. Het 
functioneel testen van de geïdentificeerde genen en het bestuderen van deze genen in 
interactie met elkaar is een enorme uitdaging die in de nabije toekomst uitvoerig zal 
worden onderzocht. 
8.2 Summary
Osteoporosis is the most common bone disease and is characterized by low bone mass, 
micro architectural deterioration and decreased bone quality resulting in increased risk 
of fractures. Osteoblasts, the bone forming cells, play a crucial role in the regulation 
of bone mass and bone quality. Osteoblasts are of mesenchymal origin and undergo a 
complex differentiation process regulated by many endocrine and autocrine factors 
(Chapter 1). In order to develop novel bone anabolic drugs, more knowledge concerning 
osteoblast biology is required. In this thesis we investigated the processes of human 
osteoblast differentiation and matrix mineralization. Human osteoblast-based models of 
bone formation were used in which the role of glucocorticoids (GCs), 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), the Wnt signaling pathway and the activin A-follistatin 
system were studied.  
GCs such as cortisol are crucial initiators of human osteoblast differentiation. 
Despite the clear stimulation of bone formation by GCs in vitro, GCs are still regarded 
as negative regulators of bone formation. This is mainly based on the negative side 
effects initiated by the clinical use of GCs, like bone loss and increased risk of 
fractures. Chapter 2 emphasizes the crucial role of physiological levels of GCs for 
proper differentiation of human osteoblasts. We demonstrated that human osteoblast 
differentiation needs to be triggered by GCs in a specific time-window during the 
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early stages of development. GCs increased the expression of several genes positively 
involved in osteoblast differentiation. Other genes such as osteopontin and osteocalcin, 
which are negatively involved in mineralization, were suppressed by GCs. Moreover, 
GC treatment increased osteoblast proliferation, whereas apoptosis was unchanged. In 
conclusion, the data in Chapter 2 indicates that the negative side effects of GCs are not 
caused by direct effects on osteoblast but are probably caused by several other indirect 
mechanisms that affect bone formation. 
At the tissue and cellular level GC activity is enhanced by local expression of 11β-
HSD1.  This enzyme is expressed in several GC-target cells including osteoblasts and 
converts the inactive GC cortisone into the biologically active cortisol. In Chapter 3 
we investigated the control and functional consequences of osteoblastic 11β-HSD1 
activity.  We demonstrated that the activity of 11β-HSD1 was inversely related to the 
differentiation stage of human osteoblasts. In other words, when pre-osteoblasts were 
differentiated towards mature osteoblasts, 11β-HSD1 activity was suppressed, whereas 
in the absence of osteoblastic differentiation (no GC treatment) 11β-HSD1 expression 
and cortisol production strongly increased. In order to reveal the molecular mechanism 
behind this differentiation dependent regulation of 11β-HSD1, the promoter of the 11β-
HSD1 gene was analyzed. This provided evidence that specific regions of the 11β-HSD1 
promoter were involved in the differentiation-controlled regulation of this enzyme. The 
functional consequence of osteoblastic 11β-HSD1 expression was demonstrated by the 
induction of differentiation in the presence of the inactive GC cortisone, which shows 
that osteoblasts auto control their differentiation by converting cortisone into cortisol. 
Although GCs are crucial for osteoblast differentiation, little is known about the 
genes and molecular networks underlying GC-induced osteoblast differentiation and 
mineralization. In Chapter 4 the process of GC-induced osteoblast differentiation was 
studied at the molecular level using genome-wide gene expression microarrays. GCs 
were used to create nonmineralizing (non GC treated) and mineralizing (GC treated) 
osteoblast cultures. Subsequently, the gene expression profiles of these nonmineralizing 
and mineralizing cultures were compared to identify novel osteoblast regulatory 
genes. A wide variety of genes, processes and gene networks were identified that 
were differentially expressed between nonmineralizing and mineralizing cultures. A 
proof of principle was given by the identification of the cannabinoid receptor 1. This 
receptor was specifically up-regulated during stages of mineralization and its activation 
resulted in increased matrix mineralization in human osteoblast cultures. Moreover, in 
Chapter 4 the processes of osteoblast- and vascular smooth muscle cell (VSMC)-induced 
matrix mineralization were compared. These data indicate that in both processes GC 
treatment was essential to induce matrix mineralization. Comparative gene expression 
analysis demonstrated that there was a large subset of genes similarly regulated during 
osteoblast- and VSMC-induced matrix mineralization, indicating strong similarities 
between bone and vascular mineralization. 
Several members of the transforming growth factor-β (TGFβ) superfamily, including 
TGFβ and bone morphogenic proteins (BMPs), are well-known regulators of bone 
formation. Activins also belong to the TGFβ superfamily, but their precise role in bone 
formation is unknown. Chapter 5 describes the studies regarding the role and impact of 
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activin signaling in human osteoblasts. We demonstrated that activin A strongly inhibits 
matrix mineralization in osteoblast cultures. In contrast, when endogenous activin A 
was inhibited, using the activin A binding protein follistatin, matrix mineralization was 
increased. These findings implicate that it is possible to control matrix mineralization in 
two directions using either follistatin or activin A. Moreover, we demonstrated in Chapter 
5 that activin signaling changes the composition of the extracellular matrix in such way 
that it leads to an extracellular matrix with no or reduced mineralizing capacity. This 
reasoning was substantiated by gene expression microarray studies of follistatin and 
activin A treated osteoblasts, which identified a group of extracellular matrix genes that 
was under control of activin signaling. Finally, we showed that activin A inhibited VSMC-
induced matrix mineralization, which indicates that, besides osteoporosis, these findings 
can also be of great importance for understanding the process of atherosclerosis.   
The Wnt signaling pathway controls cellular differentiation in a variety of cell types 
including osteoblasts. Conflicting data have been published demonstrating both positive 
and negative effects of Wnt signaling on osteoblasts. We show in Chapter 6 that the 
effects of Wnt signaling are dependent on the stage of osteoblast differentiation. Wnt 
signaling stimulated early osteoblasts in their capacity to differentiate, whereas mature 
osteoblasts were strongly inhibited in their capacity to induce matrix mineralization. 
Moreover, we showed that endogenous Wnt signaling was under control of the GC-
induced osteoblast differentiation process. Differentiating osteoblasts had suppressed 
Wnt signal and changed expression of various Wnt signaling related genes. 
In conclusion, many aspects of human osteoblast differentiation were studied in 
this thesis. The studies regarding GCs, Wnt signaling and the activin A-follistatin system 
resulted in a significant increase in fundamental knowledge about the role and control 
of these signaling pathways in osteoblasts (discussed in Chapter 7). The novel findings 
concerning the potent effects of the activin A-follistatin system on matrix mineralization 
are of particular interest since we identified a novel therapeutic target in the control 
of both bone formation and vascular mineralization. In addition, we believe that the 
microarray data generated by unique phenotype-based selection queries described in 
Chapter 4 and 5 have great potential to discover other novel therapeutic targets that 
control bone formation. Studying these genes in interaction with each other and to 
perform a functional characterization is a major challenge for the near future.
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8.4 Abbreviations
11β-HSD  11β-hydroxysteroid dehydrogenase 
1α,25-(OH)2D3 1α,25-dihydroxyvitamin D3
ACEA  arachidonyl-2’-chloroethylamide
ACVR1B activin A receptor, type IB 
ACVR2A activin A receptor, type IIA
ACVR2B activin A receptor, type IIB
AHM anti-Mullerian hormone 
ALP alkaline phosphatase
ALPL  alkaline phosphatase
αMEM minimum essential medium, alpha
aP2 adipocyte lipid-binding protein / fatty acid binding protein 4
APC adenomatosis polyposis coli
BMP bone morphogenic protein
BRE bone morphogenic protein responsive element
C/EBP CAAT/enhancer binding protein
Ca10[PO4]6[OH]2 hydroxyapatite
CBG cortisol binding globulin
c-Fms  macrophage colony stimulating factor receptor
CNR1  cannabinoid receptor 1 
CT-FCS charcoal-treated fetal calf serum 
D day
DAB 3′3-diaminobenzidine hydroxy chloride
DEX  dexamethasone
DKK dickkopf
DMEM dulbecco’s modified eagle’s medium 
DNA deoxyribonucleic acid
EC50 half maximal effective concentration
ECM  extracellular matrix
EDTA ethylenediamine tetraacetic acid 
ELISA enzyme-linked immuno sorbent assay
FCS fetal calf serum 
FSH follicle stimulating hormone 
g gravity
GA 18β-glycyrrhetinic acid
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GC  glucocorticoid
GDF growth and differentiation factor
GO gene ontology
GR  glucocorticoid receptor
GSK3 glycogen synthase kinase 3 
h hour
HSD11B1 11β-hydroxysteroid dehydrogenase 1
IGF-I insulin-growth factor I
INHA inhibin, alpha
INHBA inhibin, beta A 
INHBB inhibin, beta B 
LDL low density lipoprotein
LiCl  lithium chloride
LRP5 low density lipoprotein receptor-related protein 5
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M molar
MCSF macrophage colony-stimulating factor
MgCl magnesium chloride
micro CT microfocus computed tomograhy 
Min minute
MR mineralocorticoid receptor
mRNA mesenger RNA
MSC mesenchymal stem cells
MSX2 msh homeo box homolog 2 
MV matrix vesicles
NaCl sodium chloride
NaOH sodium hydroxide 
NF-kB nuclear factor kappa B
NHOst normal human osteoblasts
OCN bone gamma-carboxyglutamate (gla) protein / osteocalcin
OPG osteoprotegerin
OPN secreted phosphoprotein 1  / osteopontin
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PI propidium iodide 
qPCR quantitative polymerase chain reaction 
RANK tumor necrosis factor receptor superfamily, member 11a /
 receptor activator of NF-κB 
RANKL tumor necrosis factor (ligand) superfamily, member 11 /
 receptor activator of NF-κB ligand
RNA ribonucleic acid
RNAi RNA interference
RT-PCR reverse transcription polymerase chain reaction 
RU RU 38486 / mifepristone 
RUNX2 runt-related transcription factor 2 
SEM standard error of the mean
SFRP secreted frizzled-related protein 
siRNA short interference RNA
SP7 sp7 transcription factor / osterix
SV-HFO simian virus 40 immortalized - human fetal osteoblasts
TGFβ transforming growth factor β
TWIST1 twist homolog 1
VDRE  vitamin D responsive element
vitD 1α,25-dihydroxyvitamin D3
VSMC  vascular smooth muscle cell
WIF WNT inhibitory factor 1
ZBTB16 zinc finger and BTB domain containing 16
Gene abbreviations in Chapter 4 to 7 are according to the HUGO Gene Nomenclature 
Committee 
(Wain et al., Guidelines for human gene nomenclature. Genomics. Apr 2002;79(4):464-470).
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Jan van de Meent, voor de opmaak van mijn proefschrift. Het heeft je heel wat uurtjes 
achter de computer gekost.
Mijn paranimfen; Bram en Ingrid, voor alle hulp rond mijn promotie. Leuk dat jullie naast 
me staan tijdens mijn verdediging, ook naast het werk was het gezellig.
Huib Pols, uiteindelijk is Hans nu mijn promotor, maar zeker nog bedankt voor jouw 
bijdrage, inzet en klinische blik op mijn onderzoek.
Hans van Leeuwen, Hans ik denk dat weinig promovendi zo boffen. Je maakt altijd tijd, 
kijkt manuscripten en abstracts snel na, hebt altijd een positieve houding en bent vaak 
in voor nieuwe ideeën. Kortom, ik vond het een hele leuke tijd en ik verheug me op de 
komende jaren.
En als allerlaatst Marian, bedankt voor alle steun. Na mijn promotie gaan we lekker op 
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